<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialResultsOutput hits="10" offset="1" totalResults="135474"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="100"><FilterOption id="762" count="71328" label="Small molecule therapeutic"/><FilterOption id="648" count="48616" label="Intravenous formulation"/><FilterOption id="585" count="47455" label="Oral formulation"/><FilterOption id="740" count="40063" label="Infusion"/><FilterOption id="761" count="35409" label="Biological therapeutic"/><FilterOption id="595" count="31667" label="Tablet formulation"/><FilterOption id="746" count="27013" label="Solution"/><FilterOption id="751" count="20529" label="Film coating"/><FilterOption id="586" count="20514" label="Capsule formulation"/><FilterOption id="898" count="16954" label="Formulation powder"/><FilterOption id="750" count="16270" label="Freeze drying"/><FilterOption id="85" count="15054" label="Protein recombinant"/><FilterOption id="573" count="14939" label="Immunoglobulin-G"/><FilterOption id="647" count="14105" label="Subcutaneous formulation"/><FilterOption id="1647" count="11216" label="Natural product"/><FilterOption id="1263" count="8916" label="Immuno-oncology"/><FilterOption id="169" count="8852" label="Monoclonal antibody humanized"/><FilterOption id="1652" count="8214" label="Prodrug"/><FilterOption id="80" count="6861" label="Peptide"/><FilterOption id="766" count="6700" label="Parenteral formulation unspecified"/><FilterOption id="902" count="6263" label="Orally disintegrating tablet"/><FilterOption id="594" count="6111" label="Oral suspension formulation"/><FilterOption id="168" count="5104" label="Monoclonal antibody human"/><FilterOption id="651" count="4499" label="Intramuscular formulation"/><FilterOption id="175" count="4341" label="Drug combination"/><FilterOption id="166" count="4019" label="Chimeric monoclonal antibody"/><FilterOption id="745" count="3809" label="Suspension"/><FilterOption id="603" count="3640" label="Systemic formulation unspecified"/><FilterOption id="593" count="3501" label="Oral liquid formulation"/><FilterOption id="589" count="3409" label="Sustained release formulation"/><FilterOption id="894" count="3166" label="Liquid formulation"/><FilterOption id="596" count="2949" label="Injectable formulation"/><FilterOption id="805" count="2786" label="Daily dosing"/><FilterOption id="66" count="2639" label="Antibiotic"/><FilterOption id="127" count="2530" label="Cell culture"/><FilterOption id="743" count="2380" label="Granule"/><FilterOption id="348" count="2199" label="PEGylated formulation"/><FilterOption id="84" count="2166" label="Protein fusion"/><FilterOption id="102" count="2086" label="Nucleotide and derivatives"/><FilterOption id="641" count="1976" label="Controlled release formulation"/><FilterOption id="599" count="1888" label="Nanoparticle formulation injectable"/><FilterOption id="680" count="1804" label="Buccal formulation systemic"/><FilterOption id="611" count="1790" label="Dermatological formulation"/><FilterOption id="207" count="1704" label="Protein conjugated"/><FilterOption id="90" count="1690" label="Steroid"/><FilterOption id="731" count="1627" label="Imaging"/><FilterOption id="649" count="1626" label="Intraperitoneal formulation"/><FilterOption id="630" count="1612" label="Stereochemistry"/><FilterOption id="852" count="1594" label="Intravesical formulation"/><FilterOption id="112" count="1448" label="DNA technology"/><FilterOption id="590" count="1433" label="Enteric coated formulation"/><FilterOption id="616" count="1430" label="Inhalant formulation"/><FilterOption id="558" count="1374" label="Transdermal formulation"/><FilterOption id="180" count="1371" label="Antibody fragment"/><FilterOption id="724" count="1303" label="Radiolabeling"/><FilterOption id="660" count="1301" label="Oral sustained release formulation"/><FilterOption id="167" count="1300" label="Monoclonal antibody murine"/><FilterOption id="62" count="1264" label="Virus recombinant"/><FilterOption id="723" count="1229" label="Drug coating"/><FilterOption id="598" count="1180" label="Liposome formulation injectable"/><FilterOption id="171" count="1114" label="Monoclonal antibody conjugated"/><FilterOption id="347" count="1079" label="Intratumoral formulation"/><FilterOption id="74" count="1055" label="Glycoprotein"/><FilterOption id="756" count="1031" label="Pharmaceutical carrier"/><FilterOption id="570" count="917" label="Cell therapy"/><FilterOption id="236" count="883" label="Macrolide"/><FilterOption id="851" count="808" label="Intradermal formulation"/><FilterOption id="776" count="803" label="Oral gel formulation"/><FilterOption id="615" count="777" label="Aerosol formulation dermatological"/><FilterOption id="753" count="775" label="Microparticle formulation"/><FilterOption id="135" count="775" label="T-lymphocyte"/><FilterOption id="559" count="756" label="Oral controlled release formulation"/><FilterOption id="617" count="747" label="Aerosol formulation inhalant"/><FilterOption id="618" count="660" label="Powder formulation inhalant"/><FilterOption id="51" count="646" label="Monoclonal antibody"/><FilterOption id="667" count="596" label="Peptidomimetic"/><FilterOption id="128" count="590" label="Cell culture technique"/><FilterOption id="612" count="585" label="Emulsion dermatological"/><FilterOption id="1646" count="582" label="Injectable controlled release formulation"/><FilterOption id="654" count="561" label="Intrathecal formulation"/><FilterOption id="742" count="542" label="Pellet"/><FilterOption id="701" count="541" label="Nucleoside synthesis"/><FilterOption id="582" count="539" label="Antibody polyclonal"/><FilterOption id="159" count="523" label="Oligosaccharide"/><FilterOption id="661" count="509" label="Oral quick release formulation"/><FilterOption id="345" count="494" label="Receptor chimeric"/><FilterOption id="962" count="483" label="Biosimilar product"/><FilterOption id="1247" count="475" label="Chimeric antigen receptor T cell therapy"/><FilterOption id="620" count="474" label="Ophthalmic formulation"/><FilterOption id="142" count="442" label="Liposome formulation"/><FilterOption id="597" count="437" label="Injectable emulsion"/><FilterOption id="652" count="436" label="Intra-articular formulation"/><FilterOption id="67" count="429" label="Antigen"/><FilterOption id="658" count="426" label="Subcutaneous drug implant"/><FilterOption id="1164" count="424" label="Antibody drug conjugate"/><FilterOption id="103" count="408" label="Oligonucleotide"/><FilterOption id="93" count="404" label="Toxin"/><FilterOption id="349" count="400" label="Lipid"/><FilterOption id="600" count="399" label="Patch formulation"/><FilterOption id="1669" count="387" label="Emulsion formulation"/></Filter><Filter label="Indications" name="indications" total="100"><FilterOption id="49" count="5515" label="Breast tumor"/><FilterOption id="3665" count="4112" label="Metastatic non small cell lung cancer"/><FilterOption id="3657" count="3639" label="Metastatic breast cancer"/><FilterOption id="1262" count="3330" label="Non-small-cell lung cancer"/><FilterOption id="3713" count="3223" label="Advanced solid tumor"/><FilterOption id="1069" count="3191" label="Metastasis"/><FilterOption id="837" count="2870" label="Non-insulin dependent diabetes"/><FilterOption id="1731" count="2742" label="Acute myelogenous leukemia"/><FilterOption id="3658" count="2721" label="Metastatic colorectal cancer"/><FilterOption id="276" count="2609" label="Prostate tumor"/><FilterOption id="2399" count="2501" label="Adenocarcinoma"/><FilterOption id="725" count="2421" label="Solid tumor"/><FilterOption id="1767" count="2401" label="Hepatocellular carcinoma"/><FilterOption id="1828" count="2390" label="Multiple myeloma"/><FilterOption id="20" count="2364" label="Pain"/><FilterOption id="307" count="2345" label="Squamous cell carcinoma"/><FilterOption id="319" count="2230" label="Non-Hodgkin lymphoma"/><FilterOption id="799" count="2029" label="Ovary tumor"/><FilterOption id="989" count="1931" label="Colorectal tumor"/><FilterOption id="651" count="1916" label="Cancer"/><FilterOption id="3246" count="1748" label="Hormone refractory prostate cancer"/><FilterOption id="3257" count="1730" label="Stage IV melanoma"/><FilterOption id="249" count="1653" label="Pancreas tumor"/><FilterOption id="1272" count="1580" label="Myelodysplastic syndrome"/><FilterOption id="2454" count="1547" label="Glioblastoma"/><FilterOption id="623" count="1543" label="Head and neck tumor"/><FilterOption id="3666" count="1516" label="Metastatic stomach cancer"/><FilterOption id="158" count="1437" label="HIV infection"/><FilterOption id="127" count="1419" label="Stomach tumor"/><FilterOption id="3669" count="1412" label="Metastatic pancreas cancer"/><FilterOption id="203" count="1392" label="Lymphoma"/><FilterOption id="1734" count="1363" label="Chronic lymphocytic leukemia"/><FilterOption id="4250" count="1313" label="Metastatic renal cell carcinoma"/><FilterOption id="1011" count="1287" label="Esophagus tumor"/><FilterOption id="427" count="1279" label="Uterine cervix tumor"/><FilterOption id="1108" count="1239" label="Glioma"/><FilterOption id="1728" count="1232" label="Acute lymphoblastic leukemia"/><FilterOption id="1735" count="1212" label="Chronic myelocytic leukemia"/><FilterOption id="1185" count="1179" label="Chronic obstructive pulmonary disease"/><FilterOption id="1749" count="1177" label="Diffuse large B-cell lymphoma"/><FilterOption id="3083" count="1151" label="Peritoneal tumor"/><FilterOption id="238" count="1141" label="Obesity"/><FilterOption id="755" count="1065" label="Lung tumor"/><FilterOption id="291" count="1051" label="Rheumatoid arthritis"/><FilterOption id="205" count="1039" label="Melanoma"/><FilterOption id="161" count="989" label="Hodgkins disease"/><FilterOption id="1261" count="985" label="Small-cell lung cancer"/><FilterOption id="178" count="935" label="Hypertension"/><FilterOption id="3664" count="934" label="Metastatic prostate cancer"/><FilterOption id="3673" count="929" label="Metastatic head and neck cancer"/><FilterOption id="760" count="897" label="Brain tumor"/><FilterOption id="2380" count="886" label="Bladder cancer"/><FilterOption id="3866" count="882" label="Metastatic ovary cancer"/><FilterOption id="31" count="880" label="Asthma"/><FilterOption id="2243" count="877" label="Fallopian tube cancer"/><FilterOption id="1745" count="834" label="Follicle center lymphoma"/><FilterOption id="80" count="827" label="Coronary artery disease"/><FilterOption id="3667" count="810" label="Metastatic esophageal cancer"/><FilterOption id="245" count="806" label="Osteoarthritis"/><FilterOption id="1705" count="789" label="Endometrioid carcinoma"/><FilterOption id="316" count="760" label="B-cell lymphoma"/><FilterOption id="1771" count="736" label="Transitional cell carcinoma"/><FilterOption id="2054" count="735" label="Hematological neoplasm"/><FilterOption id="55" count="732" label="Cardiac failure"/><FilterOption id="153" count="724" label="Hepatitis C virus infection"/><FilterOption id="17" count="714" label="Anemia"/><FilterOption id="152" count="698" label="Hepatitis B virus infection"/><FilterOption id="281" count="696" label="Psoriasis"/><FilterOption id="3251" count="680" label="End stage renal disease"/><FilterOption id="836" count="674" label="Insulin dependent diabetes"/><FilterOption id="191" count="665" label="Influenza virus infection"/><FilterOption id="1744" count="661" label="Mantle cell lymphoma"/><FilterOption id="14" count="650" label="Alzheimers disease"/><FilterOption id="3378" count="615" label="Soft tissue sarcoma"/><FilterOption id="159" count="606" label="HIV-1 infection"/><FilterOption id="1766" count="604" label="Renal cell carcinoma"/><FilterOption id="1768" count="590" label="Nasopharyngeal carcinoma"/><FilterOption id="1055" count="588" label="Rectal tumor"/><FilterOption id="616" count="581" label="Graft versus host disease"/><FilterOption id="202" count="573" label="Liver tumor"/><FilterOption id="1128" count="567" label="Neuroendocrine tumor"/><FilterOption id="194" count="563" label="Sarcoma"/><FilterOption id="199" count="560" label="Leukemia"/><FilterOption id="57" count="541" label="Cardiovascular disease"/><FilterOption id="1765" count="537" label="Cholangiocarcinoma"/><FilterOption id="224" count="532" label="Myocardial infarction"/><FilterOption id="759" count="512" label="Central nervous system tumor"/><FilterOption id="255" count="499" label="Parkinsons disease"/><FilterOption id="2726" count="496" label="Neuroblastoma"/><FilterOption id="3256" count="493" label="Stage III melanoma"/><FilterOption id="767" count="466" label="Colon tumor"/><FilterOption id="3668" count="465" label="Metastatic lung cancer"/><FilterOption id="97" count="464" label="Diabetes mellitus"/><FilterOption id="84" count="462" label="Crohns disease"/><FilterOption id="1240" count="457" label="Mesothelioma"/><FilterOption id="3211" count="444" label="Cancer pain"/><FilterOption id="3676" count="443" label="Ischemic stroke"/><FilterOption id="1829" count="442" label="Bone metastases"/><FilterOption id="793" count="431" label="Mouth tumor"/><FilterOption id="1134" count="428" label="Thyroid tumor"/></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="8639" count="4398" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="8481" count="3721" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8489" count="3633" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15312" count="3594" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="7679" count="2774" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="8996" count="2745" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="15285" count="2740" label="Solid tumor - Assessment of Safety and Tolerability"/><FilterOption id="8998" count="2737" label="Breast tumor - Assessment of adverse events"/><FilterOption id="8077" count="2673" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="7879" count="2500" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="15287" count="2472" label="Solid tumor - Assessment of adverse events"/><FilterOption id="8712" count="2438" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7538" count="2307" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="8078" count="2215" label="Leukemia - Assessment of adverse events"/><FilterOption id="8430" count="2140" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7547" count="2098" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8663" count="2029" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="7680" count="2009" label="Lymphoma - Assessment of adverse events"/><FilterOption id="8640" count="1981" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="8719" count="1942" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="19282" count="1938" label="Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8713" count="1862" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8151" count="1842" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="19374" count="1836" label="Cancer supportive care - Assessment of Safety and Tolerability"/><FilterOption id="8505" count="1821" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="9122" count="1806" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="15293" count="1798" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="7189" count="1757" label="Prostate tumor - Assessment of Safety and Tolerability"/><FilterOption id="7563" count="1744" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7908" count="1706" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8163" count="1640" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7569" count="1632" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8429" count="1607" label="Colorectal tumor - Assessment of Safety and Tolerability"/><FilterOption id="12048" count="1590" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"/><FilterOption id="19412" count="1552" label="Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes"/><FilterOption id="8508" count="1534" label="Lung tumor - Assessment of Overall Response"/><FilterOption id="8187" count="1532" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="8451" count="1460" label="Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="7311" count="1449" label="Head and neck tumor - Assessment of Safety and Tolerability"/><FilterOption id="8140" count="1421" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"/><FilterOption id="13344" count="1416" label="Pancreas tumor - Assessment of Overall Survival (OS)"/><FilterOption id="26033" count="1408" label="Pain - Assessment of adverse events"/><FilterOption id="8513" count="1360" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="8721" count="1359" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="9153" count="1358" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="19407" count="1341" label="Cancer supportive care - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="25874" count="1339" label="Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]"/><FilterOption id="7564" count="1327" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="26044" count="1326" label="Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication"/><FilterOption id="7244" count="1319" label="Head and neck tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7190" count="1317" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="15212" count="1300" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="7981" count="1295" label="Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="7611" count="1275" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="7312" count="1269" label="Head and neck tumor - Assessment of adverse events"/><FilterOption id="8523" count="1267" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="7906" count="1256" label="Leukemia - Assessment of Response Rates (RR)"/><FilterOption id="8514" count="1244" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7868" count="1233" label="Lymphoma - Protocol Specified Other Endpoints - Assessment of Efficacy"/><FilterOption id="13433" count="1193" label="Pancreas tumor - Assessment of Safety and Tolerability"/><FilterOption id="10900" count="1190" label="Ovary tumor - Assessment of Safety and Tolerability"/><FilterOption id="17405" count="1180" label="Stem cell transplantation - Assessment of Overall Survival (OS)"/><FilterOption id="12148" count="1166" label="Stomach tumor - Assessment of Overall Survival (OS)"/><FilterOption id="1" count="1165" label="Hypertension - Assessment of Blood Pressure (BP)"/><FilterOption id="26032" count="1161" label="Pain - Assessment of Safety and Tolerability"/><FilterOption id="8563" count="1155" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8720" count="1139" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="9152" count="1139" label="Lung tumor - Assessment of Other/Unspecified Efficacy Parameters"/><FilterOption id="8726" count="1123" label="Breast tumor - Assessment of Response Rates (RR)"/><FilterOption id="1345" count="1114" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"/><FilterOption id="37159" count="1113" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8759" count="1096" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="1358" count="1094" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"/><FilterOption id="12118" count="1088" label="Hepatobiliary system tumor - Assessment of adverse events"/><FilterOption id="6940" count="1081" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="8670" count="1069" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"/><FilterOption id="12117" count="1065" label="Hepatobiliary system tumor - Assessment of Safety and Tolerability"/><FilterOption id="7217" count="1060" label="Prostate tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8999" count="1059" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="15207" count="1054" label="Solid tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9218" count="1051" label="HIV infection - Assessment of Immune Response"/><FilterOption id="7354" count="1050" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="9147" count="1049" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities"/><FilterOption id="8651" count="1048" label="Lung tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="19376" count="1047" label="Cancer supportive care - Assessment of adverse events"/><FilterOption id="12051" count="1035" label="Hepatobiliary system tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7988" count="1035" label="Leukemia - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="1624" count="1034" label="Non-insulin dependent diabetes - Assessment of Safety and Tolerability"/><FilterOption id="7891" count="1024" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15318" count="1017" label="Solid tumor - Protocol Specified Other Endpoints - Assessment of Anti-tumor Activity"/><FilterOption id="8522" count="1000" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="7987" count="999" label="Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"/><FilterOption id="7256" count="995" label="Head and neck tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="13352" count="993" label="Pancreas tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="13435" count="988" label="Pancreas tumor - Assessment of adverse events"/><FilterOption id="9133" count="975" label="Lymphoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"/><FilterOption id="12209" count="971" label="Stomach tumor - Assessment of adverse events"/><FilterOption id="7909" count="969" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="12207" count="946" label="Stomach tumor - Assessment of Safety and Tolerability"/><FilterOption id="7921" count="943" label="Leukemia - Assessment of Disease Relapse/Recurrence"/></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="12"><FilterOption id="L" count="72016" label="Launched"/><FilterOption id="C2" count="8248" label="Phase 2 Clinical"/><FilterOption id="DX" count="6234" label="Discontinued"/><FilterOption id="C3" count="4935" label="Phase 3 Clinical"/><FilterOption id="NDR" count="4252" label="No Development Reported"/><FilterOption id="C1" count="2585" label="Phase 1 Clinical"/><FilterOption id="DR" count="1062" label="Discovery"/><FilterOption id="PR" count="899" label="Pre-registration"/><FilterOption id="R" count="692" label="Registered"/><FilterOption id="W" count="407" label="Withdrawn"/><FilterOption id="CU" count="163" label="Clinical"/><FilterOption id="S" count="150" label="Suspended"/></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="100"><FilterOption id="20519" count="2681" label="National Cancer Institute"/><FilterOption id="23382" count="1729" label="MD Anderson Cancer Center"/><FilterOption id="23137" count="1622" label="Novartis AG"/><FilterOption id="28355" count="1359" label="GlaxoSmithKline plc"/><FilterOption id="18767" count="1267" label="Pfizer Inc"/><FilterOption id="20520" count="1180" label="National Institute of Allergy and Infectious Diseases"/><FilterOption id="19446" count="1140" label="Roche Holding AG"/><FilterOption id="22122" count="1098" label="Memorial Sloan-Kettering Cancer Center"/><FilterOption id="17810" count="1046" label="Eli Lilly &amp; Co"/><FilterOption id="14190" count="1037" label="AstraZeneca plc"/><FilterOption id="15065" count="915" label="Bristol-Myers Squibb Co"/><FilterOption id="1009547" count="896" label="Sanofi SA"/><FilterOption id="1059823" count="836" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="21569" count="814" label="Massachusetts General Hospital"/><FilterOption id="21111" count="770" label="Mayo Clinic Foundation"/><FilterOption id="15615" count="624" label="Dana-Farber Cancer Institute Inc"/><FilterOption id="1004360" count="620" label="Sun Yat-Sen University"/><FilterOption id="14881" count="565" label="Boehringer Ingelheim International GmbH"/><FilterOption id="14109" count="559" label="Amgen Inc"/><FilterOption id="14455" count="551" label="Bayer AG"/><FilterOption id="26113" count="440" label="Washington University in St Louis"/><FilterOption id="15331" count="435" label="Celgene Corp"/><FilterOption id="20679" count="431" label="Stanford University"/><FilterOption id="19453" count="426" label="Genentech Inc"/><FilterOption id="20567" count="418" label="Duke University"/><FilterOption id="1042135" count="415" label="Sidney Kimmel Comprehensive Cancer Center"/><FilterOption id="24773" count="389" label="University of California San Francisco"/><FilterOption id="1040381" count="387" label="Cancer and Leukemia Group B"/><FilterOption id="DOL1000375" count="382" label="Fudan University"/><FilterOption id="26013" count="373" label="University of Chicago"/><FilterOption id="20645" count="351" label="Northwestern University"/><FilterOption id="20659" count="351" label="University of Pittsburgh"/><FilterOption id="16218" count="343" label="Fred Hutchinson Cancer Research Center"/><FilterOption id="1004334" count="342" label="Samsung Medical Center (SMC)"/><FilterOption id="16450" count="338" label="Gilead Sciences Inc"/><FilterOption id="28443" count="336" label="The University Health Network"/><FilterOption id="20300" count="332" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="20658" count="328" label="University of Pennsylvania"/><FilterOption id="20534" count="326" label="Baylor College of Medicine"/><FilterOption id="1003017" count="319" label="Seoul National University Hospital"/><FilterOption id="29603" count="318" label="H Lee Moffitt Cancer Center and Research Institute"/><FilterOption id="18077" count="315" label="Merck &amp; Co Inc"/><FilterOption id="1039242" count="306" label="Case Comprehensive Cancer Center"/><FilterOption id="25760" count="300" label="University of Texas Southwestern Medical Center"/><FilterOption id="23948" count="299" label="Assistance Publique Hopitaux de Paris"/><FilterOption id="20573" count="298" label="Emory University"/><FilterOption id="1038961" count="298" label="National Taiwan University Hospital"/><FilterOption id="1013295" count="293" label="Astellas Pharma Inc"/><FilterOption id="1041378" count="290" label="Children's Oncology Group"/><FilterOption id="1028858" count="289" label="Southwest Oncology Group"/><FilterOption id="20518" count="285" label="National Institutes of Health"/><FilterOption id="1051922" count="282" label="City of Hope Medical Center"/><FilterOption id="23119" count="281" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="1060642" count="280" label="National Cancer Center Hospital"/><FilterOption id="DOL1000742" count="278" label="University of Wisconsin-Madison"/><FilterOption id="20524" count="277" label="University of Alabama at Birmingham"/><FilterOption id="20701" count="274" label="University of Washington"/><FilterOption id="1072507" count="268" label="AbbVie Inc"/><FilterOption id="21099" count="268" label="Roswell Park Comprehensive Cancer Center"/><FilterOption id="13601" count="257" label="Abbott Laboratories"/><FilterOption id="20623" count="257" label="University of Michigan"/><FilterOption id="1036320" count="252" label="Asan Medical Center"/><FilterOption id="25184" count="249" label="Yonsei University"/><FilterOption id="20631" count="248" label="Mount Sinai School of Medicine"/><FilterOption id="20653" count="247" label="Osaka University"/><FilterOption id="20559" count="241" label="Columbia University"/><FilterOption id="26178" count="239" label="F Hoffmann-La Roche AG"/><FilterOption id="20634" count="236" label="University of North Carolina"/><FilterOption id="26109" count="235" label="Jonsson Comprehensive Cancer Center"/><FilterOption id="1067538" count="232" label="Janssen Research &amp; Development LLC"/><FilterOption id="1039740" count="230" label="National Natural Science Foundation of China"/><FilterOption id="18101" count="219" label="Merck KGaA"/><FilterOption id="1043016" count="219" label="Tehran University of Medical Sciences"/><FilterOption id="20703" count="216" label="Yale University"/><FilterOption id="1007827" count="213" label="University Medical Center Groningen"/><FilterOption id="20673" count="213" label="University of Southern California"/><FilterOption id="24771" count="203" label="Eastern Cooperative Oncology Group"/><FilterOption id="1041702" count="202" label="Gynecologic Oncology Group"/><FilterOption id="21189" count="201" label="Chinese Academy of Medical Sciences"/><FilterOption id="22487" count="198" label="The University of Hong Kong"/><FilterOption id="20669" count="198" label="University of Rochester"/><FilterOption id="1039932" count="197" label="Peking Union Medical College Hospital"/><FilterOption id="1053899" count="196" label="Abramson Cancer Center of the University of Pennsylvania"/><FilterOption id="1042263" count="195" label="Ohio State University Comprehensive Cancer Center"/><FilterOption id="1040998" count="194" label="Masonic Cancer Center"/><FilterOption id="30810" count="194" label="VU University Medical Center"/><FilterOption id="1015721" count="192" label="Medical University of Vienna"/><FilterOption id="18614" count="192" label="Novo Nordisk A/S"/><FilterOption id="1003379" count="192" label="Sichuan University"/><FilterOption id="1021685" count="190" label="Chinese PLA General Hospital"/><FilterOption id="21991" count="189" label="Takeda Oncology"/><FilterOption id="1018611" count="188" label="Erasmus University Medical Center Rotterdam"/><FilterOption id="22182" count="188" label="University of Oxford"/><FilterOption id="29469" count="187" label="Cancer Research UK"/><FilterOption id="18720" count="187" label="Taiho Pharmaceutical Co Ltd"/><FilterOption id="29481" count="186" label="Johnson &amp; Johnson Pharmaceutical Research &amp; Development LLC"/><FilterOption id="30065" count="185" label="Charite Universitaetsmedizin Berlin"/><FilterOption id="26334" count="185" label="National Institute of Diabetes, Digestive and Kidney Diseases"/><FilterOption id="26112" count="181" label="All India Institute of Medical Sciences"/><FilterOption id="1025024" count="181" label="Assiut University"/></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="8"><FilterOption id="4" count="50413" label="Completed"/><FilterOption id="2" count="34506" label="Recruiting"/><FilterOption id="12" count="14354" label="Status not specified"/><FilterOption id="3" count="12979" label="No longer recruiting"/><FilterOption id="6" count="11625" label="Terminated"/><FilterOption id="1" count="10260" label="Not yet recruiting"/><FilterOption id="15" count="730" label="Planned"/><FilterOption id="5" count="607" label="Suspended"/></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="NO" count="97782" label="No"/><FilterOption id="YES" count="37692" label="Yes"/></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="100"><FilterOption id="3713" count="1497" label="Advanced solid tumor"/><FilterOption id="725" count="939" label="Solid tumor"/><FilterOption id="3665" count="841" label="Metastatic non small cell lung cancer"/><FilterOption id="1069" count="832" label="Metastasis"/><FilterOption id="3657" count="798" label="Metastatic breast cancer"/><FilterOption id="49" count="747" label="Breast tumor"/><FilterOption id="651" count="701" label="Cancer"/><FilterOption id="3658" count="613" label="Metastatic colorectal cancer"/><FilterOption id="2399" count="567" label="Adenocarcinoma"/><FilterOption id="1262" count="560" label="Non-small-cell lung cancer"/><FilterOption id="319" count="559" label="Non-Hodgkin lymphoma"/><FilterOption id="1731" count="539" label="Acute myelogenous leukemia"/><FilterOption id="3257" count="522" label="Stage IV melanoma"/><FilterOption id="799" count="519" label="Ovary tumor"/><FilterOption id="307" count="507" label="Squamous cell carcinoma"/><FilterOption id="203" count="501" label="Lymphoma"/><FilterOption id="1828" count="498" label="Multiple myeloma"/><FilterOption id="3669" count="489" label="Metastatic pancreas cancer"/><FilterOption id="3246" count="488" label="Hormone refractory prostate cancer"/><FilterOption id="1767" count="426" label="Hepatocellular carcinoma"/><FilterOption id="276" count="420" label="Prostate tumor"/><FilterOption id="989" count="419" label="Colorectal tumor"/><FilterOption id="2454" count="403" label="Glioblastoma"/><FilterOption id="3866" count="393" label="Metastatic ovary cancer"/><FilterOption id="205" count="379" label="Melanoma"/><FilterOption id="249" count="374" label="Pancreas tumor"/><FilterOption id="1734" count="367" label="Chronic lymphocytic leukemia"/><FilterOption id="3666" count="367" label="Metastatic stomach cancer"/><FilterOption id="1272" count="361" label="Myelodysplastic syndrome"/><FilterOption id="4250" count="358" label="Metastatic renal cell carcinoma"/><FilterOption id="623" count="349" label="Head and neck tumor"/><FilterOption id="3673" count="340" label="Metastatic head and neck cancer"/><FilterOption id="3083" count="340" label="Peritoneal tumor"/><FilterOption id="1108" count="335" label="Glioma"/><FilterOption id="1749" count="331" label="Diffuse large B-cell lymphoma"/><FilterOption id="158" count="308" label="HIV infection"/><FilterOption id="1261" count="300" label="Small-cell lung cancer"/><FilterOption id="427" count="289" label="Uterine cervix tumor"/><FilterOption id="2243" count="285" label="Fallopian tube cancer"/><FilterOption id="1728" count="284" label="Acute lymphoblastic leukemia"/><FilterOption id="316" count="276" label="B-cell lymphoma"/><FilterOption id="2054" count="269" label="Hematological neoplasm"/><FilterOption id="3667" count="265" label="Metastatic esophageal cancer"/><FilterOption id="194" count="265" label="Sarcoma"/><FilterOption id="1771" count="256" label="Transitional cell carcinoma"/><FilterOption id="127" count="255" label="Stomach tumor"/><FilterOption id="1745" count="254" label="Follicle center lymphoma"/><FilterOption id="1705" count="251" label="Endometrioid carcinoma"/><FilterOption id="3664" count="251" label="Metastatic prostate cancer"/><FilterOption id="760" count="250" label="Brain tumor"/><FilterOption id="755" count="246" label="Lung tumor"/><FilterOption id="1735" count="234" label="Chronic myelocytic leukemia"/><FilterOption id="161" count="229" label="Hodgkins disease"/><FilterOption id="199" count="219" label="Leukemia"/><FilterOption id="1744" count="217" label="Mantle cell lymphoma"/><FilterOption id="1011" count="214" label="Esophagus tumor"/><FilterOption id="837" count="208" label="Non-insulin dependent diabetes"/><FilterOption id="2380" count="207" label="Bladder cancer"/><FilterOption id="1766" count="206" label="Renal cell carcinoma"/><FilterOption id="759" count="205" label="Central nervous system tumor"/><FilterOption id="291" count="204" label="Rheumatoid arthritis"/><FilterOption id="1240" count="193" label="Mesothelioma"/><FilterOption id="3378" count="191" label="Soft tissue sarcoma"/><FilterOption id="2726" count="179" label="Neuroblastoma"/><FilterOption id="3256" count="174" label="Stage III melanoma"/><FilterOption id="1765" count="171" label="Cholangiocarcinoma"/><FilterOption id="20" count="165" label="Pain"/><FilterOption id="1128" count="161" label="Neuroendocrine tumor"/><FilterOption id="3466" count="158" label="Metastatic bladder cancer"/><FilterOption id="202" count="155" label="Liver tumor"/><FilterOption id="159" count="153" label="HIV-1 infection"/><FilterOption id="230" count="147" label="Neoplasm"/><FilterOption id="281" count="143" label="Psoriasis"/><FilterOption id="3668" count="142" label="Metastatic lung cancer"/><FilterOption id="191" count="137" label="Influenza virus infection"/><FilterOption id="767" count="134" label="Colon tumor"/><FilterOption id="14" count="124" label="Alzheimers disease"/><FilterOption id="999" count="121" label="Renal tumor"/><FilterOption id="616" count="119" label="Graft versus host disease"/><FilterOption id="1746" count="115" label="Marginal zone B-cell lymphoma"/><FilterOption id="1772" count="114" label="Osteosarcoma"/><FilterOption id="311" count="114" label="T-cell lymphoma"/><FilterOption id="2567" count="112" label="Anaplastic astrocytoma"/><FilterOption id="3462" count="112" label="Metastatic liver cancer"/><FilterOption id="1134" count="112" label="Thyroid tumor"/><FilterOption id="2975" count="111" label="Ewing sarcoma"/><FilterOption id="793" count="110" label="Mouth tumor"/><FilterOption id="1185" count="108" label="Chronic obstructive pulmonary disease"/><FilterOption id="836" count="107" label="Insulin dependent diabetes"/><FilterOption id="3251" count="106" label="End stage renal disease"/><FilterOption id="54" count="105" label="Carcinoma"/><FilterOption id="2436" count="105" label="Myelofibrosis"/><FilterOption id="1516" count="104" label="Biliary cancer"/><FilterOption id="131" count="104" label="Gastrointestinal tumor"/><FilterOption id="1754" count="102" label="Cutaneous T-cell lymphoma"/><FilterOption id="153" count="102" label="Hepatitis C virus infection"/><FilterOption id="1768" count="102" label="Nasopharyngeal carcinoma"/><FilterOption id="31" count="100" label="Asthma"/><FilterOption id="2727" count="99" label="Gliosarcoma"/><FilterOption id="152" count="99" label="Hepatitis B virus infection"/></Filter><Filter label="Registry Id" name="trialRegistries" total="37"><FilterOption id="1000" count="90631" label="CT.gov"/><FilterOption id="1001" count="17327" label="EudraCT"/><FilterOption id="1003" count="8853" label="UMIN"/><FilterOption id="1007" count="5578" label="ChiCTR"/><FilterOption id="1012" count="2584" label="CTRI"/><FilterOption id="1002" count="2571" label="ISRCTN"/><FilterOption id="1006" count="2122" label="JapicCTI"/><FilterOption id="1030" count="1779" label="RSRM CTR"/><FilterOption id="1004" count="1766" label="WHO ICTRP"/><FilterOption id="1019" count="1609" label="DRKS"/><FilterOption id="1039" count="1540" label="CDE"/><FilterOption id="1011" count="1516" label="ANZCTR"/><FilterOption id="1023" count="1356" label="UKCRN"/><FilterOption id="1014" count="1205" label="IRCT"/><FilterOption id="1015" count="946" label="NTR"/><FilterOption id="1010" count="825" label="CRiS"/><FilterOption id="1035" count="563" label="Singapore HSA CTR"/><FilterOption id="1009" count="501" label="HKClinicalTrials.com"/><FilterOption id="1021" count="440" label="NMRR"/><FilterOption id="1033" count="326" label="Mexico CTR"/><FilterOption id="1037" count="295" label="TCTR"/><FilterOption id="1020" count="234" label="ReBec"/><FilterOption id="1038" count="218" label="PHRR"/><FilterOption id="1013" count="164" label="RPCEC"/><FilterOption id="1005" count="79" label="JMACCT CTR"/><FilterOption id="1040" count="44" label="REec"/><FilterOption id="1008" count="42" label="Hong Kong CCTCTR"/><FilterOption id="1018" count="34" label="SLCTR"/><FilterOption id="1016" count="31" label="PACTR"/><FilterOption id="1017" count="10" label="CTR Freiburg"/><FilterOption id="1031" count="5" label="Estonia CTR"/><FilterOption id="1036" count="5" label="JAZMP CTR"/><FilterOption id="1026" count="3" label="SANCTR"/><FilterOption id="1024" count="3" label="TzCTR"/><FilterOption id="1034" count="2" label="INFARMA CTR"/><FilterOption id="1027" count="2" label="SUKL CTR"/><FilterOption id="1032" count="1" label="Chile CTR"/></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="8"><FilterOption id="2" count="3374" label="Not Reported"/><FilterOption id="5" count="3288" label="Patient Enrollment Issues"/><FilterOption id="4" count="1800" label="Other"/><FilterOption id="3" count="1331" label="Operational Issues"/><FilterOption id="8" count="865" label="Sponsor/Business Decision"/><FilterOption id="1" count="710" label="Lack of Efficacy"/><FilterOption id="7" count="466" label="Safety Issues"/><FilterOption id="6" count="290" label="Planned, not Initiated"/></Filter><Filter label="Active Controls" name="trialActiveControls" total="100"><FilterOption id="3803" count="577" label="paclitaxel"/><FilterOption id="2953" count="529" label="docetaxel"/><FilterOption id="44383" count="525" label="carboplatin"/><FilterOption id="3199" count="514" label="gemcitabine"/><FilterOption id="12205" count="322" label="capecitabine"/><FilterOption id="3792" count="322" label="oxaliplatin"/><FilterOption id="8047" count="221" label="bevacizumab"/><FilterOption id="6050" count="207" label="metformin hydrochloride"/><FilterOption id="6736" count="206" label="rituximab"/><FilterOption id="3536" count="195" label="pemetrexed disodium"/><FilterOption id="2871" count="192" label="irinotecan"/><FilterOption id="3072" count="160" label="etoposide phosphate"/><FilterOption id="13022" count="151" label="epirubicin"/><FilterOption id="6386" count="151" label="trastuzumab"/><FilterOption id="4510" count="138" label="tacrolimus"/><FilterOption id="10252" count="120" label="insulin glargine"/><FilterOption id="6408" count="113" label="vinorelbine"/><FilterOption id="29016" count="110" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="3669" count="102" label="mycophenolate mofetil"/><FilterOption id="4529" count="101" label="temozolomide"/><FilterOption id="29831" count="94" label="sorafenib"/><FilterOption id="11961" count="89" label="erlotinib"/><FilterOption id="2836" count="88" label="clopidogrel"/><FilterOption id="2807" count="84" label="atorvastatin"/><FilterOption id="44314" count="81" label="tamoxifen"/><FilterOption id="10084" count="80" label="tegafur + gimeracil + oteracil potassium"/><FilterOption id="10388" count="79" label="cetuximab"/><FilterOption id="7934" count="79" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="2784" count="74" label="letrozole"/><FilterOption id="3750" count="74" label="ondansetron"/><FilterOption id="14163" count="71" label="adalimumab"/><FilterOption id="6156" count="71" label="fludarabine"/><FilterOption id="48945" count="68" label="bupivacaine, AstraZeneca"/><FilterOption id="7286" count="67" label="goserelin acetate"/><FilterOption id="8165" count="67" label="tiotropium bromide"/><FilterOption id="27572" count="66" label="lenalidomide"/><FilterOption id="5267" count="66" label="leuprorelin acetate"/><FilterOption id="3130" count="65" label="filgrastim"/><FilterOption id="11460" count="64" label="imatinib"/><FilterOption id="21374" count="64" label="pegfilgrastim"/><FilterOption id="15954" count="60" label="bortezomib"/><FilterOption id="70667" count="60" label="pembrolizumab"/><FilterOption id="8832" count="59" label="glimepiride"/><FilterOption id="44305" count="58" label="omeprazole"/><FilterOption id="3321" count="57" label="anastrozole"/><FilterOption id="44375" count="57" label="warfarin"/><FilterOption id="44279" count="56" label="amoxicillin"/><FilterOption id="44403" count="56" label="lidocaine"/><FilterOption id="3313" count="54" label="fulvestrant"/><FilterOption id="11603" count="54" label="gefitinib"/><FilterOption id="54804" count="53" label="nivolumab"/><FilterOption id="13486" count="51" label="entecavir"/><FilterOption id="44308" count="51" label="propofol, AstraZeneca/Fresenius"/><FilterOption id="3081" count="50" label="exemestane"/><FilterOption id="14493" count="49" label="tenofovir disoproxil fumarate"/><FilterOption id="4577" count="49" label="topotecan"/><FilterOption id="2829" count="48" label="clarithromycin"/><FilterOption id="3353" count="48" label="insulin lispro"/><FilterOption id="44499" count="47" label="sitagliptin"/><FilterOption id="2500" count="46" label="amlodipine"/><FilterOption id="12978" count="46" label="moxifloxacin"/><FilterOption id="44303" count="45" label="midazolam hydrochloride"/><FilterOption id="12973" count="45" label="sunitinib"/><FilterOption id="12135" count="44" label="celecoxib"/><FilterOption id="14336" count="43" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"/><FilterOption id="37370" count="42" label="azacitidine"/><FilterOption id="16026" count="42" label="esomeprazole"/><FilterOption id="4271" count="42" label="ropivacaine"/><FilterOption id="4513" count="42" label="tamsulosin hydrochloride"/><FilterOption id="47000" count="41" label="bendamustine"/><FilterOption id="6140" count="41" label="formoterol"/><FilterOption id="11519" count="40" label="mitoxantrone"/><FilterOption id="10411" count="39" label="insulin aspart"/><FilterOption id="23625" count="39" label="peginterferon alfa-2a"/><FilterOption id="12150" count="39" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="44409" count="38" label="Fluzone"/><FilterOption id="3474" count="38" label="lamivudine"/><FilterOption id="5999" count="37" label="ciclosporin, Novartis"/><FilterOption id="13928" count="37" label="enoxaparin sodium"/><FilterOption id="3311" count="36" label="bicalutamide"/><FilterOption id="3492" count="36" label="levofloxacin"/><FilterOption id="44312" count="36" label="salmeterol"/><FilterOption id="44401" count="36" label="vancomycin"/><FilterOption id="36630" count="35" label="ipilimumab"/><FilterOption id="44313" count="35" label="simvastatin"/><FilterOption id="10309" count="34" label="abiraterone"/><FilterOption id="13340" count="33" label="everolimus"/><FilterOption id="5148" count="33" label="liraglutide"/><FilterOption id="4126" count="33" label="pioglitazone"/><FilterOption id="49219" count="33" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="2765" count="33" label="zoledronic acid"/><FilterOption id="10172" count="32" label="efavirenz"/><FilterOption id="6104" count="32" label="lansoprazole"/><FilterOption id="12420" count="32" label="rosuvastatin"/><FilterOption id="3159" count="31" label="fluticasone propionate"/><FilterOption id="4567" count="30" label="etanercept"/><FilterOption id="5369" count="30" label="ribavirin"/><FilterOption id="5356" count="30" label="sevoflurane"/><FilterOption id="7310" count="29" label="ritonavir"/><FilterOption id="7413" count="27" label="darbepoetin alfa"/></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="10704" count="5132" label="Solid tumor - Subjects with Co-morbid Conditions"/><FilterOption id="4702" count="4846" label="Lymphoma - Subjects with Co-morbid Conditions"/><FilterOption id="6554" count="4822" label="Leukemia - Subjects with Co-morbid Conditions"/><FilterOption id="5132" count="4716" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5365" count="4416" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="5193" count="4355" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6258" count="4349" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="20282" count="4142" label="Lung tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="10881" count="3969" label="Cancer supportive care - Subjects with Co-morbid Conditions"/><FilterOption id="6294" count="3761" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5125" count="3591" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"/><FilterOption id="6272" count="3551" label="Breast tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="925" count="3429" label="Non-insulin dependent diabetes - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6252" count="3344" label="Breast tumor - Subjects with Co-morbid Conditions"/><FilterOption id="5291" count="3313" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"/><FilterOption id="6393" count="3180" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"/><FilterOption id="5282" count="3169" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"/><FilterOption id="5270" count="3167" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="5349" count="3141" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"/><FilterOption id="6253" count="3138" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"/><FilterOption id="20281" count="3120" label="Lung tumor - Subjects with Co-morbid Conditions"/><FilterOption id="5139" count="3104" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="6328" count="3086" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"/><FilterOption id="20124" count="3070" label="Pain - Immunocompromised Subjects - Subjects immunocompromised with cancer/malignancy"/><FilterOption id="6377" count="2938" label="Breast tumor - Subjects with history of/planned radiotherapy"/><FilterOption id="5128" count="2922" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"/><FilterOption id="5744" count="2751" label="Head and neck tumor - Subjects with Co-morbid Conditions"/><FilterOption id="20114" count="2731" label="Pain - Subjects with Co-morbid Conditions - Subjects co-morbid with CNS disorders/diseases"/><FilterOption id="5841" count="2687" label="Colorectal tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="6247" count="2672" label="Breast tumor - Subjects by disease severity - Subjects with Brain/Leptomeningeal metastases"/><FilterOption id="4692" count="2643" label="Lymphoma - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5856" count="2599" label="Colorectal tumor - Subjects co-morbid with inflammatory disorders"/><FilterOption id="5864" count="2593" label="Colorectal tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="15723" count="2572" label="Stem cell transplantation - Subjects with Co-morbid Conditions - Subjects with history of infections"/><FilterOption id="5879" count="2527" label="Colorectal tumor - Subjects with Co-morbid Conditions"/><FilterOption id="5962" count="2519" label="Colorectal tumor - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="4769" count="2487" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="9412" count="2479" label="Hepatobiliary system tumor - Subjects with Co-morbid Conditions"/><FilterOption id="10761" count="2467" label="Solid tumor - Subjects with Evidence of Metastasis - Subjects with brain/CNS metastasis"/><FilterOption id="10739" count="2339" label="Solid tumor - Subjects with History of Other Non Anti-cancer Drugs/Agents"/><FilterOption id="6331" count="2307" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="10378" count="2306" label="Pancreas tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6756" count="2305" label="Lung tumor - Subjects with History of/Scheduled for Other Cancer Therapies"/><FilterOption id="5149" count="2299" label="Lung tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="10916" count="2291" label="Cancer supportive care - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="5345" count="2284" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="6534" count="2276" label="Leukemia - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="4918" count="2271" label="Prostate tumor - Subjects with Co-morbid Conditions"/><FilterOption id="6065" count="2249" label="Multiple myeloma - Subjects with Co-morbid Conditions"/><FilterOption id="4864" count="2203" label="Prostate tumor - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5236" count="2199" label="Lung tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"/><FilterOption id="4909" count="2173" label="Prostate tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="10736" count="2169" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="9484" count="2137" label="Stomach tumor - Subjects with Co-morbid Conditions"/><FilterOption id="10732" count="2135" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="17533" count="2127" label="End stage renal disease - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="5344" count="2093" label="Lung tumor - Protocol Specified Other Exclusion Criteria"/><FilterOption id="9810" count="2082" label="Ovary tumor - Subjects with Co-morbid Conditions"/><FilterOption id="20115" count="2048" label="Pain - Subjects co-morbid with cardiovascular diseases/disorders"/><FilterOption id="5826" count="2046" label="Colorectal tumor - Subjects with Metastatic Colorectal Cancer - Subjects with brain metastases or leptomeningeal carcinomatosis"/><FilterOption id="20290" count="1986" label="Breast tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/><FilterOption id="5949" count="1973" label="Colorectal tumor - Subjects with history of/scheduled to receive radiation therapy"/><FilterOption id="4810" count="1961" label="Lymphoma - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="10738" count="1957" label="Solid tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="5163" count="1951" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="5848" count="1947" label="Colorectal tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="6302" count="1945" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindication to any investigational agents"/><FilterOption id="20112" count="1938" label="Pain - Subjects with Co-morbid Conditions"/><FilterOption id="6261" count="1932" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hepatobiliary diseases/disorders"/><FilterOption id="6474" count="1916" label="Breast tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"/><FilterOption id="4762" count="1902" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subject with history of radiotherapy"/><FilterOption id="4968" count="1897" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects on prior/concurrent radiotherapy"/><FilterOption id="20123" count="1885" label="Pain - Subjects with Co-morbid Conditions - Subjects with infectious disorders/disease"/><FilterOption id="837" count="1880" label="Non-insulin dependent diabetes - Subjects co-morbid with renal disease/disorder"/><FilterOption id="5751" count="1875" label="Head and neck tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="10717" count="1827" label="Solid tumor - Subjects with Abnormal Organ Function - Subjects with abnormal/unacceptable cardiac function"/><FilterOption id="5934" count="1826" label="Colorectal tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="20182" count="1825" label="Pain - Protocol Specified Other Exclusion Criteria"/><FilterOption id="5176" count="1792" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with hematological disease/disorders"/><FilterOption id="4967" count="1788" label="Prostate tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="6660" count="1765" label="Leukemia - Subjects with History of Treatment with Non-chemotherapeutic Drugs"/><FilterOption id="6260" count="1743" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"/><FilterOption id="6767" count="1738" label="Lymphoma - Lymphoma Subjects with Advanced Disease - Subjects with central nervous system involvement of lymphoma"/><FilterOption id="12316" count="1732" label="Solid tumor - Subjects with History of/Active Malignancy/Cancer"/><FilterOption id="4783" count="1726" label="Lymphoma - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"/><FilterOption id="4975" count="1699" label="Prostate tumor - Subjects with history of/scheduled to receive therapy for other indication"/><FilterOption id="10900" count="1689" label="Cancer supportive care - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"/><FilterOption id="10641" count="1681" label="Central nervous system tumor - Subjects with Co-morbid Conditions"/><FilterOption id="5168" count="1681" label="Lung tumor - Subjects co-morbid with endocrine/metabolic diseases/disorders"/><FilterOption id="6618" count="1653" label="Leukemia - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"/><FilterOption id="17531" count="1604" label="End stage renal disease - Subjects co-morbid with infections"/><FilterOption id="5470" count="1600" label="Melanoma - Subjects co-morbid with inflammatory disorders"/><FilterOption id="5277" count="1597" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for biological therapy"/><FilterOption id="6259" count="1588" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"/><FilterOption id="5589" count="1560" label="Coronary artery disease - Immunocompromised Subjects - Subjects immunocompromised with cancer/malignancy"/><FilterOption id="5285" count="1552" label="Lung tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"/><FilterOption id="911" count="1547" label="Non-insulin dependent diabetes - Subjects co-morbid with hepatobiliary disorders/diseases"/><FilterOption id="5781" count="1539" label="Head and neck tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of radiotherapy"/><FilterOption id="9161" count="1528" label="Myelodysplastic syndrome - Subjects with Co-morbid Conditions"/><FilterOption id="6301" count="1520" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"/></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="100"><FilterOption count="322" label="201905"/><FilterOption count="311" label="201703"/><FilterOption count="304" label="201904"/><FilterOption count="302" label="201902"/><FilterOption count="301" label="201708"/><FilterOption count="297" label="201609"/><FilterOption count="290" label="201601"/><FilterOption count="289" label="201603"/><FilterOption count="289" label="201801"/><FilterOption count="287" label="201901"/><FilterOption count="286" label="201701"/><FilterOption count="285" label="201802"/><FilterOption count="284" label="201705"/><FilterOption count="283" label="201604"/><FilterOption count="283" label="201803"/><FilterOption count="277" label="201702"/><FilterOption count="276" label="201903"/><FilterOption count="274" label="201710"/><FilterOption count="274" label="201805"/><FilterOption count="269" label="201503"/><FilterOption count="268" label="201610"/><FilterOption count="267" label="201608"/><FilterOption count="267" label="201706"/><FilterOption count="267" label="201804"/><FilterOption count="263" label="201605"/><FilterOption count="262" label="201602"/><FilterOption count="258" label="201106"/><FilterOption count="257" label="201403"/><FilterOption count="257" label="201510"/><FilterOption count="257" label="201512"/><FilterOption count="257" label="201612"/><FilterOption count="256" label="201711"/><FilterOption count="253" label="201807"/><FilterOption count="252" label="201404"/><FilterOption count="252" label="201509"/><FilterOption count="247" label="201806"/><FilterOption count="247" label="201812"/><FilterOption count="243" label="201506"/><FilterOption count="242" label="201504"/><FilterOption count="242" label="201712"/><FilterOption count="241" label="201412"/><FilterOption count="240" label="200710"/><FilterOption count="240" label="201401"/><FilterOption count="240" label="201507"/><FilterOption count="239" label="201607"/><FilterOption count="239" label="201704"/><FilterOption count="239" label="201808"/><FilterOption count="238" label="201810"/><FilterOption count="235" label="201303"/><FilterOption count="232" label="201305"/><FilterOption count="232" label="201707"/><FilterOption count="231" label="201505"/><FilterOption count="229" label="201301"/><FilterOption count="223" label="201207"/><FilterOption count="223" label="201410"/><FilterOption count="223" label="201606"/><FilterOption count="223" label="201811"/><FilterOption count="221" label="201502"/><FilterOption count="220" label="201809"/><FilterOption count="219" label="201208"/><FilterOption count="219" label="201405"/><FilterOption count="219" label="201501"/><FilterOption count="219" label="201709"/><FilterOption count="219" label="201906"/><FilterOption count="217" label="201210"/><FilterOption count="217" label="201211"/><FilterOption count="216" label="201201"/><FilterOption count="215" label="201407"/><FilterOption count="213" label="201109"/><FilterOption count="213" label="201611"/><FilterOption count="209" label="201508"/><FilterOption count="209" label="201511"/><FilterOption count="208" label="201304"/><FilterOption count="208" label="201409"/><FilterOption count="203" label="201202"/><FilterOption count="203" label="201302"/><FilterOption count="203" label="201402"/><FilterOption count="203" label="201408"/><FilterOption count="202" label="201108"/><FilterOption count="202" label="201312"/><FilterOption count="201" label="201310"/><FilterOption count="200" label="201406"/><FilterOption count="199" label="201212"/><FilterOption count="199" label="201309"/><FilterOption count="197" label="200901"/><FilterOption count="197" label="201103"/><FilterOption count="197" label="201206"/><FilterOption count="195" label="201307"/><FilterOption count="194" label="201204"/><FilterOption count="193" label="201102"/><FilterOption count="193" label="201203"/><FilterOption count="192" label="200902"/><FilterOption count="192" label="201411"/><FilterOption count="190" label="200909"/><FilterOption count="190" label="201205"/><FilterOption count="189" label="201005"/><FilterOption count="188" label="201306"/><FilterOption count="187" label="201001"/><FilterOption count="187" label="201007"/><FilterOption count="185" label="201311"/></Filter><Filter label="Funder Type" name="trialFunderType" total="5"><FilterOption id="CMP" count="70443" label="Company"/><FilterOption id="ACA" count="66205" label="Academic"/><FilterOption id="GOV" count="18598" label="Government"/><FilterOption id="OTH" count="5437" label="Others"/><FilterOption id="NGO" count="3999" label="Non-Government"/></Filter><Filter label="Trial Region" name="trialRegions" total="11"><FilterOption id="USCA" count="53150" label="US &amp; Canada"/><FilterOption id="EAPO" count="32861" label="East Asia &amp; Pacific Ocean"/><FilterOption id="NSWE" count="32244" label="Northern, Southern &amp; Western Europe"/><FilterOption id="EEUR" count="7512" label="Eastern Europe"/><FilterOption id="MENA" count="5691" label="Middle East &amp; North Africa"/><FilterOption id="AUNZ" count="5640" label="Australia &amp; New Zealand"/><FilterOption id="SOAM" count="3795" label="South America"/><FilterOption id="SOCA" count="3770" label="Southern &amp; Central Asia"/><FilterOption id="CAAC" count="3417" label="Central America &amp; Caribbean"/><FilterOption id="CSAF" count="1762" label="Central &amp; Southern Africa"/><FilterOption id="INDO" count="8" label="Indian Ocean"/></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="100"><FilterOption id="3617" count="5433" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="3634" count="4841" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"/><FilterOption id="7961" count="4257" label="Solid tumor - Subjects with Advanced/Metastatic Solid Tumors"/><FilterOption id="3954" count="4232" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"/><FilterOption id="10295" count="3571" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"/><FilterOption id="3824" count="3457" label="Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer"/><FilterOption id="7967" count="3321" label="Solid tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3623" count="3075" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"/><FilterOption id="3977" count="2763" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="3530" count="2718" label="Lymphoma - Subjects with Treatment Resistant Disease"/><FilterOption id="3525" count="2573" label="Lymphoma - Subjects with Relapse/Recurrent Lymphoma"/><FilterOption id="9010" count="2475" label="Cancer supportive care - Solid tumor subjects for supportive care"/><FilterOption id="3489" count="2441" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"/><FilterOption id="3564" count="2380" label="Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer"/><FilterOption id="11487" count="2197" label="Stem cell transplantation - Subjects with H/O Hematological Malignancies Indicated for SCT"/><FilterOption id="3814" count="2168" label="Colorectal tumor - Subjects with Colon Cancer"/><FilterOption id="3952" count="2066" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"/><FilterOption id="3813" count="2057" label="Colorectal tumor - Subjects with Rectal Cancer"/><FilterOption id="3975" count="1938" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="12053" count="1938" label="Lung tumor - Treatment Naive Subjects"/><FilterOption id="3965" count="1922" label="Breast tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3565" count="1891" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"/><FilterOption id="4003" count="1871" label="Leukemia - Subjects with Relapsed/Recurrent Leukemia"/><FilterOption id="3650" count="1843" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"/><FilterOption id="10714" count="1835" label="Stem cell transplantation - Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)"/><FilterOption id="3667" count="1811" label="Melanoma - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3647" count="1810" label="Lung tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="10713" count="1801" label="Stem cell transplantation - Subjects with History of/Indicated for Allogenic Stem Cell Transplantation(SCT)"/><FilterOption id="3490" count="1745" label="Lymphoma - Subjects with T Cell Non Hodgkin's Lymphoma"/><FilterOption id="12018" count="1718" label="Prostate tumor - Subjects with adenocarcinoma of prostate"/><FilterOption id="3999" count="1689" label="Leukemia - Subjects with Treatment Resistant Disease"/><FilterOption id="3944" count="1682" label="Breast tumor - Subjects with Stage II Breast Cancer"/><FilterOption id="3979" count="1662" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"/><FilterOption id="3778" count="1650" label="Head and neck tumor - Subjects with Specific Histological Sub-type of HNC - Subjects with squamous cell carcinoma"/><FilterOption id="145" count="1591" label="Non-insulin dependent diabetes - Subjects with Moderate Glycemic Control"/><FilterOption id="3680" count="1552" label="Melanoma - Subjects with Stage IV Melanoma"/><FilterOption id="3937" count="1551" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"/><FilterOption id="8073" count="1545" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"/><FilterOption id="7126" count="1535" label="HIV infection - Subjects with HIV Infection - Subjects with HIV-1 Infection"/><FilterOption id="3586" count="1510" label="Prostate tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="3502" count="1498" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Aggressive (high grade) Lymphoma"/><FilterOption id="3950" count="1464" label="Breast tumor - Subjects with Early Stage Breast Cancer"/><FilterOption id="3936" count="1452" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"/><FilterOption id="3774" count="1439" label="Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer"/><FilterOption id="3931" count="1428" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"/><FilterOption id="3980" count="1424" label="Leukemia - Subjects with Chronic Lymphocytic Leukemia (CLL)"/><FilterOption id="10712" count="1415" label="Stem cell transplantation - Subjects with History of/Indicated for Autologous Stem Cell Transplantation(SCT)"/><FilterOption id="8010" count="1410" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"/><FilterOption id="3500" count="1389" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Indolent (slow-growing, low grade) Lymphoma"/><FilterOption id="3976" count="1388" label="Leukemia - Subjects with Chronic Leukemia Unspecified Type"/><FilterOption id="3945" count="1373" label="Breast tumor - Subjects with Stage III Breast Cancer"/><FilterOption id="3583" count="1347" label="Prostate tumor - Subjects with Castrate Resistant Prostate Cancer"/><FilterOption id="9624" count="1340" label="Central nervous system tumor - Subjects with Brain Tumors"/><FilterOption id="103" count="1313" label="Non-insulin dependent diabetes - Subjects with Poor/Inadequate Glycemic Control"/><FilterOption id="3978" count="1293" label="Leukemia - Subjects with Chronic Myeloid Leukemia (CML)"/><FilterOption id="3966" count="1282" label="Breast tumor - Subjects with Relapsed/Recurrent Breast cancer"/><FilterOption id="3637" count="1258" label="Lung tumor - Subjects with Unresectable/In-operable Lung Cancer"/><FilterOption id="3472" count="1223" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with diffuse large B cell lymphoma"/><FilterOption id="9632" count="1212" label="Central nervous system tumor - Subjects with Gliomas"/><FilterOption id="7415" count="1192" label="Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma"/><FilterOption id="3775" count="1164" label="Head and neck tumor - Subjects with Locally Advanced Head and Neck Cancer"/><FilterOption id="8754" count="1155" label="Myeloproliferative disorder - Subjects with Chronic Myelogenous Leukemia"/><FilterOption id="11424" count="1155" label="Pancreas tumor - Subjects with Adenocarcinoma of Pancreas"/><FilterOption id="3943" count="1151" label="Breast tumor - Subjects with Stage I Breast Cancer"/><FilterOption id="3926" count="1144" label="Multiple myeloma - Subjects with Relapsed/Recurrent Multiple Myeloma"/><FilterOption id="3681" count="1138" label="Melanoma - Subjects with Evidence of Metastasis"/><FilterOption id="3467" count="1130" label="Lymphoma - Subjects with Hodgkin's Lymphoma"/><FilterOption id="10289" count="1108" label="Head and neck tumor - Subjects with TNM Stage III Head and Neck Cancer"/><FilterOption id="3923" count="1105" label="Multiple myeloma - Subjects with Treatment Resistant Disease"/><FilterOption id="8062" count="1098" label="Hepatobiliary system tumor - Subjects with Unresectable Hepato-biliary Cancer"/><FilterOption id="7877" count="1094" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"/><FilterOption id="3860" count="1074" label="Colorectal tumor - Subjects with Treatment Resistant Disease"/><FilterOption id="7411" count="1059" label="Renal cell carcinoma - Subjects with TNM Stage IV Renal Cell Carcinoma"/><FilterOption id="8426" count="1041" label="Pain - Subjects with Cancer Related Pain"/><FilterOption id="7879" count="1040" label="Ovary tumor - Subjects with Ovarian Epithelial Tumor"/><FilterOption id="7966" count="1026" label="Solid tumor - Subjects with Relapsed/Recurrent Solid Tumors"/><FilterOption id="7894" count="1020" label="Ovary tumor - Subjects with Recurrent or Persistent Ovarian Cancer"/><FilterOption id="3473" count="1018" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma - Subjects with follicular lymphoma"/><FilterOption id="102" count="1007" label="Non-insulin dependent diabetes - Subjects with Good Glycemic Control"/><FilterOption id="3501" count="998" label="Lymphoma - Subjects with Specific Grade of Lymphoma - Subjects with Moderately Aggressive (intermediate grade) Lymphoma"/><FilterOption id="3955" count="983" label="Breast tumor - Subjects with Resectable/Operable Breast Cancer"/><FilterOption id="8424" count="964" label="Pain - Subjects with Post-Operative Pain"/><FilterOption id="3638" count="953" label="Lung tumor - Subjects with Resectable/Operable Lung Cancer"/><FilterOption id="11612" count="949" label="Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects"/><FilterOption id="3498" count="946" label="Lymphoma - Subjects with specific Ann Arbor stage - Subjects with Ann Arbor Stage IV Lymphoma"/><FilterOption id="12009" count="942" label="Prostate tumor - Subjects With Prostate Cancer"/><FilterOption id="7895" count="938" label="Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects"/><FilterOption id="10129" count="936" label="Lung tumor - Subjects with EGFR Positive Lung Cancer"/><FilterOption id="16345" count="922" label="Hepatobiliary system tumor - Subjects with specific disease - Subjects with hepatocellular carcinoma"/><FilterOption id="8075" count="915" label="Pancreas tumor - Subjects with Unresectable Pancreatic Cancer"/><FilterOption id="8059" count="908" label="Hepatobiliary system tumor - Subjects with Advanced/Metastatic Primary Liver Cancer"/><FilterOption id="7918" count="891" label="Ovary tumor - Advanced Ovarian Cancer Subjects - Stage IV or metastatic ovarian cancer subjects"/><FilterOption id="7962" count="891" label="Solid tumor - Subjects with Unresectable Solid Tumors"/><FilterOption id="3973" count="886" label="Leukemia - Subjects at risk of developing disease"/><FilterOption id="3823" count="885" label="Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer"/><FilterOption id="3932" count="877" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"/><FilterOption id="8387" count="875" label="Pain - Subjects with Chronic Pain"/><FilterOption id="8998" count="869" label="Cancer supportive care - Other Chemotherapy Induced Adverse Events"/><FilterOption id="3559" count="868" label="Prostate tumor - Subjects with Early Stage/Localized Prostate Cancer"/><FilterOption id="7988" count="861" label="Glioblastoma - Subjects with Relapse/Recurrent Glioblastoma Multiforme"/></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="100"><FilterOption count="2134" label="201912"/><FilterOption count="1355" label="201812"/><FilterOption count="1233" label="202012"/><FilterOption count="1143" label="201712"/><FilterOption count="1116" label="201906"/><FilterOption count="904" label="201612"/><FilterOption count="826" label="201909"/><FilterOption count="796" label="202006"/><FilterOption count="781" label="201907"/><FilterOption count="745" label="202001"/><FilterOption count="737" label="201512"/><FilterOption count="720" label="201908"/><FilterOption count="716" label="201910"/><FilterOption count="673" label="201412"/><FilterOption count="658" label="202003"/><FilterOption count="645" label="201706"/><FilterOption count="622" label="201312"/><FilterOption count="620" label="201806"/><FilterOption count="599" label="201903"/><FilterOption count="596" label="201212"/><FilterOption count="595" label="201807"/><FilterOption count="585" label="202112"/><FilterOption count="574" label="201809"/><FilterOption count="574" label="201911"/><FilterOption count="572" label="201904"/><FilterOption count="570" label="201905"/><FilterOption count="558" label="202004"/><FilterOption count="553" label="201901"/><FilterOption count="539" label="201808"/><FilterOption count="538" label="201805"/><FilterOption count="536" label="202002"/><FilterOption count="533" label="202007"/><FilterOption count="529" label="201801"/><FilterOption count="528" label="201606"/><FilterOption count="528" label="202009"/><FilterOption count="525" label="201810"/><FilterOption count="524" label="201803"/><FilterOption count="520" label="201112"/><FilterOption count="514" label="202005"/><FilterOption count="512" label="201709"/><FilterOption count="509" label="201701"/><FilterOption count="504" label="201707"/><FilterOption count="498" label="201811"/><FilterOption count="486" label="201703"/><FilterOption count="484" label="201012"/><FilterOption count="477" label="201506"/><FilterOption count="466" label="201804"/><FilterOption count="460" label="201710"/><FilterOption count="456" label="200912"/><FilterOption count="454" label="201603"/><FilterOption count="448" label="202008"/><FilterOption count="447" label="201708"/><FilterOption count="445" label="202106"/><FilterOption count="444" label="201705"/><FilterOption count="439" label="201704"/><FilterOption count="431" label="201605"/><FilterOption count="429" label="201601"/><FilterOption count="427" label="201607"/><FilterOption count="427" label="201711"/><FilterOption count="426" label="201608"/><FilterOption count="422" label="201609"/><FilterOption count="419" label="201306"/><FilterOption count="414" label="201610"/><FilterOption count="410" label="201406"/><FilterOption count="410" label="201902"/><FilterOption count="409" label="201501"/><FilterOption count="408" label="200812"/><FilterOption count="407" label="201802"/><FilterOption count="407" label="202010"/><FilterOption count="404" label="201604"/><FilterOption count="404" label="201611"/><FilterOption count="401" label="201206"/><FilterOption count="399" label="201507"/><FilterOption count="389" label="201508"/><FilterOption count="389" label="201702"/><FilterOption count="387" label="201509"/><FilterOption count="379" label="201301"/><FilterOption count="379" label="201410"/><FilterOption count="377" label="201404"/><FilterOption count="376" label="201503"/><FilterOption count="375" label="201510"/><FilterOption count="374" label="202101"/><FilterOption count="370" label="201303"/><FilterOption count="370" label="201505"/><FilterOption count="368" label="201409"/><FilterOption count="367" label="201305"/><FilterOption count="366" label="202103"/><FilterOption count="362" label="201006"/><FilterOption count="362" label="202011"/><FilterOption count="361" label="201407"/><FilterOption count="359" label="201109"/><FilterOption count="358" label="201209"/><FilterOption count="358" label="201210"/><FilterOption count="356" label="201405"/><FilterOption count="354" label="201207"/><FilterOption count="353" label="201307"/><FilterOption count="353" label="201511"/><FilterOption count="353" label="201602"/><FilterOption count="352" label="201408"/><FilterOption count="350" label="201105"/></Filter><Filter label="Trial Country" name="trialCountries" total="100"><FilterOption id="US" count="50459" label="US"/><FilterOption id="CN" count="13453" label="China"/><FilterOption id="JP" count="12308" label="Japan"/><FilterOption id="DE" count="9939" label="Germany"/><FilterOption id="GB" count="9547" label="UK"/><FilterOption id="CA" count="8607" label="Canada"/><FilterOption id="FR" count="8600" label="France"/><FilterOption id="IT" count="7615" label="Italy"/><FilterOption id="ES" count="7152" label="Spain"/><FilterOption id="NL" count="5548" label="Netherlands"/><FilterOption id="AU" count="5338" label="Australia"/><FilterOption id="KR" count="5182" label="South Korea"/><FilterOption id="BE" count="4833" label="Belgium"/><FilterOption id="PL" count="3876" label="Poland"/><FilterOption id="IN" count="3558" label="India"/><FilterOption id="RU" count="3271" label="Russian Federation"/><FilterOption id="DK" count="3039" label="Denmark"/><FilterOption id="AT" count="2947" label="Austria"/><FilterOption id="HU" count="2828" label="Hungary"/><FilterOption id="SE" count="2740" label="Sweden"/><FilterOption id="TW" count="2729" label="Taiwan"/><FilterOption id="CZ" count="2728" label="Czech Republic"/><FilterOption id="BR" count="2553" label="Brazil"/><FilterOption id="IL" count="2537" label="Israel"/><FilterOption id="CH" count="2452" label="Switzerland"/><FilterOption id="MX" count="2029" label="Mexico"/><FilterOption id="AR" count="1694" label="Argentina"/><FilterOption id="GR" count="1631" label="Greece"/><FilterOption id="RO" count="1538" label="Romania"/><FilterOption id="ZA" count="1503" label="South Africa"/><FilterOption id="FI" count="1470" label="Finland"/><FilterOption id="HK" count="1428" label="Hong Kong"/><FilterOption id="IR" count="1402" label="Iran"/><FilterOption id="TR" count="1388" label="Turkey"/><FilterOption id="NO" count="1379" label="Norway"/><FilterOption id="NZ" count="1376" label="New Zealand"/><FilterOption id="PR" count="1305" label="Puerto Rico"/><FilterOption id="BG" count="1296" label="Bulgaria"/><FilterOption id="SG" count="1268" label="Singapore"/><FilterOption id="TH" count="1257" label="Thailand"/><FilterOption id="UA" count="1249" label="Ukraine"/><FilterOption id="PT" count="1218" label="Portugal"/><FilterOption id="SK" count="1171" label="Slovakia"/><FilterOption id="IE" count="1091" label="Ireland"/><FilterOption id="CL" count="865" label="Chile"/><FilterOption id="X5" count="809" label="Europe"/><FilterOption id="PE" count="728" label="Peru"/><FilterOption id="LT" count="707" label="Lithuania"/><FilterOption id="CO" count="697" label="Colombia"/><FilterOption id="MY" count="685" label="Malaysia"/><FilterOption id="RS" count="672" label="Serbia"/><FilterOption id="EG" count="663" label="Egypt"/><FilterOption id="EE" count="596" label="Estonia"/><FilterOption id="LV" count="596" label="Latvia"/><FilterOption id="HR" count="595" label="Croatia"/><FilterOption id="PH" count="546" label="Philippines"/><FilterOption id="SI" count="383" label="Slovenia"/><FilterOption id="XD" count="254" label="North America"/><FilterOption id="GE" count="229" label="Georgia"/><FilterOption id="SA" count="228" label="Saudi Arabia"/><FilterOption id="X2" count="208" label="Asia"/><FilterOption id="CU" count="190" label="Cuba"/><FilterOption id="VN" count="183" label="Vietnam"/><FilterOption id="LB" count="181" label="Lebanon"/><FilterOption id="BY" count="180" label="Belarus"/><FilterOption id="GT" count="164" label="Guatemala"/><FilterOption id="BA" count="147" label="Bosnia and Herzegovina"/><FilterOption id="PA" count="133" label="Panama"/><FilterOption id="ID" count="123" label="Indonesia"/><FilterOption id="PK" count="110" label="Pakistan"/><FilterOption id="TN" count="100" label="Tunisia"/><FilterOption id="CR" count="99" label="Costa Rica"/><FilterOption id="UG" count="96" label="Uganda"/><FilterOption id="MD" count="94" label="Moldova, Republic of"/><FilterOption id="EU" count="93" label="EU"/><FilterOption id="IS" count="92" label="Iceland"/><FilterOption id="VE" count="87" label="Venezuela"/><FilterOption id="JO" count="81" label="Jordan"/><FilterOption id="KP" count="73" label="North Korea"/><FilterOption id="XE" count="73" label="South America"/><FilterOption id="DO" count="72" label="Dominican Republic"/><FilterOption id="LU" count="72" label="Luxembourg"/><FilterOption id="AE" count="72" label="United Arab Emirates"/><FilterOption id="TZ" count="66" label="Tanzania"/><FilterOption id="BD" count="64" label="Bangladesh"/><FilterOption id="KE" count="62" label="Kenya"/><FilterOption id="MK" count="62" label="Macedonia, The Former Yugoslav Republic of"/><FilterOption id="EC" count="58" label="Ecuador"/><FilterOption id="MA" count="55" label="Morocco"/><FilterOption id="DZ" count="48" label="Algeria"/><FilterOption id="LK" count="47" label="Sri Lanka"/><FilterOption id="KZ" count="44" label="Kazakhstan"/><FilterOption id="UY" count="38" label="Uruguay"/><FilterOption id="CY" count="36" label="Cyprus"/><FilterOption id="ZW" count="35" label="Zimbabwe"/><FilterOption id="MW" count="34" label="Malawi"/><FilterOption id="KW" count="31" label="Kuwait"/><FilterOption id="ME" count="31" label="Montenegro"/><FilterOption id="QA" count="31" label="Qatar"/><FilterOption id="XW" count="25" label="Western Europe"/></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="19"><FilterOption id="EAMAA" count="107533" label="Middle-aged Adults (45-64 yrs)"/><FilterOption id="EAYAD" count="107476" label="Young Adults (18-44 yrs)"/><FilterOption id="EAAAD" count="99865" label="Aged Adults (65-79 yrs)"/><FilterOption id="EAELD" count="74963" label="Elderly Adults (80 and over)"/><FilterOption id="EGFEM" count="13578" label="Female"/><FilterOption id="EVHVA" count="10669" label="Healthy volunteers accepted"/><FilterOption id="EAADL" count="10545" label="Adolescents (13-17 yrs)"/><FilterOption id="EACHI" count="7959" label="Children (6-12 yrs)"/><FilterOption id="EGMAL" count="7139" label="Male"/><FilterOption id="EAPRE" count="5918" label="Preschool Children (2-5 yrs)"/><FilterOption id="EAINF" count="4209" label="Infants (6-23 months)"/><FilterOption id="EANEW" count="2865" label="Newborn Infants (up to 5 months)"/><FilterOption id="EVHVO" count="2219" label="Healthy volunteers only"/><FilterOption id="ECASI" count="2173" label="Asian Ancestry"/><FilterOption id="ECJAP" count="1712" label="Japanese Ancestry"/><FilterOption id="ECEUR" count="554" label="European Ancestry"/><FilterOption id="ECAFR" count="303" label="African Ancestry"/><FilterOption id="ECNAM" count="42" label="Native American Ancestry"/><FilterOption id="ECOCE" count="10" label="Oceanic Ancestry"/></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="29"><FilterOption id="SSTINV" count="117736" label="Interventional"/><FilterOption id="SIPTRE" count="105227" label="Treatment"/><FilterOption id="SIMOPN" count="68422" label="Open Label"/><FilterOption id="SIARND" count="57308" label="Randomized"/><FilterOption id="SISPRL" count="49123" label="Parallel Assignment"/><FilterOption id="SISSNG" count="38906" label="Single Group Assignment"/><FilterOption id="SIMMBD" count="26297" label="Multiple Blind"/><FilterOption id="SIANON" count="23751" label="Non-Randomized"/><FilterOption id="SICPLC" count="23190" label="Placebo Control"/><FilterOption id="SICACT" count="18244" label="Active Control"/><FilterOption id="SSTOBS" count="14340" label="Observational"/><FilterOption id="SICNOC" count="10107" label="No Control"/><FilterOption id="SOTPRO" count="8025" label="Prospective"/><FilterOption id="SIPPRE" count="7811" label="Prevention"/><FilterOption id="SOSCOH" count="6447" label="Cohort"/><FilterOption id="SISXOV" count="5259" label="Crossover Assignment"/><FilterOption id="SIMSBD" count="4982" label="Single Blind"/><FilterOption id="SOTRET" count="4403" label="Retrospective"/><FilterOption id="SIPDIA" count="3685" label="Diagnosis"/><FilterOption id="SOSCSC" count="2041" label="Case Control"/><FilterOption id="SICHST" count="1583" label="Historical Control"/><FilterOption id="SODXSC" count="1073" label="Cross-sectional"/><FilterOption id="SISFCT" count="926" label="Factorial Assignment"/><FilterOption id="SICDSC" count="871" label="Dose Comparison"/><FilterOption id="SODLNG" count="488" label="Longitudinal"/><FilterOption id="SOSDEF" count="130" label="Defined Population"/><FilterOption id="SISEAA" count="71" label="Expanded Access Assignment"/><FilterOption id="SOSRND" count="9" label="Random Sample"/><FilterOption id="SOSCON" count="8" label="Convenience Sample"/></Filter><Filter label="Trial Source" name="trialSources" total="3"><FilterOption id="CTGOV" count="58703" label="ClinicalTrials.gov only"/><FilterOption id="CTGOVOTHERS" count="31682" label="ClinicalTrials.gov and others"/><FilterOption id="OTHERS" count="28433" label="Others only"/></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="100"><FilterOption id="1545" count="52604" label="Anticancer"/><FilterOption id="62255" count="17250" label="Anticancer protein kinase inhibitor"/><FilterOption id="2953" count="17192" label="Anti-inflammatory"/><FilterOption id="55685" count="15633" label="Anticancer monoclonal antibody"/><FilterOption id="767" count="13890" label="Cell cycle inhibitor"/><FilterOption id="140" count="11215" label="DNA synthesis inhibitor"/><FilterOption id="61" count="11199" label="Angiogenesis inhibitor"/><FilterOption id="1589" count="10503" label="Apoptosis stimulator"/><FilterOption id="991" count="10452" label="Antiviral"/><FilterOption id="50" count="10318" label="Anticancer alkylating agent"/><FilterOption id="1569" count="10291" label="Anticancer antimetabolite"/><FilterOption id="393" count="6942" label="Immunostimulant"/><FilterOption id="7293" count="6382" label="Synergist"/><FilterOption id="7761" count="5700" label="T-lymphocyte stimulator"/><FilterOption id="2575" count="5296" label="Microtubule inhibitor"/><FilterOption id="2946" count="4991" label="Analgesic"/><FilterOption id="2576" count="4734" label="Microtubule stabilizer"/><FilterOption id="2660" count="3726" label="Vasoprotectant"/><FilterOption id="396" count="3651" label="Immunosuppressant"/><FilterOption id="399" count="3559" label="Hypoglycemic agent"/><FilterOption id="59620" count="3394" label="Unspecified drug target"/><FilterOption id="1596" count="3300" label="Immunomodulator"/><FilterOption id="12379" count="2668" label="Therapeutic vaccine"/><FilterOption id="1594" count="2497" label="Antibacterial"/><FilterOption id="750" count="2305" label="DNA intercalator"/><FilterOption id="2657" count="2257" label="Antihypertensive"/><FilterOption id="15184" count="2246" label="Systemic antipsoriatic product"/><FilterOption id="12378" count="2020" label="Prophylactic vaccine"/><FilterOption id="1615" count="1922" label="Neuroprotectant"/><FilterOption id="610" count="1801" label="Hematopoietic stimulator"/><FilterOption id="70" count="1709" label="Anticonvulsant agent"/><FilterOption id="2947" count="1613" label="Antiparkinsonian"/><FilterOption id="382" count="1495" label="TNF alpha synthesis inhibitor"/><FilterOption id="7220" count="1475" label="Neoplasm diagnostic agent"/><FilterOption id="2941" count="1433" label="Antidepressant"/><FilterOption id="695" count="1356" label="Metastasis inhibitor"/><FilterOption id="664" count="1234" label="Fibrosuppressant"/><FilterOption id="2942" count="1169" label="Anxiolytic"/><FilterOption id="62254" count="1160" label="Anticancer hormone antagonist"/><FilterOption id="805" count="1128" label="Folate modulator"/><FilterOption id="7760" count="1128" label="T-lymphocyte inhibitor"/><FilterOption id="2970" count="1089" label="Anti-emetic"/><FilterOption id="71" count="1057" label="Antihypercholesterolemic agent"/><FilterOption id="2667" count="1051" label="Antiarteriosclerotic"/><FilterOption id="89" count="991" label="Bone resorption inhibitor"/><FilterOption id="72" count="971" label="Antihyperlipidemic agent"/><FilterOption id="12372" count="963" label="Protein subunit vaccine"/><FilterOption id="646" count="948" label="Bronchodilator"/><FilterOption id="1669" count="925" label="Local anesthetic"/><FilterOption id="2659" count="895" label="Cardioprotectant"/><FilterOption id="38206" count="888" label="Biguanide antidiabetic product"/><FilterOption id="2955" count="859" label="Non-steroidal anti-inflammatory"/><FilterOption id="388" count="859" label="Vasodilator"/><FilterOption id="5720" count="836" label="Radiodiagnostic"/><FilterOption id="1748" count="805" label="Fungicide"/><FilterOption id="15187" count="793" label="Systemic dermatological antibacterial product"/><FilterOption id="539" count="784" label="Immunotoxin"/><FilterOption id="38200" count="757" label="Acid pump inhibitor antiulcerant product"/><FilterOption id="747" count="731" label="HIV replication inhibitor"/><FilterOption id="312" count="728" label="Platelet aggregation inhibitor"/><FilterOption id="3272" count="719" label="Growth hormone release inhibitor"/><FilterOption id="4155" count="719" label="Imaging agent"/><FilterOption id="12596" count="702" label="Osteoclast inhibitor"/><FilterOption id="4790" count="700" label="Genetically engineered autologous cell therapy"/><FilterOption id="7212" count="695" label="Endocrine diagnostic agent"/><FilterOption id="659" count="689" label="Coagulation inhibitor"/><FilterOption id="449" count="684" label="Antiarrhythmic agent"/><FilterOption id="2943" count="662" label="Antipsychotic"/><FilterOption id="284" count="651" label="Nootropic agent"/><FilterOption id="1332" count="648" label="Gastrointestinal system agent"/><FilterOption id="5555" count="635" label="PET contrast agent"/><FilterOption id="1532" count="633" label="Viral replication inhibitor"/><FilterOption id="339" count="627" label="Protein synthesis inhibitor"/><FilterOption id="12370" count="626" label="Recombinant viral vector vaccine"/><FilterOption id="182" count="624" label="Gastric secretion inhibitor"/><FilterOption id="3189" count="574" label="Corticosteroid agonist"/><FilterOption id="2954" count="566" label="Steroidal anti-inflammatory"/><FilterOption id="1538" count="553" label="Bacterial protein synthesis inhibitor"/><FilterOption id="7213" count="552" label="Gastrointestinal diagnostic agent"/><FilterOption id="3" count="531" label="5-HT uptake inhibitor"/><FilterOption id="439" count="530" label="RNA synthesis inhibitor"/><FilterOption id="104" count="523" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="12367" count="509" label="Inactivated viral vaccine"/><FilterOption id="1552" count="502" label="Radioimmunotherapeutic"/><FilterOption id="1668" count="499" label="General anesthetic"/><FilterOption id="7210" count="489" label="Cardiovascular diagnostic agent"/><FilterOption id="38439" count="478" label="DPP IV inhibitor antidiabetic product"/><FilterOption id="7018" count="463" label="Antihypertriglyceridemic agent"/><FilterOption id="524" count="459" label="Adjuvant"/><FilterOption id="2638" count="459" label="Antiparasitic"/><FilterOption id="285" count="451" label="Norepinephrine uptake inhibitor"/><FilterOption id="463" count="444" label="Ribosome binding agent"/><FilterOption id="55686" count="441" label="Anticancer polyclonal antibody"/><FilterOption id="55684" count="434" label="Anticancer antibody"/><FilterOption id="15128" count="402" label="Ophthalmological agent"/><FilterOption id="1586" count="385" label="Anticancer chemosensitizer"/><FilterOption id="1540" count="385" label="Macrolide antibiotic"/><FilterOption id="7757" count="381" label="Natural killer cell stimulator"/><FilterOption id="1470" count="380" label="Respiratory system agent"/><FilterOption id="7211" count="376" label="CNS diagnostic agent"/></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="35938" label="Unspecified"/><FilterOption id="YES" count="7053" label="Yes"/><FilterOption id="NO" count="2658" label="No"/></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8481" count="2836" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8639" count="2368" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="15312" count="2292" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8489" count="2284" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8712" count="1957" label="Breast tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7538" count="1799" label="Lymphoma - Assessment of Overall Survival (OS)"/><FilterOption id="7879" count="1776" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="8998" count="1587" label="Breast tumor - Assessment of adverse events"/><FilterOption id="8151" count="1472" label="Colorectal tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7547" count="1453" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8663" count="1321" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8996" count="1311" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="19282" count="1276" label="Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8430" count="1229" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8719" count="1180" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8713" count="1124" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8640" count="1123" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="8505" count="1108" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="7679" count="1106" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="8163" count="1070" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="12048" count="1065" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7680" count="1016" label="Lymphoma - Assessment of adverse events"/><FilterOption id="8078" count="1004" label="Leukemia - Assessment of adverse events"/><FilterOption id="15287" count="999" label="Solid tumor - Assessment of adverse events"/><FilterOption id="7244" count="972" label="Head and neck tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7611" count="963" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of tumor response rate (Duration of response)"/><FilterOption id="19374" count="959" label="Cancer supportive care - Assessment of Safety and Tolerability"/><FilterOption id="15212" count="956" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="26044" count="953" label="Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication"/><FilterOption id="26033" count="950" label="Pain - Assessment of adverse events"/><FilterOption id="8077" count="944" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="9153" count="942" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="9122" count="923" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8187" count="915" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="13344" count="907" label="Pancreas tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7563" count="905" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="15207" count="905" label="Solid tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8522" count="903" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"/><FilterOption id="15285" count="895" label="Solid tumor - Assessment of Safety and Tolerability"/><FilterOption id="7569" count="858" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="19407" count="855" label="Cancer supportive care - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="7908" count="853" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="12148" count="846" label="Stomach tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7354" count="844" label="Multiple myeloma - Assessment of Overall Survival (OS)"/><FilterOption id="8563" count="840" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="19412" count="837" label="Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes"/><FilterOption id="1345" count="824" label="Non-insulin dependent diabetes - Glycemic Control Analysis - Assessment of fasting blood glucose"/><FilterOption id="8451" count="811" label="Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8508" count="801" label="Lung tumor - Assessment of Overall Response"/><FilterOption id="17405" count="801" label="Stem cell transplantation - Assessment of Overall Survival (OS)"/><FilterOption id="8514" count="783" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8513" count="777" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7891" count="755" label="Leukemia - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7981" count="738" label="Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8429" count="737" label="Colorectal tumor - Assessment of Safety and Tolerability"/><FilterOption id="8721" count="732" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8759" count="732" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="1503" count="728" label="Non-insulin dependent diabetes - Anthropometric Assessments - Assessment of body weight"/><FilterOption id="13352" count="721" label="Pancreas tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7190" count="721" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="15199" count="718" label="Solid tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7189" count="713" label="Prostate tumor - Assessment of Safety and Tolerability"/><FilterOption id="12051" count="704" label="Hepatobiliary system tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="7311" count="695" label="Head and neck tumor - Assessment of Safety and Tolerability"/><FilterOption id="19376" count="694" label="Cancer supportive care - Assessment of adverse events"/><FilterOption id="8523" count="694" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="8999" count="692" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="8738" count="680" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"/><FilterOption id="7312" count="679" label="Head and neck tumor - Assessment of adverse events"/><FilterOption id="1" count="674" label="Hypertension - Assessment of Blood Pressure (BP)"/><FilterOption id="7256" count="672" label="Head and neck tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="25874" count="671" label="Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]"/><FilterOption id="7045" count="670" label="Prostate tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7360" count="669" label="Multiple myeloma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="15318" count="668" label="Solid tumor - Protocol Specified Other Endpoints - Assessment of Anti-tumor Activity"/><FilterOption id="8726" count="659" label="Breast tumor - Assessment of Response Rates (RR)"/><FilterOption id="26827" count="658" label="Solid tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="6919" count="641" label="Melanoma - Assessment of Overall Survival (OS)"/><FilterOption id="7564" count="635" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7906" count="634" label="Leukemia - Assessment of Response Rates (RR)"/><FilterOption id="37159" count="628" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="12118" count="624" label="Hepatobiliary system tumor - Assessment of adverse events"/><FilterOption id="7921" count="622" label="Leukemia - Assessment of Disease Relapse/Recurrence"/><FilterOption id="7217" count="620" label="Prostate tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="2" count="618" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"/><FilterOption id="10828" count="618" label="Ovary tumor - Assessment of Overall Survival (OS)"/><FilterOption id="6940" count="612" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="8720" count="607" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="12151" count="607" label="Stomach tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="25959" count="606" label="Pain - Assessment of Functional Disability/Physical Function"/><FilterOption id="12209" count="606" label="Stomach tumor - Assessment of adverse events"/><FilterOption id="9147" count="592" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of toxicities"/><FilterOption id="8519" count="589" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)"/><FilterOption id="11950" count="588" label="Esophagus tumor - Assessment of Overall Survival (OS)"/><FilterOption id="10830" count="586" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8651" count="584" label="Lung tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="6924" count="574" label="Melanoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8524" count="573" label="Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"/><FilterOption id="7988" count="563" label="Leukemia - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="1358" count="555" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"/></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="100"><FilterOption id="1735" count="5305" label="Glucose"/><FilterOption id="12058" count="5169" label="Total body mass"/><FilterOption id="2586" count="4527" label="Blood pressure"/><FilterOption id="46" count="4424" label="C-reactive protein"/><FilterOption id="1211" count="3908" label="Alanine transaminase"/><FilterOption id="3" count="3896" label="HER2"/><FilterOption id="213" count="3760" label="Creatinine"/><FilterOption id="1904" count="3597" label="Heart rate"/><FilterOption id="2527" count="3344" label="Aspartate aminotransferase"/><FilterOption id="289" count="3215" label="Hemoglobin A, glycosylated"/><FilterOption id="2054" count="3211" label="Blood platelets"/><FilterOption id="1236" count="3166" label="Hemoglobin"/><FilterOption id="8" count="2892" label="Epidermal growth factor receptor"/><FilterOption id="1925" count="2874" label="Neutrophils"/><FilterOption id="38" count="2815" label="Prostate-specific antigen"/><FilterOption id="176" count="2676" label="Interleukin-6"/><FilterOption id="133" count="2544" label="Total cholesterol"/><FilterOption id="36136" count="2511" label="Cytokines"/><FilterOption id="217" count="2451" label="Triglycerides"/><FilterOption id="113" count="2446" label="Body Mass Index"/><FilterOption id="153" count="2321" label="High-density lipoprotein cholesterol"/><FilterOption id="125" count="2307" label="Leukocyte count"/><FilterOption id="152" count="2299" label="Low-density lipoprotein cholesterol"/><FilterOption id="808" count="2234" label="Insulin"/><FilterOption id="1857" count="2189" label="T-cell surface glycoprotein CD4"/><FilterOption id="46506" count="2186" label="T-Lymphocytes"/><FilterOption id="2387" count="2141" label="Bilirubin"/><FilterOption id="330" count="2131" label="Systolic blood pressure"/><FilterOption id="274" count="2069" label="Tumor necrosis factor"/><FilterOption id="1289" count="2026" label="Tumor mass"/><FilterOption id="118" count="1987" label="Albumin"/><FilterOption id="5" count="1931" label="Estrogen receptor"/><FilterOption id="14767" count="1899" label="Lipids"/><FilterOption id="3447" count="1813" label="T-cell surface glycoprotein CD8 alpha chain"/><FilterOption id="332" count="1772" label="Diastolic blood pressure"/><FilterOption id="28899" count="1698" label="Alkaline phosphatase"/><FilterOption id="4806" count="1664" label="Lymphocytes"/><FilterOption id="44216" count="1626" label="Body temperature"/><FilterOption id="1880" count="1572" label="T-Helper Lymphocytes"/><FilterOption id="7895" count="1534" label="Estimated glomerular filtration rate"/><FilterOption id="46505" count="1512" label="Cytotoxic T-Lymphocytes"/><FilterOption id="2713" count="1483" label="Forced expiratory volume"/><FilterOption id="824" count="1393" label="Programmed cell death 1 ligand 1"/><FilterOption id="19714" count="1370" label="Muscle strength"/><FilterOption id="6" count="1315" label="Progesterone receptor"/><FilterOption id="147" count="1314" label="Six-minute walk distance"/><FilterOption id="10684" count="1270" label="Blood cells"/><FilterOption id="7" count="1258" label="Antigen KI-67"/><FilterOption id="52" count="1246" label="GTPase KRas"/><FilterOption id="252" count="1242" label="Interferon gamma"/><FilterOption id="6663" count="1238" label="B-lymphocytes"/><FilterOption id="418" count="1227" label="Waist circumference"/><FilterOption id="2417" count="1222" label="Calcium"/><FilterOption id="17697" count="1164" label="Body height"/><FilterOption id="64" count="1060" label="Circulating Tumor Cells"/><FilterOption id="82" count="1033" label="B-Raf proto-oncogene serine/threonine-protein kinase"/><FilterOption id="3374" count="1002" label="Bone mineral density"/><FilterOption id="2098" count="970" label="Potassium"/><FilterOption id="175" count="942" label="Interleukin-10"/><FilterOption id="46731" count="940" label="Standardized uptake value"/><FilterOption id="2662" count="934" label="Sodium"/><FilterOption id="3451" count="919" label="Immunoglobulin G"/><FilterOption id="2358" count="909" label="Urea nitrogen"/><FilterOption id="9" count="904" label="Cellular tumor antigen p53"/><FilterOption id="1387" count="878" label="Testosterone"/><FilterOption id="10260" count="873" label="Respiratory frequency"/><FilterOption id="1912" count="870" label="Forced Vital Capacity"/><FilterOption id="1945" count="864" label="Left ventricular ejection fraction"/><FilterOption id="2706" count="860" label="Natural killer cells"/><FilterOption id="4522" count="859" label="Erythrocytes"/><FilterOption id="5022" count="857" label="Regulatory T-Lymphocytes"/><FilterOption id="8458" count="848" label="gamma-Glutamyltransferase"/><FilterOption id="554" count="843" label="Interleukin-8"/><FilterOption id="126" count="841" label="BCR-ABL1 fusion protein"/><FilterOption id="1221" count="819" label="Hematocrit"/><FilterOption id="148" count="801" label="QT interval"/><FilterOption id="1566" count="785" label="HLA class I histocompatibility antigen, A alpha chain"/><FilterOption id="71" count="770" label="CA-125 antigen"/><FilterOption id="11359" count="767" label="Vascular endothelial growth factors"/><FilterOption id="154" count="755" label="Lactate dehydrogenase"/><FilterOption id="5700" count="748" label="ALK receptor"/><FilterOption id="288" count="745" label="Uric acid"/><FilterOption id="1731" count="727" label="B-lymphocyte antigen CD20"/><FilterOption id="8097" count="697" label="Monocytes"/><FilterOption id="425" count="690" label="C-peptide"/><FilterOption id="8024" count="658" label="Creatine kinase"/><FilterOption id="248" count="639" label="Eosinophils"/><FilterOption id="172" count="628" label="Adiponectin"/><FilterOption id="46244" count="625" label="Circulating tumor DNA"/><FilterOption id="22" count="620" label="Breast cancer type 1 susceptibility protein"/><FilterOption id="1175" count="608" label="B-lymphocyte antigen CD19"/><FilterOption id="5326" count="606" label="Estradiol"/><FilterOption id="70" count="600" label="CA19-9 antigen"/><FilterOption id="3614" count="599" label="RAC-alpha serine/threonine-protein kinase"/><FilterOption id="2534" count="596" label="Hydrocortisone"/><FilterOption id="1855" count="590" label="CD3 Antigens"/><FilterOption id="781" count="580" label="Erythrocyte sedimentation rate"/><FilterOption id="106" count="562" label="N-terminal Pro Brain Natriuretic Peptide"/><FilterOption id="1688" count="555" label="Follicle-stimulating hormone"/><FilterOption id="10" count="548" label="Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN"/></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="6"><FilterOption id="SIEEFC" count="110313" label="Efficacy"/><FilterOption id="SIESFT" count="93638" label="Safety"/><FilterOption id="SIEPCK" count="22691" label="Pharmacokinetics"/><FilterOption id="SIEPCD" count="10202" label="Pharmacodynamics"/><FilterOption id="SIEBAV" count="1079" label="Bioavailability"/><FilterOption id="SIEBEQ" count="965" label="Bioequivalence"/></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="100"><FilterOption id="44383" count="3250" label="carboplatin"/><FilterOption id="3803" count="3082" label="paclitaxel"/><FilterOption id="3199" count="3075" label="gemcitabine"/><FilterOption id="2953" count="2842" label="docetaxel"/><FilterOption id="3792" count="2673" label="oxaliplatin"/><FilterOption id="8047" count="2087" label="bevacizumab"/><FilterOption id="12205" count="1956" label="capecitabine"/><FilterOption id="2871" count="1955" label="irinotecan"/><FilterOption id="3072" count="1869" label="etoposide phosphate"/><FilterOption id="6736" count="1717" label="rituximab"/><FilterOption id="6156" count="1428" label="fludarabine"/><FilterOption id="10084" count="981" label="tegafur + gimeracil + oteracil potassium"/><FilterOption id="3130" count="927" label="filgrastim"/><FilterOption id="3536" count="925" label="pemetrexed disodium"/><FilterOption id="10388" count="877" label="cetuximab"/><FilterOption id="6386" count="872" label="trastuzumab"/><FilterOption id="54804" count="841" label="nivolumab"/><FilterOption id="13022" count="799" label="epirubicin"/><FilterOption id="70667" count="790" label="pembrolizumab"/><FilterOption id="15954" count="789" label="bortezomib"/><FilterOption id="29016" count="789" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="27572" count="733" label="lenalidomide"/><FilterOption id="4529" count="696" label="temozolomide"/><FilterOption id="11961" count="651" label="erlotinib"/><FilterOption id="6408" count="615" label="vinorelbine"/><FilterOption id="4510" count="594" label="tacrolimus"/><FilterOption id="3669" count="574" label="mycophenolate mofetil"/><FilterOption id="6050" count="507" label="metformin hydrochloride"/><FilterOption id="36630" count="495" label="ipilimumab"/><FilterOption id="29831" count="490" label="sorafenib"/><FilterOption id="13340" count="487" label="everolimus"/><FilterOption id="11519" count="366" label="mitoxantrone"/><FilterOption id="7934" count="351" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="6306" count="335" label="aldesleukin"/><FilterOption id="9298" count="329" label="Thymoglobulin"/><FilterOption id="47000" count="327" label="bendamustine"/><FilterOption id="4577" count="320" label="topotecan"/><FilterOption id="7121" count="311" label="sargramostim"/><FilterOption id="81193" count="306" label="durvalumab"/><FilterOption id="2784" count="304" label="letrozole"/><FilterOption id="37370" count="296" label="azacitidine"/><FilterOption id="5369" count="293" label="ribavirin"/><FilterOption id="4200" count="289" label="sirolimus"/><FilterOption id="21374" count="283" label="pegfilgrastim"/><FilterOption id="11603" count="277" label="gefitinib"/><FilterOption id="72699" count="271" label="atezolizumab"/><FilterOption id="11460" count="271" label="imatinib"/><FilterOption id="12135" count="268" label="celecoxib"/><FilterOption id="12150" count="266" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="54452" count="264" label="rivoceranib mesylate"/><FilterOption id="44314" count="263" label="tamoxifen"/><FilterOption id="33591" count="251" label="lapatinib"/><FilterOption id="12646" count="239" label="panitumumab"/><FilterOption id="24142" count="236" label="mesna"/><FilterOption id="2716" count="233" label="alemtuzumab"/><FilterOption id="8050" count="227" label="thalidomide, Celgene"/><FilterOption id="55237" count="219" label="ibrutinib"/><FilterOption id="44279" count="214" label="amoxicillin"/><FilterOption id="10309" count="213" label="abiraterone"/><FilterOption id="7286" count="207" label="goserelin acetate"/><FilterOption id="3081" count="204" label="exemestane"/><FilterOption id="5999" count="202" label="ciclosporin, Novartis"/><FilterOption id="2829" count="202" label="clarithromycin"/><FilterOption id="3313" count="201" label="fulvestrant"/><FilterOption id="3321" count="198" label="anastrozole"/><FilterOption id="12973" count="197" label="sunitinib"/><FilterOption id="13239" count="193" label="decitabine"/><FilterOption id="48945" count="188" label="bupivacaine, AstraZeneca"/><FilterOption id="28532" count="188" label="pertuzumab"/><FilterOption id="54601" count="182" label="carfilzomib"/><FilterOption id="23625" count="181" label="peginterferon alfa-2a"/><FilterOption id="7310" count="180" label="ritonavir"/><FilterOption id="17625" count="180" label="vorinostat (oral), Merck &amp; Co"/><FilterOption id="2836" count="173" label="clopidogrel"/><FilterOption id="55288" count="164" label="trametinib"/><FilterOption id="48946" count="163" label="dasatinib"/><FilterOption id="44403" count="162" label="lidocaine"/><FilterOption id="3474" count="161" label="lamivudine"/><FilterOption id="70895" count="161" label="venetoclax"/><FilterOption id="44303" count="159" label="midazolam hydrochloride"/><FilterOption id="22965" count="152" label="temsirolimus"/><FilterOption id="44305" count="151" label="omeprazole"/><FilterOption id="44308" count="151" label="propofol, AstraZeneca/Fresenius"/><FilterOption id="44316" count="151" label="zidovudine"/><FilterOption id="16063" count="150" label="olaparib"/><FilterOption id="5267" count="149" label="leuprorelin acetate"/><FilterOption id="3311" count="148" label="bicalutamide"/><FilterOption id="10271" count="146" label="palbociclib"/><FilterOption id="2765" count="146" label="zoledronic acid"/><FilterOption id="45562" count="145" label="tremelimumab"/><FilterOption id="16748" count="144" label="aprepitant"/><FilterOption id="9049" count="143" label="cytarabine (sustained release, DepoFoam), Pacira/Sigma-Tau/Pfizer/Napp Pharmaceutical"/><FilterOption id="2807" count="142" label="atorvastatin"/><FilterOption id="3688" count="141" label="nedaplatin"/><FilterOption id="23624" count="139" label="clofarabine"/><FilterOption id="2573" count="139" label="pegaspargase"/><FilterOption id="83065" count="138" label="avelumab"/><FilterOption id="53981" count="138" label="enzalutamide"/><FilterOption id="3750" count="137" label="ondansetron"/><FilterOption id="27696" count="133" label="pomalidomide"/></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="SERIAL" count="33244" label="Serial Publications"/><FilterOption id="OTHER" count="17933" label="Other Publications"/><FilterOption id="PR" count="15904" label="Press Releases"/><FilterOption id="CONFERENCE" count="3305" label="Conference Reports"/><FilterOption id="CORPORATE" count="2342" label="Corporate Publications"/></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="100"><FilterOption id="54804" count="619" label="nivolumab"/><FilterOption id="29831" count="591" label="sorafenib"/><FilterOption id="8047" count="558" label="bevacizumab"/><FilterOption id="2953" count="548" label="docetaxel"/><FilterOption id="3199" count="546" label="gemcitabine"/><FilterOption id="11961" count="496" label="erlotinib"/><FilterOption id="6736" count="487" label="rituximab"/><FilterOption id="70667" count="485" label="pembrolizumab"/><FilterOption id="12973" count="480" label="sunitinib"/><FilterOption id="4529" count="470" label="temozolomide"/><FilterOption id="11460" count="440" label="imatinib"/><FilterOption id="12205" count="423" label="capecitabine"/><FilterOption id="3803" count="412" label="paclitaxel"/><FilterOption id="6050" count="408" label="metformin hydrochloride"/><FilterOption id="11603" count="351" label="gefitinib"/><FilterOption id="44314" count="344" label="tamoxifen"/><FilterOption id="10084" count="344" label="tegafur + gimeracil + oteracil potassium"/><FilterOption id="6386" count="324" label="trastuzumab"/><FilterOption id="13340" count="315" label="everolimus"/><FilterOption id="10388" count="279" label="cetuximab"/><FilterOption id="2765" count="270" label="zoledronic acid"/><FilterOption id="27572" count="268" label="lenalidomide"/><FilterOption id="54452" count="248" label="rivoceranib mesylate"/><FilterOption id="2871" count="247" label="irinotecan"/><FilterOption id="48946" count="240" label="dasatinib"/><FilterOption id="43738" count="236" label="pazopanib"/><FilterOption id="3536" count="235" label="pemetrexed disodium"/><FilterOption id="3130" count="229" label="filgrastim"/><FilterOption id="14163" count="227" label="adalimumab"/><FilterOption id="44383" count="227" label="carboplatin"/><FilterOption id="36630" count="226" label="ipilimumab"/><FilterOption id="15954" count="209" label="bortezomib"/><FilterOption id="2784" count="206" label="letrozole"/><FilterOption id="2807" count="202" label="atorvastatin"/><FilterOption id="51388" count="187" label="nilotinib"/><FilterOption id="3792" count="187" label="oxaliplatin"/><FilterOption id="29016" count="184" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="53981" count="182" label="enzalutamide"/><FilterOption id="44403" count="182" label="lidocaine"/><FilterOption id="4126" count="179" label="pioglitazone"/><FilterOption id="12135" count="170" label="celecoxib"/><FilterOption id="54449" count="169" label="afatinib"/><FilterOption id="4567" count="165" label="etanercept"/><FilterOption id="3321" count="161" label="anastrozole"/><FilterOption id="5148" count="161" label="liraglutide"/><FilterOption id="6850" count="156" label="infliximab"/><FilterOption id="37370" count="155" label="azacitidine"/><FilterOption id="4200" count="154" label="sirolimus"/><FilterOption id="4510" count="152" label="tacrolimus"/><FilterOption id="81193" count="150" label="durvalumab"/><FilterOption id="6156" count="147" label="fludarabine"/><FilterOption id="8783" count="144" label="dexmedetomidine"/><FilterOption id="54624" count="144" label="regorafenib"/><FilterOption id="12420" count="144" label="rosuvastatin"/><FilterOption id="49721" count="141" label="denosumab"/><FilterOption id="6306" count="139" label="aldesleukin"/><FilterOption id="3081" count="136" label="exemestane"/><FilterOption id="2836" count="135" label="clopidogrel"/><FilterOption id="4577" count="135" label="topotecan"/><FilterOption id="3669" count="132" label="mycophenolate mofetil"/><FilterOption id="16063" count="131" label="olaparib"/><FilterOption id="3072" count="130" label="etoposide phosphate"/><FilterOption id="72699" count="129" label="atezolizumab"/><FilterOption id="6408" count="128" label="vinorelbine"/><FilterOption id="55237" count="127" label="ibrutinib"/><FilterOption id="33591" count="127" label="lapatinib"/><FilterOption id="83873" count="127" label="osimertinib"/><FilterOption id="28773" count="124" label="eribulin mesylate"/><FilterOption id="10309" count="123" label="abiraterone"/><FilterOption id="4271" count="122" label="ropivacaine"/><FilterOption id="39209" count="119" label="axitinib"/><FilterOption id="7413" count="117" label="darbepoetin alfa"/><FilterOption id="44499" count="115" label="sitagliptin"/><FilterOption id="7934" count="114" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="3313" count="113" label="fulvestrant"/><FilterOption id="48945" count="112" label="bupivacaine, AstraZeneca"/><FilterOption id="21374" count="112" label="pegfilgrastim"/><FilterOption id="8050" count="112" label="thalidomide, Celgene"/><FilterOption id="17814" count="111" label="pregabalin"/><FilterOption id="2716" count="110" label="alemtuzumab"/><FilterOption id="16026" count="110" label="esomeprazole"/><FilterOption id="44313" count="110" label="simvastatin"/><FilterOption id="67892" count="109" label="epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson"/><FilterOption id="23625" count="108" label="peginterferon alfa-2a"/><FilterOption id="55798" count="107" label="crizotinib"/><FilterOption id="7121" count="107" label="sargramostim"/><FilterOption id="9000" count="106" label="onabotulinumtoxinA"/><FilterOption id="32677" count="106" label="rivaroxaban"/><FilterOption id="51160" count="105" label="nintedanib"/><FilterOption id="22965" count="104" label="temsirolimus"/><FilterOption id="2888" count="100" label="abatacept"/><FilterOption id="5267" count="100" label="leuprorelin acetate"/><FilterOption id="44375" count="100" label="warfarin"/><FilterOption id="4119" count="99" label="tadalafil"/><FilterOption id="8165" count="99" label="tiotropium bromide"/><FilterOption id="44316" count="96" label="zidovudine"/><FilterOption id="13486" count="95" label="entecavir"/><FilterOption id="50935" count="94" label="cabozantinib S-malate"/><FilterOption id="52192" count="92" label="dapagliflozin propanediol"/><FilterOption id="44308" count="92" label="propofol, AstraZeneca/Fresenius"/></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="100"><FilterOption id="44383" count="506" label="carboplatin"/><FilterOption id="3803" count="427" label="paclitaxel"/><FilterOption id="3199" count="341" label="gemcitabine"/><FilterOption id="3792" count="315" label="oxaliplatin"/><FilterOption id="2953" count="305" label="docetaxel"/><FilterOption id="12205" count="190" label="capecitabine"/><FilterOption id="8047" count="158" label="bevacizumab"/><FilterOption id="3072" count="152" label="etoposide phosphate"/><FilterOption id="2871" count="148" label="irinotecan"/><FilterOption id="3536" count="148" label="pemetrexed disodium"/><FilterOption id="13022" count="145" label="epirubicin"/><FilterOption id="6736" count="144" label="rituximab"/><FilterOption id="6386" count="116" label="trastuzumab"/><FilterOption id="6050" count="113" label="metformin hydrochloride"/><FilterOption id="4510" count="85" label="tacrolimus"/><FilterOption id="29016" count="83" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="3669" count="81" label="mycophenolate mofetil"/><FilterOption id="6408" count="74" label="vinorelbine"/><FilterOption id="10252" count="67" label="insulin glargine"/><FilterOption id="6156" count="61" label="fludarabine"/><FilterOption id="44279" count="52" label="amoxicillin"/><FilterOption id="10084" count="49" label="tegafur + gimeracil + oteracil potassium"/><FilterOption id="10388" count="48" label="cetuximab"/><FilterOption id="2836" count="48" label="clopidogrel"/><FilterOption id="15954" count="47" label="bortezomib"/><FilterOption id="3750" count="45" label="ondansetron"/><FilterOption id="2829" count="41" label="clarithromycin"/><FilterOption id="27572" count="41" label="lenalidomide"/><FilterOption id="12150" count="39" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="7286" count="37" label="goserelin acetate"/><FilterOption id="7934" count="36" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="47000" count="34" label="bendamustine"/><FilterOption id="11519" count="34" label="mitoxantrone"/><FilterOption id="8832" count="31" label="glimepiride"/><FilterOption id="11961" count="29" label="erlotinib"/><FilterOption id="5999" count="28" label="ciclosporin, Novartis"/><FilterOption id="3353" count="28" label="insulin lispro"/><FilterOption id="44403" count="28" label="lidocaine"/><FilterOption id="44308" count="28" label="propofol, AstraZeneca/Fresenius"/><FilterOption id="5369" count="28" label="ribavirin"/><FilterOption id="2784" count="27" label="letrozole"/><FilterOption id="44305" count="27" label="omeprazole"/><FilterOption id="49219" count="27" label="tenofovir disoproxil fumarate + emtricitabine (fixed dose), Gilead Sciences"/><FilterOption id="10309" count="26" label="abiraterone"/><FilterOption id="10172" count="26" label="efavirenz"/><FilterOption id="3130" count="26" label="filgrastim"/><FilterOption id="7310" count="26" label="ritonavir"/><FilterOption id="3474" count="24" label="lamivudine"/><FilterOption id="44314" count="23" label="tamoxifen"/><FilterOption id="48945" count="22" label="bupivacaine, AstraZeneca"/><FilterOption id="44303" count="22" label="midazolam hydrochloride"/><FilterOption id="2807" count="21" label="atorvastatin"/><FilterOption id="23625" count="21" label="peginterferon alfa-2a"/><FilterOption id="28532" count="21" label="pertuzumab"/><FilterOption id="25880" count="20" label="enteric-coated mycophenolate sodium, Novartis"/><FilterOption id="3081" count="20" label="exemestane"/><FilterOption id="10411" count="20" label="insulin aspart"/><FilterOption id="5267" count="20" label="leuprorelin acetate"/><FilterOption id="54804" count="20" label="nivolumab"/><FilterOption id="4529" count="20" label="temozolomide"/><FilterOption id="3321" count="19" label="anastrozole"/><FilterOption id="36630" count="19" label="ipilimumab"/><FilterOption id="33591" count="19" label="lapatinib"/><FilterOption id="21374" count="19" label="pegfilgrastim"/><FilterOption id="5356" count="19" label="sevoflurane"/><FilterOption id="44499" count="19" label="sitagliptin"/><FilterOption id="15254" count="18" label="atazanavir"/><FilterOption id="8050" count="18" label="thalidomide, Celgene"/><FilterOption id="9298" count="18" label="Thymoglobulin"/><FilterOption id="44375" count="18" label="warfarin"/><FilterOption id="14163" count="17" label="adalimumab"/><FilterOption id="16026" count="17" label="esomeprazole"/><FilterOption id="9754" count="17" label="palanosetron hydrochloride"/><FilterOption id="14493" count="17" label="tenofovir disoproxil fumarate"/><FilterOption id="13486" count="16" label="entecavir"/><FilterOption id="3311" count="15" label="bicalutamide"/><FilterOption id="16915" count="15" label="calcium levofolinate"/><FilterOption id="32981" count="15" label="darunavir"/><FilterOption id="3492" count="15" label="levofloxacin"/><FilterOption id="12420" count="15" label="rosuvastatin"/><FilterOption id="16748" count="14" label="aprepitant"/><FilterOption id="4271" count="14" label="ropivacaine"/><FilterOption id="37370" count="13" label="azacitidine"/><FilterOption id="11603" count="13" label="gefitinib"/><FilterOption id="6104" count="13" label="lansoprazole"/><FilterOption id="70667" count="13" label="pembrolizumab"/><FilterOption id="27696" count="13" label="pomalidomide"/><FilterOption id="34281" count="13" label="Prevnar 13"/><FilterOption id="4577" count="13" label="topotecan"/><FilterOption id="11141" count="12" label="basiliximab"/><FilterOption id="48181" count="12" label="lamivudine + abacavir, GlaxoSmithKline"/><FilterOption id="44316" count="12" label="zidovudine"/><FilterOption id="2500" count="11" label="amlodipine"/><FilterOption id="13239" count="11" label="decitabine"/><FilterOption id="2997" count="11" label="rabeprazole"/><FilterOption id="29831" count="11" label="sorafenib"/><FilterOption id="13340" count="10" label="everolimus"/><FilterOption id="3159" count="10" label="fluticasone propionate"/><FilterOption id="3313" count="10" label="fulvestrant"/><FilterOption id="5148" count="10" label="liraglutide"/></Filter><Filter label="Trial Category" name="trialCategory" total="18"><FilterOption id="4" count="84835" label="Small molecule"/><FilterOption id="3" count="33271" label="Biological"/><FilterOption id="9" count="10174" label="Medical procedure"/><FilterOption id="15" count="9651" label="Radiation therapy"/><FilterOption id="8" count="7519" label="Medical device"/><FilterOption id="5" count="5954" label="Vaccine"/><FilterOption id="11" count="5709" label="Dietary supplement"/><FilterOption id="16" count="5072" label="Behavioral intervention"/><FilterOption id="6" count="4976" label="Cell therapy"/><FilterOption id="14" count="2909" label="Diagnostic"/><FilterOption id="7" count="2504" label="Gene therapy"/><FilterOption id="18" count="2487" label="Pathophysiology"/><FilterOption id="17" count="1911" label="Biomarker identification"/><FilterOption id="12" count="564" label="Herbal preparation"/><FilterOption id="10" count="424" label="Borderline product"/><FilterOption id="19" count="205" label="Surgical procedure"/><FilterOption id="2" count="83" label="Drug"/><FilterOption id="13" count="79" label="Hospital solutions"/></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="NO" count="89864" label="No"/><FilterOption id="YES" count="45610" label="Yes"/></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="100"><FilterOption id="3848" count="4351" label="VEGF-2 receptor antagonist"/><FilterOption id="3808" count="4112" label="Kit tyrosine kinase inhibitor"/><FilterOption id="740" count="3871" label="Epidermal growth factor receptor antagonist"/><FilterOption id="142" count="3744" label="Topoisomerase II inhibitor"/><FilterOption id="372" count="3669" label="Thymidylate synthase inhibitor"/><FilterOption id="3846" count="3330" label="VEGF-1 receptor antagonist"/><FilterOption id="3850" count="3211" label="VEGF-3 receptor antagonist"/><FilterOption id="141" count="3129" label="Topoisomerase I inhibitor"/><FilterOption id="67136" count="2888" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="12521" count="2640" label="VEGF ligand inhibitor"/><FilterOption id="948" count="2623" label="PDGF receptor antagonist"/><FilterOption id="48492" count="2529" label="PDGF receptor beta antagonist"/><FilterOption id="5085" count="2512" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="3806" count="2449" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="3754" count="2330" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="3756" count="2172" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="1722" count="2161" label="VEGF receptor antagonist"/><FilterOption id="3816" count="2109" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="138" count="1842" label="DNA polymerase inhibitor"/><FilterOption id="346" count="1774" label="Ribonucleotide reductase inhibitor"/><FilterOption id="10240" count="1675" label="mTOR inhibitor"/><FilterOption id="3151" count="1608" label="GCSF receptor agonist"/><FilterOption id="4548" count="1575" label="Raf B protein kinase inhibitor"/><FilterOption id="6830" count="1572" label="DNA primase inhibitor"/><FilterOption id="51708" count="1565" label="DNA polymerase alpha inhibitor"/><FilterOption id="48489" count="1505" label="PDGF receptor alpha antagonist"/><FilterOption id="13571" count="1427" label="Bcr protein inhibitor"/><FilterOption id="782" count="1321" label="Dihydropyrimidine dehydrogenase inhibitor"/><FilterOption id="4917" count="1314" label="Proteasome inhibitor"/><FilterOption id="3524" count="1309" label="Abl tyrosine kinase inhibitor"/><FilterOption id="6661" count="1291" label="Orotate phosphoribosyltransferase inhibitor"/><FilterOption id="135" count="1278" label="DHFR inhibitor"/><FilterOption id="3154" count="1266" label="CSF-1 antagonist"/><FilterOption id="4550" count="1254" label="Raf 1 protein kinase inhibitor"/><FilterOption id="374" count="1163" label="Transferase inhibitor"/><FilterOption id="181" count="1121" label="GAR transformylase inhibitor"/><FilterOption id="4010" count="1101" label="Calcineurin inhibitor"/><FilterOption id="4542" count="1096" label="Raf protein kinase inhibitor"/><FilterOption id="14007" count="1077" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="3688" count="1053" label="FGF3 receptor antagonist"/><FilterOption id="3682" count="1047" label="FGF1 receptor antagonist"/><FilterOption id="385" count="979" label="Protein tyrosine kinase inhibitor"/><FilterOption id="76469" count="975" label="26S proteasome complex inhibitor"/><FilterOption id="498" count="972" label="Sodium channel inhibitor"/><FilterOption id="76" count="947" label="Aromatase inhibitor"/><FilterOption id="76090" count="932" label="mTOR complex 1 inhibitor"/><FilterOption id="3576" count="929" label="Src tyrosine kinase inhibitor"/><FilterOption id="8805" count="917" label="AMP activated protein kinase stimulator"/><FilterOption id="3584" count="916" label="Lck tyrosine kinase inhibitor"/><FilterOption id="5482" count="914" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="286" count="890" label="Estrogen receptor antagonist"/><FilterOption id="82444" count="867" label="DNA helicase inhibitor"/><FilterOption id="205" count="834" label="HMG CoA reductase inhibitor"/><FilterOption id="629" count="823" label="Inosine monophosphate dehydrogenase inhibitor"/><FilterOption id="2574" count="789" label="Histone deacetylase inhibitor"/><FilterOption id="208" count="788" label="H+ K+ ATPase inhibitor"/><FilterOption id="721" count="777" label="TNF binding agent"/><FilterOption id="1832" count="757" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="168" count="745" label="FGF receptor antagonist"/><FilterOption id="60" count="701" label="Androgen receptor antagonist"/><FilterOption id="11778" count="701" label="PurH purine biosynthesis protein inhibitor"/><FilterOption id="7025" count="697" label="Signal transduction inhibitor"/><FilterOption id="381" count="683" label="TNF alpha ligand inhibitor"/><FilterOption id="1016" count="665" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="3685" count="657" label="FGF2 receptor antagonist"/><FilterOption id="1120" count="648" label="Somatostatin receptor agonist"/><FilterOption id="2585" count="621" label="Glucagon-like peptide 1 receptor agonist"/><FilterOption id="12481" count="618" label="Interleukin-2 ligand"/><FilterOption id="38283" count="614" label="Poly ADP ribose polymerase 1 inhibitor"/><FilterOption id="3834" count="585" label="Tek tyrosine kinase receptor inhibitor"/><FilterOption id="3762" count="583" label="EPH family tyrosine kinase inhibitor"/><FilterOption id="38286" count="583" label="Poly ADP ribose polymerase 2 inhibitor"/><FilterOption id="1001" count="580" label="Cyclooxygenase 2 inhibitor"/><FilterOption id="675" count="573" label="Hepatocyte growth factor receptor antagonist"/><FilterOption id="1092" count="567" label="GNRH receptor agonist"/><FilterOption id="1919" count="566" label="Insulin sensitizer"/><FilterOption id="15" count="562" label="5-HT 3 receptor antagonist"/><FilterOption id="4762" count="550" label="MEK-1 protein kinase inhibitor"/><FilterOption id="431" count="538" label="DNA gyrase inhibitor"/><FilterOption id="7841" count="533" label="Histone deacetylase-1 inhibitor"/><FilterOption id="410" count="532" label="GM-CSF receptor agonist"/><FilterOption id="7844" count="532" label="Histone deacetylase-2 inhibitor"/><FilterOption id="4764" count="531" label="MEK-2 protein kinase inhibitor"/><FilterOption id="214" count="516" label="Interferon alpha 2 ligand"/><FilterOption id="6512" count="515" label="DNA methyltransferase inhibitor"/><FilterOption id="7847" count="513" label="Histone deacetylase-3 inhibitor"/><FilterOption id="4314" count="509" label="Cyclin-dependent kinase-4 inhibitor"/><FilterOption id="814" count="509" label="Tubulin modulator"/><FilterOption id="40" count="502" label="Beta 2 adrenoceptor agonist"/><FilterOption id="5537" count="484" label="Dipeptidyl peptidase IV inhibitor"/><FilterOption id="3574" count="479" label="Fyn tyrosine kinase inhibitor"/><FilterOption id="4318" count="478" label="Cyclin-dependent kinase-6 inhibitor"/><FilterOption id="3592" count="476" label="Btk tyrosine kinase inhibitor"/><FilterOption id="293" count="453" label="Opioid receptor mu agonist"/><FilterOption id="2507" count="442" label="PARP inhibitor"/><FilterOption id="2480" count="442" label="PPAR gamma agonist"/><FilterOption id="23014" count="432" label="Insulin ligand"/><FilterOption id="400" count="432" label="Insulin receptor agonist"/><FilterOption id="420" count="429" label="CSF-1 agonist"/><FilterOption id="7856" count="428" label="Histone deacetylase-6 inhibitor"/></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="100"><FilterOption id="20519" count="8230" label="National Cancer Institute"/><FilterOption id="20518" count="1037" label="National Institutes of Health"/><FilterOption id="1069368" count="1022" label="National Institutes of Health Clinical Center"/><FilterOption id="23137" count="968" label="Novartis AG"/><FilterOption id="15065" count="811" label="Bristol-Myers Squibb Co"/><FilterOption id="18767" count="745" label="Pfizer Inc"/><FilterOption id="19453" count="728" label="Genentech Inc"/><FilterOption id="14190" count="688" label="AstraZeneca plc"/><FilterOption id="1059823" count="617" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="1009547" count="586" label="Sanofi SA"/><FilterOption id="15331" count="556" label="Celgene Corp"/><FilterOption id="28355" count="555" label="GlaxoSmithKline plc"/><FilterOption id="1003240" count="503" label="National Heart Lung and Blood Institute"/><FilterOption id="19446" count="488" label="Roche Holding AG"/><FilterOption id="29469" count="385" label="Cancer Research UK"/><FilterOption id="14455" count="384" label="Bayer AG"/><FilterOption id="14109" count="359" label="Amgen Inc"/><FilterOption id="17810" count="353" label="Eli Lilly &amp; Co"/><FilterOption id="1041701" count="323" label="Japanese Ministry of Health, Labor and Welfare"/><FilterOption id="1039740" count="316" label="National Natural Science Foundation of China"/><FilterOption id="26334" count="304" label="National Institute of Diabetes, Digestive and Kidney Diseases"/><FilterOption id="21048" count="271" label="Brigham &amp; Women's Hospital"/><FilterOption id="1013295" count="266" label="Astellas Pharma Inc"/><FilterOption id="20520" count="263" label="National Institute of Allergy and Infectious Diseases"/><FilterOption id="1043068" count="249" label="Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development"/><FilterOption id="20300" count="244" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="21569" count="243" label="Massachusetts General Hospital"/><FilterOption id="1107695" count="241" label="Japan Agency for Medical Research and Development"/><FilterOption id="1065861" count="213" label="Ministry of Education, Culture, Sports, Science and Technology of Japan"/><FilterOption id="18077" count="212" label="Merck &amp; Co Inc"/><FilterOption id="1041928" count="207" label="National Institute on Aging"/><FilterOption id="15615" count="192" label="Dana-Farber Cancer Institute Inc"/><FilterOption id="24877" count="175" label="Beth Israel Deaconess Medical Center"/><FilterOption id="1042032" count="175" label="National Institute for Health Research (NIHR)"/><FilterOption id="1036091" count="162" label="National Institute of Neurological Disorders and Stroke"/><FilterOption id="21991" count="155" label="Takeda Oncology"/><FilterOption id="23382" count="153" label="MD Anderson Cancer Center"/><FilterOption id="18101" count="150" label="Merck KGaA"/><FilterOption id="18681" count="147" label="Ono Pharmaceutical Co Ltd"/><FilterOption id="19620" count="146" label="Eisai Inc"/><FilterOption id="1041243" count="146" label="US Department of Defense"/><FilterOption id="1034426" count="145" label="Canadian Institutes of Health Research"/><FilterOption id="17332" count="145" label="Johnson &amp; Johnson"/><FilterOption id="1039583" count="144" label="The National Institute of Mental Health"/><FilterOption id="13601" count="137" label="Abbott Laboratories"/><FilterOption id="DOL1000129" count="134" label="Texas Children's Hospital"/><FilterOption id="14881" count="130" label="Boehringer Ingelheim International GmbH"/><FilterOption id="19601" count="128" label="National Institute on Drug Abuse"/><FilterOption id="18438" count="119" label="Medical Research Council"/><FilterOption id="24771" count="118" label="Eastern Cooperative Oncology Group"/><FilterOption id="16299" count="118" label="Sanofi Genzyme"/><FilterOption id="1006925" count="117" label="Jiangsu Hengrui Medicine Co Ltd"/><FilterOption id="1038146" count="113" label="National Health and Medical Research Council"/><FilterOption id="20596" count="111" label="Johns Hopkins University"/><FilterOption id="16450" count="107" label="Gilead Sciences Inc"/><FilterOption id="20348" count="105" label="Teva Pharmaceutical Industries Ltd"/><FilterOption id="20567" count="103" label="Duke University"/><FilterOption id="1041019" count="103" label="National Center for Research Resources"/><FilterOption id="18614" count="102" label="Novo Nordisk A/S"/><FilterOption id="24773" count="102" label="University of California San Francisco"/><FilterOption id="1003755" count="101" label="Japan Society for the Promotion of Science (JSPS)"/><FilterOption id="1072507" count="100" label="AbbVie Inc"/><FilterOption id="20701" count="97" label="University of Washington"/><FilterOption id="1041750" count="94" label="National Comprehensive Cancer Network"/><FilterOption id="1040754" count="94" label="The Netherlands Organisation for Health Research and Development"/><FilterOption id="1046733" count="91" label="Dutch Cancer Society"/><FilterOption id="DOL1000375" count="91" label="Fudan University"/><FilterOption id="19461" count="90" label="Hoffmann-La Roche Inc"/><FilterOption id="20559" count="87" label="Columbia University"/><FilterOption id="1039403" count="87" label="German Federal Ministry of Education and Research"/><FilterOption id="1040381" count="85" label="Cancer and Leukemia Group B"/><FilterOption id="22122" count="85" label="Memorial Sloan-Kettering Cancer Center"/><FilterOption id="20658" count="84" label="University of Pennsylvania"/><FilterOption id="1043079" count="83" label="FDA Office of Orphan Products Development"/><FilterOption id="18720" count="82" label="Taiho Pharmaceutical Co Ltd"/><FilterOption id="1034427" count="81" label="Juvenile Diabetes Research Foundation"/><FilterOption id="1041623" count="79" label="Houston Methodist"/><FilterOption id="21111" count="79" label="Mayo Clinic Foundation"/><FilterOption id="1004360" count="79" label="Sun Yat-Sen University"/><FilterOption id="25623" count="79" label="University of California Los Angeles"/><FilterOption id="20623" count="79" label="University of Michigan"/><FilterOption id="1081121" count="78" label="Center for Cell and Gene Therapy"/><FilterOption id="1039415" count="78" label="Ministry of Science and Technology of the Peoples Republic of China"/><FilterOption id="1028858" count="78" label="Southwest Oncology Group"/><FilterOption id="20659" count="78" label="University of Pittsburgh"/><FilterOption id="17216" count="77" label="Incyte Corp"/><FilterOption id="1101929" count="77" label="IQVIA Holdings Inc"/><FilterOption id="1036410" count="77" label="National Center for Complementary and Alternative Medicine"/><FilterOption id="1033116" count="77" label="PAREXEL International"/><FilterOption id="19711" count="76" label="Schering-Plough Corp"/><FilterOption id="1034431" count="74" label="National Institute of Arthritis and Musculoskeletal and Skin Diseases"/><FilterOption id="DOL1000190" count="72" label="Aarhus University Hospital"/><FilterOption id="1005244" count="72" label="Biogen Inc"/><FilterOption id="20685" count="72" label="Thomas Jefferson University"/><FilterOption id="26113" count="72" label="Washington University in St Louis"/><FilterOption id="17229" count="71" label="INSERM"/><FilterOption id="1004516" count="70" label="Deutsche Forschungsgemeinschaft (DFG)"/><FilterOption id="26178" count="69" label="F Hoffmann-La Roche AG"/><FilterOption id="1097941" count="69" label="NRG Oncology"/><FilterOption id="1059977" count="68" label="European Commission"/></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="100"><FilterOption id="1545" count="4734" label="Anticancer"/><FilterOption id="767" count="1658" label="Cell cycle inhibitor"/><FilterOption id="2953" count="1468" label="Anti-inflammatory"/><FilterOption id="140" count="1310" label="DNA synthesis inhibitor"/><FilterOption id="1569" count="1160" label="Anticancer antimetabolite"/><FilterOption id="50" count="1110" label="Anticancer alkylating agent"/><FilterOption id="55685" count="1001" label="Anticancer monoclonal antibody"/><FilterOption id="62255" count="840" label="Anticancer protein kinase inhibitor"/><FilterOption id="991" count="800" label="Antiviral"/><FilterOption id="2575" count="689" label="Microtubule inhibitor"/><FilterOption id="2576" count="688" label="Microtubule stabilizer"/><FilterOption id="61" count="636" label="Angiogenesis inhibitor"/><FilterOption id="2660" count="601" label="Vasoprotectant"/><FilterOption id="399" count="591" label="Hypoglycemic agent"/><FilterOption id="2946" count="489" label="Analgesic"/><FilterOption id="1589" count="477" label="Apoptosis stimulator"/><FilterOption id="1594" count="470" label="Antibacterial"/><FilterOption id="396" count="324" label="Immunosuppressant"/><FilterOption id="2657" count="322" label="Antihypertensive"/><FilterOption id="7293" count="287" label="Synergist"/><FilterOption id="750" count="282" label="DNA intercalator"/><FilterOption id="12378" count="266" label="Prophylactic vaccine"/><FilterOption id="646" count="247" label="Bronchodilator"/><FilterOption id="15187" count="245" label="Systemic dermatological antibacterial product"/><FilterOption id="38206" count="223" label="Biguanide antidiabetic product"/><FilterOption id="59620" count="206" label="Unspecified drug target"/><FilterOption id="2970" count="202" label="Anti-emetic"/><FilterOption id="393" count="198" label="Immunostimulant"/><FilterOption id="805" count="195" label="Folate modulator"/><FilterOption id="15184" count="195" label="Systemic antipsoriatic product"/><FilterOption id="1596" count="188" label="Immunomodulator"/><FilterOption id="7761" count="179" label="T-lymphocyte stimulator"/><FilterOption id="38200" count="178" label="Acid pump inhibitor antiulcerant product"/><FilterOption id="104" count="174" label="Bacterial cell wall synthesis inhibitor"/><FilterOption id="1669" count="174" label="Local anesthetic"/><FilterOption id="71" count="172" label="Antihypercholesterolemic agent"/><FilterOption id="2667" count="156" label="Antiarteriosclerotic"/><FilterOption id="610" count="153" label="Hematopoietic stimulator"/><FilterOption id="7760" count="152" label="T-lymphocyte inhibitor"/><FilterOption id="2954" count="150" label="Steroidal anti-inflammatory"/><FilterOption id="3189" count="147" label="Corticosteroid agonist"/><FilterOption id="72" count="145" label="Antihyperlipidemic agent"/><FilterOption id="62254" count="142" label="Anticancer hormone antagonist"/><FilterOption id="2942" count="139" label="Anxiolytic"/><FilterOption id="182" count="139" label="Gastric secretion inhibitor"/><FilterOption id="38215" count="131" label="Human insulin long acting product"/><FilterOption id="312" count="130" label="Platelet aggregation inhibitor"/><FilterOption id="2659" count="128" label="Cardioprotectant"/><FilterOption id="747" count="123" label="HIV replication inhibitor"/><FilterOption id="1668" count="115" label="General anesthetic"/><FilterOption id="2947" count="114" label="Antiparkinsonian"/><FilterOption id="3984" count="113" label="Bacterial nucleic acid synthesis inhibitor"/><FilterOption id="1615" count="112" label="Neuroprotectant"/><FilterOption id="388" count="112" label="Vasodilator"/><FilterOption id="70" count="110" label="Anticonvulsant agent"/><FilterOption id="89" count="105" label="Bone resorption inhibitor"/><FilterOption id="382" count="104" label="TNF alpha synthesis inhibitor"/><FilterOption id="2941" count="103" label="Antidepressant"/><FilterOption id="659" count="100" label="Coagulation inhibitor"/><FilterOption id="2955" count="99" label="Non-steroidal anti-inflammatory"/><FilterOption id="12367" count="96" label="Inactivated viral vaccine"/><FilterOption id="38211" count="93" label="Human insulin fast acting product"/><FilterOption id="1538" count="92" label="Bacterial protein synthesis inhibitor"/><FilterOption id="1532" count="91" label="Viral replication inhibitor"/><FilterOption id="32411" count="88" label="Hepatitis B virus replication inhibitor"/><FilterOption id="463" count="80" label="Ribosome binding agent"/><FilterOption id="664" count="79" label="Fibrosuppressant"/><FilterOption id="1748" count="77" label="Fungicide"/><FilterOption id="3" count="72" label="5-HT uptake inhibitor"/><FilterOption id="12372" count="72" label="Protein subunit vaccine"/><FilterOption id="3246" count="71" label="Insulin release stimulator"/><FilterOption id="38439" count="68" label="DPP IV inhibitor antidiabetic product"/><FilterOption id="38205" count="68" label="Sulphonylurea antidiabetic product"/><FilterOption id="1540" count="64" label="Macrolide antibiotic"/><FilterOption id="12596" count="62" label="Osteoclast inhibitor"/><FilterOption id="285" count="61" label="Norepinephrine uptake inhibitor"/><FilterOption id="1332" count="59" label="Gastrointestinal system agent"/><FilterOption id="2944" count="58" label="Hypnotic"/><FilterOption id="1129" count="57" label="Non-steroid hormone receptor antagonist"/><FilterOption id="3313" count="55" label="Glucagon-like peptide 1 metabolism modulator"/><FilterOption id="12364" count="55" label="Live attenuated viral vaccine"/><FilterOption id="1535" count="52" label="Beta lactam antibiotic"/><FilterOption id="695" count="50" label="Metastasis inhibitor"/><FilterOption id="12373" count="50" label="Polysaccharide subunit vaccine"/><FilterOption id="449" count="48" label="Antiarrhythmic agent"/><FilterOption id="7251" count="48" label="Female contraceptive"/><FilterOption id="15178" count="47" label="Systemic dermatological antifungal product"/><FilterOption id="439" count="46" label="RNA synthesis inhibitor"/><FilterOption id="2943" count="45" label="Antipsychotic"/><FilterOption id="7018" count="44" label="Antihypertriglyceridemic agent"/><FilterOption id="73547" count="43" label="Carbapenem"/><FilterOption id="3272" count="40" label="Growth hormone release inhibitor"/><FilterOption id="7220" count="40" label="Neoplasm diagnostic agent"/><FilterOption id="12371" count="39" label="Subunit vaccine"/><FilterOption id="15148" count="38" label="Ocular antineovascularisation agent"/><FilterOption id="1479" count="36" label="RNA synthesis modulator"/><FilterOption id="937" count="34" label="Androgen synthesis inhibitor"/><FilterOption id="12379" count="34" label="Therapeutic vaccine"/><FilterOption id="1537" count="32" label="Cephalosporin"/><FilterOption id="7210" count="31" label="Cardiovascular diagnostic agent"/></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="37" count="47547" label="Proteomic"/><FilterOption id="38" count="46350" label="Genomic"/><FilterOption id="32" count="19744" label="Biochemical"/><FilterOption id="31" count="19671" label="Physiological"/><FilterOption id="75" count="14287" label="Cellular"/><FilterOption id="40" count="8087" label="Structural (imaging)"/><FilterOption id="39" count="7411" label="Anthropomorphic"/></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="4"><FilterOption id="695863716" count="51098" label="Therapeutic effect marker"/><FilterOption id="1571666123" count="23181" label="Disease marker"/><FilterOption id="730490367" count="7677" label="Toxic effect marker"/><FilterOption id="3242045531" count="423" label="Not determined"/></Filter><Filter label="Interventions" name="trialInterventions" total="100"><FilterOption id="3199" count="3492" label="gemcitabine"/><FilterOption id="44383" count="3445" label="carboplatin"/><FilterOption id="3803" count="3429" label="paclitaxel"/><FilterOption id="2953" count="3290" label="docetaxel"/><FilterOption id="3792" count="2841" label="oxaliplatin"/><FilterOption id="8047" count="2561" label="bevacizumab"/><FilterOption id="12205" count="2296" label="capecitabine"/><FilterOption id="2871" count="2172" label="irinotecan"/><FilterOption id="6736" count="2152" label="rituximab"/><FilterOption id="3072" count="1989" label="etoposide phosphate"/><FilterOption id="6156" count="1565" label="fludarabine"/><FilterOption id="54804" count="1316" label="nivolumab"/><FilterOption id="10084" count="1287" label="tegafur + gimeracil + oteracil potassium"/><FilterOption id="70667" count="1208" label="pembrolizumab"/><FilterOption id="6386" count="1165" label="trastuzumab"/><FilterOption id="3130" count="1142" label="filgrastim"/><FilterOption id="4529" count="1133" label="temozolomide"/><FilterOption id="10388" count="1115" label="cetuximab"/><FilterOption id="3536" count="1113" label="pemetrexed disodium"/><FilterOption id="11961" count="1098" label="erlotinib"/><FilterOption id="29831" count="1037" label="sorafenib"/><FilterOption id="15954" count="975" label="bortezomib"/><FilterOption id="29016" count="962" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="27572" count="952" label="lenalidomide"/><FilterOption id="13022" count="867" label="epirubicin"/><FilterOption id="6050" count="855" label="metformin hydrochloride"/><FilterOption id="13340" count="780" label="everolimus"/><FilterOption id="4510" count="740" label="tacrolimus"/><FilterOption id="6408" count="726" label="vinorelbine"/><FilterOption id="3669" count="701" label="mycophenolate mofetil"/><FilterOption id="11460" count="693" label="imatinib"/><FilterOption id="36630" count="683" label="ipilimumab"/><FilterOption id="12973" count="667" label="sunitinib"/><FilterOption id="11603" count="608" label="gefitinib"/><FilterOption id="44314" count="563" label="tamoxifen"/><FilterOption id="54452" count="503" label="rivoceranib mesylate"/><FilterOption id="2784" count="483" label="letrozole"/><FilterOption id="6306" count="463" label="aldesleukin"/><FilterOption id="7934" count="455" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="4577" count="451" label="topotecan"/><FilterOption id="4200" count="438" label="sirolimus"/><FilterOption id="37370" count="429" label="azacitidine"/><FilterOption id="12135" count="423" label="celecoxib"/><FilterOption id="7121" count="415" label="sargramostim"/><FilterOption id="9298" count="405" label="Thymoglobulin"/><FilterOption id="11519" count="401" label="mitoxantrone"/><FilterOption id="2765" count="399" label="zoledronic acid"/><FilterOption id="81193" count="394" label="durvalumab"/><FilterOption id="48946" count="392" label="dasatinib"/><FilterOption id="21374" count="392" label="pegfilgrastim"/><FilterOption id="47000" count="382" label="bendamustine"/><FilterOption id="72699" count="369" label="atezolizumab"/><FilterOption id="33591" count="364" label="lapatinib"/><FilterOption id="43738" count="347" label="pazopanib"/><FilterOption id="2716" count="337" label="alemtuzumab"/><FilterOption id="3321" count="335" label="anastrozole"/><FilterOption id="8050" count="334" label="thalidomide, Celgene"/><FilterOption id="10309" count="331" label="abiraterone"/><FilterOption id="44403" count="328" label="lidocaine"/><FilterOption id="5369" count="328" label="ribavirin"/><FilterOption id="2807" count="325" label="atorvastatin"/><FilterOption id="55237" count="321" label="ibrutinib"/><FilterOption id="3081" count="318" label="exemestane"/><FilterOption id="12646" count="314" label="panitumumab"/><FilterOption id="53981" count="297" label="enzalutamide"/><FilterOption id="3313" count="295" label="fulvestrant"/><FilterOption id="2836" count="287" label="clopidogrel"/><FilterOption id="48945" count="285" label="bupivacaine, AstraZeneca"/><FilterOption id="12150" count="284" label="vincristine sulfate (liposomal injection), Spectrum Pharmaceuticals"/><FilterOption id="7286" count="280" label="goserelin acetate"/><FilterOption id="14163" count="279" label="adalimumab"/><FilterOption id="5999" count="275" label="ciclosporin, Novartis"/><FilterOption id="23625" count="270" label="peginterferon alfa-2a"/><FilterOption id="13239" count="269" label="decitabine"/><FilterOption id="24142" count="256" label="mesna"/><FilterOption id="16063" count="256" label="olaparib"/><FilterOption id="4126" count="255" label="pioglitazone"/><FilterOption id="22965" count="251" label="temsirolimus"/><FilterOption id="54449" count="248" label="afatinib"/><FilterOption id="17625" count="247" label="vorinostat (oral), Merck &amp; Co"/><FilterOption id="51388" count="243" label="nilotinib"/><FilterOption id="44279" count="242" label="amoxicillin"/><FilterOption id="5267" count="239" label="leuprorelin acetate"/><FilterOption id="44308" count="237" label="propofol, AstraZeneca/Fresenius"/><FilterOption id="2829" count="233" label="clarithromycin"/><FilterOption id="8783" count="232" label="dexmedetomidine"/><FilterOption id="5148" count="230" label="liraglutide"/><FilterOption id="44316" count="230" label="zidovudine"/><FilterOption id="4271" count="229" label="ropivacaine"/><FilterOption id="4567" count="224" label="etanercept"/><FilterOption id="28773" count="222" label="eribulin mesylate"/><FilterOption id="44303" count="220" label="midazolam hydrochloride"/><FilterOption id="3311" count="218" label="bicalutamide"/><FilterOption id="54601" count="217" label="carfilzomib"/><FilterOption id="6850" count="213" label="infliximab"/><FilterOption id="44305" count="212" label="omeprazole"/><FilterOption id="3474" count="209" label="lamivudine"/><FilterOption id="12420" count="209" label="rosuvastatin"/><FilterOption id="28532" count="207" label="pertuzumab"/><FilterOption id="16748" count="205" label="aprepitant"/></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="15285" count="1737" label="Solid tumor - Assessment of Safety and Tolerability"/><FilterOption id="15312" count="1588" label="Solid tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="15293" count="1448" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="15287" count="1440" label="Solid tumor - Assessment of adverse events"/><FilterOption id="8489" count="1392" label="Lung tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8639" count="1177" label="Lung tumor - Assessment of Safety and Tolerability"/><FilterOption id="8077" count="1147" label="Leukemia - Assessment of Safety and Tolerability"/><FilterOption id="8078" count="916" label="Leukemia - Assessment of adverse events"/><FilterOption id="7679" count="916" label="Lymphoma - Assessment of Safety and Tolerability"/><FilterOption id="8670" count="886" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"/><FilterOption id="9122" count="869" label="Breast tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8140" count="851" label="Leukemia - Protocol Specified Other Endpoints - Assessment of Clinical Efficacy"/><FilterOption id="7563" count="849" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="7987" count="834" label="Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"/><FilterOption id="8998" count="827" label="Breast tumor - Assessment of adverse events"/><FilterOption id="25874" count="827" label="Pain - Assessment of Intensity of Pain - Based on Visual analog scale[VAS]"/><FilterOption id="8996" count="803" label="Breast tumor - Assessment of Safety and Tolerability"/><FilterOption id="19282" count="788" label="Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments"/><FilterOption id="8481" count="786" label="Lung tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7908" count="779" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="9155" count="772" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="19412" count="771" label="Cancer supportive care - Protocol Specified Other Endpoints - Assessment of Other Treatment or Procedure Related Outcomes"/><FilterOption id="9133" count="767" label="Lymphoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"/><FilterOption id="7680" count="761" label="Lymphoma - Assessment of adverse events"/><FilterOption id="8640" count="749" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"/><FilterOption id="8713" count="743" label="Breast tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8505" count="729" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"/><FilterOption id="7569" count="728" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8719" count="720" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="8090" count="701" label="Leukemia - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="7704" count="692" label="Lymphoma - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="9153" count="688" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"/><FilterOption id="8430" count="679" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="8508" count="675" label="Lung tumor - Assessment of Overall Response"/><FilterOption id="8451" count="664" label="Colorectal tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="1" count="660" label="Hypertension - Assessment of Blood Pressure (BP)"/><FilterOption id="8721" count="655" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="19407" count="642" label="Cancer supportive care - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="1359" count="631" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels - Change in HbA1c"/><FilterOption id="7189" count="613" label="Prostate tumor - Assessment of Safety and Tolerability"/><FilterOption id="9246" count="605" label="HIV infection - Assessment of Safety and Tolerability"/><FilterOption id="8663" count="590" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="7564" count="589" label="Lymphoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="9008" count="587" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="19374" count="587" label="Cancer supportive care - Assessment of Safety and Tolerability"/><FilterOption id="9218" count="586" label="HIV infection - Assessment of Immune Response"/><FilterOption id="8163" count="582" label="Colorectal tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9247" count="559" label="HIV infection - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7547" count="556" label="Lymphoma - Assessment of Progression Free Survival (PFS)"/><FilterOption id="8187" count="551" label="Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)"/><FilterOption id="7879" count="547" label="Leukemia - Assessment of Overall Survival (OS)"/><FilterOption id="15288" count="545" label="Solid tumor - Assessment of Safety and Tolerability - Assessment of safety as measured by NCI CTCAE/NCI-CTC criteria"/><FilterOption id="1358" count="533" label="Non-insulin dependent diabetes - Assessment of Hemoglobin A1c (HbA1c) Levels"/><FilterOption id="37159" count="525" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8513" count="525" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="2" count="517" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"/><FilterOption id="12048" count="507" label="Hepatobiliary system tumor - Assessment of Overall Survival (OS)"/><FilterOption id="8514" count="506" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"/><FilterOption id="8436" count="503" label="Colorectal tumor - Assessment of Safety and Tolerability - Assessment of dose limiting toxicity"/><FilterOption id="7311" count="501" label="Head and neck tumor - Assessment of Safety and Tolerability"/><FilterOption id="7312" count="501" label="Head and neck tumor - Assessment of adverse events"/><FilterOption id="7026" count="500" label="Melanoma - Assessment of Safety and Tolerability - Assessment of toxicity profile"/><FilterOption id="9152" count="494" label="Lung tumor - Assessment of Other/Unspecified Efficacy Parameters"/><FilterOption id="15309" count="488" label="Solid tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="13344" count="485" label="Pancreas tumor - Assessment of Overall Survival (OS)"/><FilterOption id="7190" count="484" label="Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="43393" count="482" label="Other gastrointestinal disease - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="8523" count="481" label="Lung tumor - Assessment of Disease Progression"/><FilterOption id="25875" count="481" label="Pain - Assessment of Intensity of Pain - Based on Numerical Rating Scale [NRS]"/><FilterOption id="13433" count="479" label="Pancreas tumor - Assessment of Safety and Tolerability"/><FilterOption id="25873" count="475" label="Pain - Assessment of Intensity of Pain"/><FilterOption id="17462" count="472" label="Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of treatment toxicities"/><FilterOption id="7218" count="469" label="Prostate tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters - Assessment of maximum tolerated dose (MTD)"/><FilterOption id="8429" count="468" label="Colorectal tumor - Assessment of Safety and Tolerability"/><FilterOption id="7188" count="464" label="Prostate tumor - Assessment of Laboratory/Diagnostic Measures - Assessments by radiography/imaging"/><FilterOption id="7025" count="462" label="Melanoma - Assessment of Safety and Tolerability"/><FilterOption id="7014" count="456" label="Melanoma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="17460" count="454" label="Stem cell transplantation - Assessment of Safety and Tolerability"/><FilterOption id="10900" count="451" label="Ovary tumor - Assessment of Safety and Tolerability"/><FilterOption id="7906" count="450" label="Leukemia - Assessment of Response Rates (RR)"/><FilterOption id="8651" count="448" label="Lung tumor - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="10939" count="446" label="Ovary tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="6940" count="445" label="Melanoma - Assessment of Response Rates (RR) - Assessment of overall/objective response rate"/><FilterOption id="7027" count="440" label="Melanoma - Assessment of adverse events"/><FilterOption id="26044" count="431" label="Pain - Assessment of Therapy Related Outcomes - Assessment of analgesic use/rescue medication"/><FilterOption id="7909" count="428" label="Leukemia - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"/><FilterOption id="17461" count="427" label="Stem cell transplantation - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events"/><FilterOption id="7520" count="422" label="Multiple myeloma - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="17220" count="419" label="Anemia - Hematological Assessments - Assessment of hemoglobin status"/><FilterOption id="7230" count="419" label="Prostate tumor - Protocol Specified Other Endpoints - Assessment of Other Efficacy Outcomes"/><FilterOption id="7981" count="409" label="Leukemia - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="8720" count="406" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"/><FilterOption id="7988" count="400" label="Leukemia - Assessment of Laboratory/Diagnostic Measures"/><FilterOption id="26033" count="399" label="Pain - Assessment of adverse events"/><FilterOption id="15212" count="399" label="Solid tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)"/><FilterOption id="7488" count="398" label="Multiple myeloma - Assessment of Safety and Tolerability"/><FilterOption id="7340" count="394" label="Head and neck tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"/><FilterOption id="10830" count="394" label="Ovary tumor - Assessment of Progression Free Survival (PFS)"/><FilterOption id="9043" count="390" label="Breast tumor - Protocol Specified Other Endpoints"/><FilterOption id="17031" count="387" label="Influenza Vaccine - Assessment of Immune Response - Assessment of anti-influenza antibodies"/></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="100"><FilterOption id="20519" count="10897" label="National Cancer Institute"/><FilterOption id="23137" count="2590" label="Novartis AG"/><FilterOption id="18767" count="2011" label="Pfizer Inc"/><FilterOption id="28355" count="1911" label="GlaxoSmithKline plc"/><FilterOption id="23382" count="1882" label="MD Anderson Cancer Center"/><FilterOption id="15065" count="1726" label="Bristol-Myers Squibb Co"/><FilterOption id="14190" count="1725" label="AstraZeneca plc"/><FilterOption id="19446" count="1628" label="Roche Holding AG"/><FilterOption id="1009547" count="1482" label="Sanofi SA"/><FilterOption id="1059823" count="1453" label="Merck Sharp &amp; Dohme Corp"/><FilterOption id="20520" count="1434" label="National Institute of Allergy and Infectious Diseases"/><FilterOption id="17810" count="1399" label="Eli Lilly &amp; Co"/><FilterOption id="20518" count="1322" label="National Institutes of Health"/><FilterOption id="22122" count="1183" label="Memorial Sloan-Kettering Cancer Center"/><FilterOption id="19453" count="1154" label="Genentech Inc"/><FilterOption id="1069368" count="1100" label="National Institutes of Health Clinical Center"/><FilterOption id="21569" count="1057" label="Massachusetts General Hospital"/><FilterOption id="15331" count="991" label="Celgene Corp"/><FilterOption id="14455" count="935" label="Bayer AG"/><FilterOption id="14109" count="917" label="Amgen Inc"/><FilterOption id="21111" count="849" label="Mayo Clinic Foundation"/><FilterOption id="15615" count="816" label="Dana-Farber Cancer Institute Inc"/><FilterOption id="1004360" count="699" label="Sun Yat-Sen University"/><FilterOption id="14881" count="695" label="Boehringer Ingelheim International GmbH"/><FilterOption id="1003240" count="670" label="National Heart Lung and Blood Institute"/><FilterOption id="20300" count="576" label="Takeda Pharmaceutical Co Ltd"/><FilterOption id="29469" count="571" label="Cancer Research UK"/><FilterOption id="1013295" count="559" label="Astellas Pharma Inc"/><FilterOption id="1039740" count="546" label="National Natural Science Foundation of China"/><FilterOption id="18077" count="527" label="Merck &amp; Co Inc"/><FilterOption id="20567" count="521" label="Duke University"/><FilterOption id="26113" count="512" label="Washington University in St Louis"/><FilterOption id="20679" count="497" label="Stanford University"/><FilterOption id="24773" count="491" label="University of California San Francisco"/><FilterOption id="26334" count="489" label="National Institute of Diabetes, Digestive and Kidney Diseases"/><FilterOption id="DOL1000375" count="473" label="Fudan University"/><FilterOption id="1040381" count="472" label="Cancer and Leukemia Group B"/><FilterOption id="16450" count="445" label="Gilead Sciences Inc"/><FilterOption id="26013" count="431" label="University of Chicago"/><FilterOption id="20659" count="429" label="University of Pittsburgh"/><FilterOption id="1042135" count="427" label="Sidney Kimmel Comprehensive Cancer Center"/><FilterOption id="21048" count="419" label="Brigham &amp; Women's Hospital"/><FilterOption id="20645" count="415" label="Northwestern University"/><FilterOption id="20658" count="412" label="University of Pennsylvania"/><FilterOption id="1041701" count="409" label="Japanese Ministry of Health, Labor and Welfare"/><FilterOption id="1004334" count="395" label="Samsung Medical Center (SMC)"/><FilterOption id="13601" count="394" label="Abbott Laboratories"/><FilterOption id="20534" count="382" label="Baylor College of Medicine"/><FilterOption id="16218" count="382" label="Fred Hutchinson Cancer Research Center"/><FilterOption id="1003017" count="371" label="Seoul National University Hospital"/><FilterOption id="20701" count="371" label="University of Washington"/><FilterOption id="1072507" count="368" label="AbbVie Inc"/><FilterOption id="18101" count="368" label="Merck KGaA"/><FilterOption id="1028858" count="367" label="Southwest Oncology Group"/><FilterOption id="28443" count="362" label="The University Health Network"/><FilterOption id="25760" count="354" label="University of Texas Southwestern Medical Center"/><FilterOption id="1038961" count="351" label="National Taiwan University Hospital"/><FilterOption id="29603" count="348" label="H Lee Moffitt Cancer Center and Research Institute"/><FilterOption id="21991" count="344" label="Takeda Oncology"/><FilterOption id="20524" count="344" label="University of Alabama at Birmingham"/><FilterOption id="20573" count="343" label="Emory University"/><FilterOption id="20623" count="336" label="University of Michigan"/><FilterOption id="23119" count="333" label="European Organisation for Research and Treatment of Cancer (EORTC)"/><FilterOption id="23948" count="328" label="Assistance Publique Hopitaux de Paris"/><FilterOption id="20559" count="328" label="Columbia University"/><FilterOption id="24771" count="320" label="Eastern Cooperative Oncology Group"/><FilterOption id="1043068" count="318" label="Eunice Kennedy Shriver National Institute of Child Health &amp; Human Development"/><FilterOption id="1041378" count="314" label="Children's Oncology Group"/><FilterOption id="19620" count="313" label="Eisai Inc"/><FilterOption id="DOL1000742" count="312" label="University of Wisconsin-Madison"/><FilterOption id="1036320" count="308" label="Asan Medical Center"/><FilterOption id="1039242" count="308" label="Case Comprehensive Cancer Center"/><FilterOption id="26178" count="308" label="F Hoffmann-La Roche AG"/><FilterOption id="20634" count="304" label="University of North Carolina"/><FilterOption id="1051922" count="298" label="City of Hope Medical Center"/><FilterOption id="1060642" count="295" label="National Cancer Center Hospital"/><FilterOption id="18614" count="294" label="Novo Nordisk A/S"/><FilterOption id="20631" count="293" label="Mount Sinai School of Medicine"/><FilterOption id="1006925" count="292" label="Jiangsu Hengrui Medicine Co Ltd"/><FilterOption id="21099" count="289" label="Roswell Park Comprehensive Cancer Center"/><FilterOption id="1067538" count="286" label="Janssen Research &amp; Development LLC"/><FilterOption id="20596" count="285" label="Johns Hopkins University"/><FilterOption id="1107695" count="282" label="Japan Agency for Medical Research and Development"/><FilterOption id="24877" count="281" label="Beth Israel Deaconess Medical Center"/><FilterOption id="1065861" count="274" label="Ministry of Education, Culture, Sports, Science and Technology of Japan"/><FilterOption id="17332" count="270" label="Johnson &amp; Johnson"/><FilterOption id="18438" count="270" label="Medical Research Council"/><FilterOption id="18720" count="269" label="Taiho Pharmaceutical Co Ltd"/><FilterOption id="20703" count="267" label="Yale University"/><FilterOption id="16299" count="265" label="Sanofi Genzyme"/><FilterOption id="25184" count="263" label="Yonsei University"/><FilterOption id="20673" count="256" label="University of Southern California"/><FilterOption id="1041928" count="255" label="National Institute on Aging"/><FilterOption id="20653" count="253" label="Osaka University"/><FilterOption id="1007827" count="246" label="University Medical Center Groningen"/><FilterOption id="20669" count="245" label="University of Rochester"/><FilterOption id="18681" count="244" label="Ono Pharmaceutical Co Ltd"/><FilterOption id="1040917" count="243" label="Weill Medical College of Cornell University"/><FilterOption id="1021685" count="239" label="Chinese PLA General Hospital"/><FilterOption id="26109" count="237" label="Jonsson Comprehensive Cancer Center"/></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="100"><FilterOption count="3262" label="2019-01-26"/><FilterOption count="3117" label="2019-03-07"/><FilterOption count="2880" label="2018-10-15"/><FilterOption count="2840" label="2019-01-25"/><FilterOption count="2621" label="2018-10-14"/><FilterOption count="2530" label="2019-01-24"/><FilterOption count="2169" label="2018-10-13"/><FilterOption count="2168" label="2018-10-12"/><FilterOption count="1243" label="2013-12-02"/><FilterOption count="1240" label="2018-10-16"/><FilterOption count="652" label="2018-07-07"/><FilterOption count="584" label="2018-06-09"/><FilterOption count="556" label="2019-07-03"/><FilterOption count="523" label="2013-09-14"/><FilterOption count="487" label="2019-06-07"/><FilterOption count="474" label="2019-06-26"/><FilterOption count="459" label="2013-09-13"/><FilterOption count="452" label="2019-06-27"/><FilterOption count="445" label="2019-06-28"/><FilterOption count="420" label="2019-06-20"/><FilterOption count="419" label="2019-06-12"/><FilterOption count="414" label="2019-06-06"/><FilterOption count="411" label="2019-07-02"/><FilterOption count="410" label="2019-06-13"/><FilterOption count="406" label="2018-06-30"/><FilterOption count="387" label="2019-06-14"/><FilterOption count="378" label="2018-06-23"/><FilterOption count="376" label="2019-05-31"/><FilterOption count="376" label="2019-06-21"/><FilterOption count="371" label="2019-06-19"/><FilterOption count="367" label="2017-08-04"/><FilterOption count="364" label="2019-04-15"/><FilterOption count="360" label="2017-08-05"/><FilterOption count="354" label="2019-06-25"/><FilterOption count="345" label="2019-06-18"/><FilterOption count="342" label="2019-07-01"/><FilterOption count="339" label="2019-06-10"/><FilterOption count="330" label="2019-04-22"/><FilterOption count="326" label="2019-05-15"/><FilterOption count="326" label="2019-05-24"/><FilterOption count="325" label="2018-07-14"/><FilterOption count="321" label="2019-04-17"/><FilterOption count="320" label="2019-05-14"/><FilterOption count="319" label="2019-05-16"/><FilterOption count="315" label="2019-05-30"/><FilterOption count="315" label="2019-06-11"/><FilterOption count="314" label="2018-06-02"/><FilterOption count="312" label="2018-11-20"/><FilterOption count="309" label="2017-08-03"/><FilterOption count="300" label="2019-06-17"/><FilterOption count="298" label="2018-11-29"/><FilterOption count="298" label="2019-05-22"/><FilterOption count="296" label="2017-03-30"/><FilterOption count="295" label="2018-12-12"/><FilterOption count="295" label="2019-06-03"/><FilterOption count="294" label="2019-04-23"/><FilterOption count="287" label="2014-03-25"/><FilterOption count="287" label="2019-05-27"/><FilterOption count="286" label="2019-05-23"/><FilterOption count="285" label="2018-05-26"/><FilterOption count="280" label="2018-05-23"/><FilterOption count="280" label="2019-05-21"/><FilterOption count="278" label="2019-05-17"/><FilterOption count="276" label="2018-12-17"/><FilterOption count="275" label="2019-06-04"/><FilterOption count="274" label="2019-05-10"/><FilterOption count="273" label="2018-12-05"/><FilterOption count="270" label="2019-04-09"/><FilterOption count="269" label="2018-12-10"/><FilterOption count="267" label="2018-05-12"/><FilterOption count="261" label="2019-04-24"/><FilterOption count="259" label="2019-04-05"/><FilterOption count="256" label="2018-05-29"/><FilterOption count="255" label="2018-11-27"/><FilterOption count="253" label="2019-05-07"/><FilterOption count="249" label="2018-12-06"/><FilterOption count="247" label="2016-09-14"/><FilterOption count="246" label="2018-12-13"/><FilterOption count="246" label="2018-12-20"/><FilterOption count="242" label="2018-12-11"/><FilterOption count="241" label="2018-05-19"/><FilterOption count="240" label="2018-12-14"/><FilterOption count="238" label="2019-04-12"/><FilterOption count="238" label="2019-05-13"/><FilterOption count="238" label="2019-06-24"/><FilterOption count="237" label="2018-12-19"/><FilterOption count="236" label="2019-04-11"/><FilterOption count="230" label="2019-05-29"/><FilterOption count="227" label="2019-03-14"/><FilterOption count="225" label="2018-12-18"/><FilterOption count="225" label="2019-05-02"/><FilterOption count="224" label="2019-05-08"/><FilterOption count="220" label="2018-04-28"/><FilterOption count="220" label="2019-04-25"/><FilterOption count="219" label="2018-07-06"/><FilterOption count="219" label="2018-07-11"/><FilterOption count="218" label="2018-01-28"/><FilterOption count="217" label="2019-04-26"/><FilterOption count="216" label="2019-04-10"/><FilterOption count="215" label="2018-05-09"/></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="100"><FilterOption count="2475" label="201912"/><FilterOption count="2037" label="202012"/><FilterOption count="1691" label="201812"/><FilterOption count="1276" label="201712"/><FilterOption count="1076" label="202112"/><FilterOption count="1069" label="201612"/><FilterOption count="952" label="201906"/><FilterOption count="950" label="202006"/><FilterOption count="856" label="201512"/><FilterOption count="836" label="201412"/><FilterOption count="727" label="201312"/><FilterOption count="726" label="202001"/><FilterOption count="714" label="201909"/><FilterOption count="705" label="202003"/><FilterOption count="691" label="201212"/><FilterOption count="651" label="201706"/><FilterOption count="641" label="201806"/><FilterOption count="635" label="201907"/><FilterOption count="633" label="202212"/><FilterOption count="632" label="201910"/><FilterOption count="628" label="201903"/><FilterOption count="619" label="202007"/><FilterOption count="613" label="202005"/><FilterOption count="605" label="201908"/><FilterOption count="601" label="201803"/><FilterOption count="597" label="201809"/><FilterOption count="588" label="201606"/><FilterOption count="585" label="202009"/><FilterOption count="582" label="201112"/><FilterOption count="582" label="201807"/><FilterOption count="576" label="201901"/><FilterOption count="571" label="202106"/><FilterOption count="563" label="201703"/><FilterOption count="552" label="201905"/><FilterOption count="552" label="202004"/><FilterOption count="551" label="201805"/><FilterOption count="547" label="201810"/><FilterOption count="545" label="201904"/><FilterOption count="537" label="202008"/><FilterOption count="536" label="201808"/><FilterOption count="531" label="201012"/><FilterOption count="528" label="201506"/><FilterOption count="517" label="200912"/><FilterOption count="514" label="201801"/><FilterOption count="500" label="201603"/><FilterOption count="500" label="201707"/><FilterOption count="497" label="201811"/><FilterOption count="490" label="201609"/><FilterOption count="490" label="201709"/><FilterOption count="488" label="201710"/><FilterOption count="485" label="202103"/><FilterOption count="482" label="201911"/><FilterOption count="480" label="202101"/><FilterOption count="475" label="201704"/><FilterOption count="468" label="201306"/><FilterOption count="467" label="201804"/><FilterOption count="467" label="202010"/><FilterOption count="465" label="201701"/><FilterOption count="458" label="201708"/><FilterOption count="458" label="201711"/><FilterOption count="458" label="202002"/><FilterOption count="445" label="201406"/><FilterOption count="445" label="201601"/><FilterOption count="443" label="201503"/><FilterOption count="443" label="201607"/><FilterOption count="441" label="201902"/><FilterOption count="440" label="201206"/><FilterOption count="439" label="201705"/><FilterOption count="434" label="202011"/><FilterOption count="432" label="201410"/><FilterOption count="430" label="201510"/><FilterOption count="430" label="201604"/><FilterOption count="428" label="201608"/><FilterOption count="425" label="200812"/><FilterOption count="423" label="201605"/><FilterOption count="422" label="201610"/><FilterOption count="417" label="201409"/><FilterOption count="416" label="201802"/><FilterOption count="415" label="201508"/><FilterOption count="413" label="201403"/><FilterOption count="413" label="201611"/><FilterOption count="410" label="201407"/><FilterOption count="408" label="201305"/><FilterOption count="408" label="201404"/><FilterOption count="406" label="201405"/><FilterOption count="405" label="201303"/><FilterOption count="405" label="201501"/><FilterOption count="405" label="201507"/><FilterOption count="402" label="202107"/><FilterOption count="398" label="201210"/><FilterOption count="396" label="201509"/><FilterOption count="394" label="201702"/><FilterOption count="392" label="201203"/><FilterOption count="386" label="201201"/><FilterOption count="386" label="201505"/><FilterOption count="385" label="201309"/><FilterOption count="382" label="202109"/><FilterOption count="379" label="201106"/><FilterOption count="374" label="201310"/><FilterOption count="371" label="201006"/></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="100"><FilterOption count="1071" label="201906"/><FilterOption count="1068" label="201901"/><FilterOption count="1009" label="201801"/><FilterOption count="997" label="201701"/><FilterOption count="944" label="201601"/><FilterOption count="943" label="201810"/><FilterOption count="906" label="201903"/><FilterOption count="900" label="201812"/><FilterOption count="898" label="201803"/><FilterOption count="895" label="201806"/><FilterOption count="889" label="201501"/><FilterOption count="888" label="201905"/><FilterOption count="887" label="201712"/><FilterOption count="877" label="201904"/><FilterOption count="873" label="201710"/><FilterOption count="852" label="201707"/><FilterOption count="847" label="201703"/><FilterOption count="841" label="201809"/><FilterOption count="835" label="201711"/><FilterOption count="833" label="201807"/><FilterOption count="827" label="201804"/><FilterOption count="822" label="201609"/><FilterOption count="822" label="201706"/><FilterOption count="822" label="201808"/><FilterOption count="820" label="201611"/><FilterOption count="817" label="201805"/><FilterOption count="810" label="201603"/><FilterOption count="802" label="201606"/><FilterOption count="796" label="201709"/><FilterOption count="793" label="201612"/><FilterOption count="793" label="201705"/><FilterOption count="793" label="201811"/><FilterOption count="790" label="201401"/><FilterOption count="789" label="201610"/><FilterOption count="775" label="201506"/><FilterOption count="774" label="201708"/><FilterOption count="766" label="201802"/><FilterOption count="764" label="201604"/><FilterOption count="757" label="201608"/><FilterOption count="753" label="201704"/><FilterOption count="752" label="201510"/><FilterOption count="749" label="201605"/><FilterOption count="739" label="201201"/><FilterOption count="738" label="201503"/><FilterOption count="731" label="201512"/><FilterOption count="726" label="201504"/><FilterOption count="718" label="201509"/><FilterOption count="710" label="201505"/><FilterOption count="710" label="201507"/><FilterOption count="703" label="201511"/><FilterOption count="701" label="201902"/><FilterOption count="700" label="201607"/><FilterOption count="697" label="201702"/><FilterOption count="692" label="201101"/><FilterOption count="690" label="201602"/><FilterOption count="689" label="201301"/><FilterOption count="674" label="201410"/><FilterOption count="671" label="201001"/><FilterOption count="669" label="201210"/><FilterOption count="663" label="201207"/><FilterOption count="663" label="201309"/><FilterOption count="641" label="201206"/><FilterOption count="639" label="201103"/><FilterOption count="636" label="201412"/><FilterOption count="630" label="201310"/><FilterOption count="624" label="201109"/><FilterOption count="624" label="201409"/><FilterOption count="623" label="201304"/><FilterOption count="620" label="200901"/><FilterOption count="619" label="201203"/><FilterOption count="619" label="201205"/><FilterOption count="613" label="201303"/><FilterOption count="610" label="201204"/><FilterOption count="608" label="201307"/><FilterOption count="606" label="201208"/><FilterOption count="605" label="201502"/><FilterOption count="604" label="200909"/><FilterOption count="601" label="201403"/><FilterOption count="599" label="201212"/><FilterOption count="599" label="201907"/><FilterOption count="598" label="201404"/><FilterOption count="597" label="201311"/><FilterOption count="596" label="201106"/><FilterOption count="593" label="201006"/><FilterOption count="592" label="201209"/><FilterOption count="591" label="201411"/><FilterOption count="588" label="201508"/><FilterOption count="583" label="201305"/><FilterOption count="582" label="200801"/><FilterOption count="581" label="201312"/><FilterOption count="579" label="201306"/><FilterOption count="577" label="201110"/><FilterOption count="576" label="201010"/><FilterOption count="573" label="201107"/><FilterOption count="569" label="201211"/><FilterOption count="567" label="201111"/><FilterOption count="565" label="201405"/><FilterOption count="561" label="201407"/><FilterOption count="560" label="201004"/><FilterOption count="559" label="201009"/></Filter><Filter label="Trial Phase" name="trialPhase" total="15"><FilterOption id="C2" count="39989" label="Phase 2 Clinical"/><FilterOption id="C1" count="19119" label="Phase 1 Clinical"/><FilterOption id="PNA" count="18451" label="Phase Not Applicable"/><FilterOption id="C3" count="16195" label="Phase 3 Clinical"/><FilterOption id="NS" count="14306" label="Phase not specified"/><FilterOption id="C4" count="10423" label="Phase 4 Clinical"/><FilterOption id="C12" count="9195" label="Phase 1/Phase 2 Clinical"/><FilterOption id="C23" count="2410" label="Phase 2/Phase 3 Clinical"/><FilterOption id="C1B" count="1614" label="Phase 1b Clinical"/><FilterOption id="C2A" count="1072" label="Phase 2a Clinical"/><FilterOption id="C0" count="1071" label="Phase 0 Clinical"/><FilterOption id="C2B" count="924" label="Phase 2b Clinical"/><FilterOption id="C3B" count="484" label="Phase 3b Clinical"/><FilterOption id="C1A" count="164" label="Phase 1a Clinical"/><FilterOption id="C3A" count="57" label="Phase 3a Clinical"/></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="3976" count="5649" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3977" count="5635" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="3900" count="5593" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"/><FilterOption id="3957" count="5344" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"/><FilterOption id="4879" count="4720" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4880" count="4706" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4024" count="4361" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4032" count="4207" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="3936" count="4181" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"/><FilterOption id="4074" count="4176" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"/><FilterOption id="13096" count="4139" label="Solid tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4840" count="4068" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3940" count="3758" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="3537" count="3559" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="3538" count="3558" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4483" count="3448" label="Colorectal tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4527" count="3385" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4528" count="3372" label="Colorectal tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="13129" count="3350" label="Solid tumor - Subjects with Treatment Refractory Disease"/><FilterOption id="3622" count="3210" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="22381" count="3204" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"/><FilterOption id="5087" count="3203" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="5086" count="3202" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="5073" count="3192" label="Leukemia - Subjects with Normal/Acceptable Organ Function - Subjects with normal/adequate liver function"/><FilterOption id="3938" count="3180" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with advanced stage lung cancer"/><FilterOption id="4073" count="3171" label="Lung tumor - Protocol Specified Other Inclusion Criteria"/><FilterOption id="3628" count="3107" label="Lymphoma - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4509" count="3101" label="Colorectal tumor - Subjects with Histologically Confirmed Colorectal Cancer"/><FilterOption id="584" count="3075" label="Non-insulin dependent diabetes - Subjects with Diabetes Mellitus - Subjects with type 2 diabetes mellitus"/><FilterOption id="5074" count="3074" label="Leukemia - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="13110" count="2860" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="13111" count="2856" label="Solid tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4569" count="2826" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematopoetic/marrow function"/><FilterOption id="3548" count="2826" label="Lymphoma - Subjects Diagnosed Based on Histo-Pathological Examination"/><FilterOption id="5088" count="2805" label="Leukemia - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4564" count="2784" label="Colorectal tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="3642" count="2757" label="Lymphoma - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="3539" count="2742" label="Lymphoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="13377" count="2739" label="Cancer supportive care - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="3978" count="2728" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4981" count="2672" label="Leukemia - Subjects with Acute Myeloid Leukemia (AML)"/><FilterOption id="4565" count="2668" label="Colorectal tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="3971" count="2648" label="Lung tumor - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of three months or more"/><FilterOption id="4106" count="2495" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"/><FilterOption id="3989" count="2460" label="Lung tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="32043" count="2460" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"/><FilterOption id="13369" count="2433" label="Cancer supportive care - Protocol Specified Other Inclusion Criteria"/><FilterOption id="3933" count="2414" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage III lung cancer"/><FilterOption id="3464" count="2404" label="Lymphoma - Subjects with B Cell Non Hodgkin's Lymphoma"/><FilterOption id="7091" count="2394" label="Prostate tumor - Subjects with Advanced/Metastatic Cancer"/><FilterOption id="4955" count="2374" label="Breast tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="4467" count="2356" label="Colorectal tumor - Subjects with Rectal Cancer"/><FilterOption id="3935" count="2355" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"/><FilterOption id="4881" count="2348" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"/><FilterOption id="4877" count="2291" label="Breast tumor - Subjects with Protocol Specified Life Expectancy"/><FilterOption id="13131" count="2285" label="Solid tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="3914" count="2275" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"/><FilterOption id="4894" count="2227" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="4468" count="2214" label="Colorectal tumor - Subjects with Colon Cancer"/><FilterOption id="13132" count="2207" label="Solid tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="3614" count="2157" label="Lymphoma - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="13133" count="2140" label="Solid tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="3738" count="2135" label="Prostate tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod status 0-2"/><FilterOption id="22417" count="2074" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"/><FilterOption id="17850" count="2034" label="Stem cell transplantation - Subjects with History of/Indicated for Hematopoietic Stem Cell Transplantation(HSCT)"/><FilterOption id="4398" count="2008" label="Head and neck tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4397" count="2007" label="Head and neck tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4973" count="1960" label="Leukemia - Subjects with Acute Leukemia Unspecified Type"/><FilterOption id="3987" count="1919" label="Lung tumor - Treatment Naive Subjects"/><FilterOption id="22262" count="1903" label="Pain - Protocol Specified Other Inclusion Criteria"/><FilterOption id="3609" count="1896" label="Lymphoma - Subjects with Relapsed/Recurrent Disease"/><FilterOption id="3695" count="1888" label="Prostate tumor - Subjects with Stage IV Prostate Cancer"/><FilterOption id="3913" count="1845" label="Lung tumor - Subjects with Measurable Disease"/><FilterOption id="3561" count="1844" label="Lymphoma - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="4545" count="1836" label="Colorectal tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="3726" count="1812" label="Prostate tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4985" count="1782" label="Leukemia - Subjects with Acute Lymphocytic Leukemia (ALL)"/><FilterOption id="4416" count="1781" label="Head and neck tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="3994" count="1778" label="Lung tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer radiotherapy"/><FilterOption id="3724" count="1777" label="Prostate tumor - Subjects with acceptable hematological value"/><FilterOption id="5164" count="1761" label="Leukemia - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="4041" count="1761" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"/><FilterOption id="4893" count="1758" label="Breast tumor - Subjects with History of Anti Cancer Therapy"/><FilterOption id="3727" count="1750" label="Prostate tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="3715" count="1743" label="Prostate tumor - Subjects with Histologically/Cytologically Confirmed Prostate Cancer - Subjects with adenocarcinoma of prostate"/><FilterOption id="3465" count="1734" label="Lymphoma - Subjects with T Cell Non Hodgkin's Lymphoma"/><FilterOption id="4856" count="1731" label="Breast tumor - Subjects with Measurable Disease"/><FilterOption id="5102" count="1723" label="Leukemia - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"/><FilterOption id="4922" count="1720" label="Breast tumor - Subjects with Progressive/Treatment Refractory Disease"/><FilterOption id="7864" count="1705" label="Hepatobiliary system tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="13138" count="1704" label="Solid tumor - Subjects with Protocol Specified Participation Status - Subjects willing/able to provide informed consent/assent"/><FilterOption id="8835" count="1688" label="Pancreas tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="5173" count="1687" label="Leukemia - Subjects with Relapsed/Recurrent Disease"/><FilterOption id="8836" count="1687" label="Pancreas tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4169" count="1684" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"/><FilterOption id="4417" count="1682" label="Head and neck tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"/><FilterOption id="4419" count="1677" label="Head and neck tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"/><FilterOption id="4170" count="1674" label="Melanoma - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="7865" count="1673" label="Hepatobiliary system tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"/><FilterOption id="4794" count="1667" label="Head and neck tumor - Subjects with Specific Histological Sub-type of Head and Neck Cancer - Subjects with squamous cell head and neck carcinoma"/></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="100"><FilterOption id="2953" count="226" label="docetaxel"/><FilterOption id="3199" count="180" label="gemcitabine"/><FilterOption id="3803" count="154" label="paclitaxel"/><FilterOption id="12205" count="140" label="capecitabine"/><FilterOption id="6050" count="101" label="metformin hydrochloride"/><FilterOption id="29831" count="83" label="sorafenib"/><FilterOption id="4529" count="82" label="temozolomide"/><FilterOption id="8047" count="66" label="bevacizumab"/><FilterOption id="6736" count="65" label="rituximab"/><FilterOption id="2807" count="63" label="atorvastatin"/><FilterOption id="11961" count="60" label="erlotinib"/><FilterOption id="44314" count="58" label="tamoxifen"/><FilterOption id="8165" count="58" label="tiotropium bromide"/><FilterOption id="11460" count="57" label="imatinib"/><FilterOption id="10252" count="57" label="insulin glargine"/><FilterOption id="14163" count="54" label="adalimumab"/><FilterOption id="4510" count="54" label="tacrolimus"/><FilterOption id="70667" count="49" label="pembrolizumab"/><FilterOption id="48945" count="48" label="bupivacaine, AstraZeneca"/><FilterOption id="3536" count="48" label="pemetrexed disodium"/><FilterOption id="2784" count="47" label="letrozole"/><FilterOption id="5267" count="46" label="leuprorelin acetate"/><FilterOption id="7934" count="45" label="doxorubicin (liposomal, STEALTH), Alza"/><FilterOption id="21374" count="45" label="pegfilgrastim"/><FilterOption id="3313" count="44" label="fulvestrant"/><FilterOption id="2871" count="44" label="irinotecan"/><FilterOption id="12978" count="43" label="moxifloxacin"/><FilterOption id="2836" count="42" label="clopidogrel"/><FilterOption id="44375" count="42" label="warfarin"/><FilterOption id="11603" count="41" label="gefitinib"/><FilterOption id="12973" count="41" label="sunitinib"/><FilterOption id="6408" count="40" label="vinorelbine"/><FilterOption id="3130" count="39" label="filgrastim"/><FilterOption id="14336" count="39" label="fluticasone propionate + salmeterol (asthma and COPD), GlaxoSmithKline"/><FilterOption id="6386" count="39" label="trastuzumab"/><FilterOption id="3321" count="38" label="anastrozole"/><FilterOption id="44409" count="38" label="Fluzone"/><FilterOption id="4513" count="37" label="tamsulosin hydrochloride"/><FilterOption id="2500" count="36" label="amlodipine"/><FilterOption id="12135" count="36" label="celecoxib"/><FilterOption id="4577" count="36" label="topotecan"/><FilterOption id="13486" count="35" label="entecavir"/><FilterOption id="6140" count="35" label="formoterol"/><FilterOption id="54804" count="34" label="nivolumab"/><FilterOption id="13928" count="33" label="enoxaparin sodium"/><FilterOption id="14493" count="33" label="tenofovir disoproxil fumarate"/><FilterOption id="10084" count="32" label="tegafur + gimeracil + oteracil potassium"/><FilterOption id="10388" count="31" label="cetuximab"/><FilterOption id="44305" count="31" label="omeprazole"/><FilterOption id="3750" count="31" label="ondansetron"/><FilterOption id="37370" count="30" label="azacitidine"/><FilterOption id="3081" count="30" label="exemestane"/><FilterOption id="7286" count="30" label="goserelin acetate"/><FilterOption id="8832" count="29" label="glimepiride"/><FilterOption id="4271" count="29" label="ropivacaine"/><FilterOption id="44499" count="29" label="sitagliptin"/><FilterOption id="27572" count="28" label="lenalidomide"/><FilterOption id="44403" count="28" label="lidocaine"/><FilterOption id="29016" count="28" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"/><FilterOption id="44312" count="28" label="salmeterol"/><FilterOption id="44313" count="28" label="simvastatin"/><FilterOption id="2765" count="28" label="zoledronic acid"/><FilterOption id="4567" count="27" label="etanercept"/><FilterOption id="44401" count="27" label="vancomycin"/><FilterOption id="16026" count="26" label="esomeprazole"/><FilterOption id="7413" count="25" label="darbepoetin alfa"/><FilterOption id="22395" count="25" label="ranibizumab"/><FilterOption id="13340" count="24" label="everolimus"/><FilterOption id="44383" count="23" label="carboplatin"/><FilterOption id="5148" count="23" label="liraglutide"/><FilterOption id="44303" count="23" label="midazolam hydrochloride"/><FilterOption id="4126" count="23" label="pioglitazone"/><FilterOption id="44308" count="23" label="propofol, AstraZeneca/Fresenius"/><FilterOption id="3492" count="22" label="levofloxacin"/><FilterOption id="17814" count="22" label="pregabalin"/><FilterOption id="3311" count="21" label="bicalutamide"/><FilterOption id="3159" count="21" label="fluticasone propionate"/><FilterOption id="6850" count="21" label="infliximab"/><FilterOption id="3517" count="21" label="losartan"/><FilterOption id="3669" count="21" label="mycophenolate mofetil"/><FilterOption id="7607" count="20" label="follitropin alfa"/><FilterOption id="3353" count="20" label="insulin lispro"/><FilterOption id="6104" count="20" label="lansoprazole"/><FilterOption id="5800" count="20" label="pantoprazole"/><FilterOption id="43738" count="20" label="pazopanib"/><FilterOption id="2773" count="20" label="valsartan"/><FilterOption id="10411" count="19" label="insulin aspart"/><FilterOption id="13460" count="19" label="oseltamivir"/><FilterOption id="67892" count="18" label="epoetin alfa (Procrit/Eprex), Johnson &amp; Johnson"/><FilterOption id="44292" count="18" label="fluconazole"/><FilterOption id="3616" count="18" label="meropenem"/><FilterOption id="23625" count="18" label="peginterferon alfa-2a"/><FilterOption id="12420" count="18" label="rosuvastatin"/><FilterOption id="6893" count="17" label="alteplase"/><FilterOption id="53981" count="17" label="enzalutamide"/><FilterOption id="7080" count="17" label="Pneumovax 23"/><FilterOption id="4579" count="17" label="tramadol hydrochloride"/><FilterOption id="72699" count="16" label="atezolizumab"/><FilterOption id="36630" count="16" label="ipilimumab"/><FilterOption id="54624" count="16" label="regorafenib"/></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="100"><FilterOption id="372" count="532" label="Thymidylate synthase inhibitor"/><FilterOption id="142" count="394" label="Topoisomerase II inhibitor"/><FilterOption id="138" count="273" label="DNA polymerase inhibitor"/><FilterOption id="3808" count="258" label="Kit tyrosine kinase inhibitor"/><FilterOption id="141" count="244" label="Topoisomerase I inhibitor"/><FilterOption id="3848" count="242" label="VEGF-2 receptor antagonist"/><FilterOption id="5085" count="234" label="B-lymphocyte antigen CD20 inhibitor"/><FilterOption id="740" count="233" label="Epidermal growth factor receptor antagonist"/><FilterOption id="12521" count="228" label="VEGF ligand inhibitor"/><FilterOption id="8805" count="227" label="AMP activated protein kinase stimulator"/><FilterOption id="3846" count="224" label="VEGF-1 receptor antagonist"/><FilterOption id="135" count="207" label="DHFR inhibitor"/><FilterOption id="374" count="198" label="Transferase inhibitor"/><FilterOption id="3850" count="197" label="VEGF-3 receptor antagonist"/><FilterOption id="181" count="195" label="GAR transformylase inhibitor"/><FilterOption id="23014" count="195" label="Insulin ligand"/><FilterOption id="400" count="195" label="Insulin receptor agonist"/><FilterOption id="40" count="187" label="Beta 2 adrenoceptor agonist"/><FilterOption id="948" count="187" label="PDGF receptor antagonist"/><FilterOption id="3756" count="186" label="Erbb2 tyrosine kinase receptor inhibitor"/><FilterOption id="4010" count="179" label="Calcineurin inhibitor"/><FilterOption id="208" count="178" label="H+ K+ ATPase inhibitor"/><FilterOption id="48492" count="174" label="PDGF receptor beta antagonist"/><FilterOption id="205" count="159" label="HMG CoA reductase inhibitor"/><FilterOption id="3816" count="159" label="RET tyrosine kinase receptor family inhibitor"/><FilterOption id="82444" count="151" label="DNA helicase inhibitor"/><FilterOption id="3806" count="151" label="Flt3 tyrosine kinase inhibitor"/><FilterOption id="498" count="150" label="Sodium channel inhibitor"/><FilterOption id="1016" count="146" label="HIV-1 reverse transcriptase inhibitor"/><FilterOption id="1722" count="144" label="VEGF receptor antagonist"/><FilterOption id="1832" count="143" label="Nucleoside reverse transcriptase inhibitor"/><FilterOption id="3754" count="141" label="EGFR family tyrosine kinase receptor inhibitor"/><FilterOption id="721" count="139" label="TNF binding agent"/><FilterOption id="3151" count="135" label="GCSF receptor agonist"/><FilterOption id="76" count="133" label="Aromatase inhibitor"/><FilterOption id="286" count="130" label="Estrogen receptor antagonist"/><FilterOption id="1092" count="124" label="GNRH receptor agonist"/><FilterOption id="15" count="123" label="5-HT 3 receptor antagonist"/><FilterOption id="4548" count="122" label="Raf B protein kinase inhibitor"/><FilterOption id="629" count="120" label="Inosine monophosphate dehydrogenase inhibitor"/><FilterOption id="67136" count="115" label="Programmed cell death protein 1 inhibitor"/><FilterOption id="381" count="115" label="TNF alpha ligand inhibitor"/><FilterOption id="431" count="114" label="DNA gyrase inhibitor"/><FilterOption id="4550" count="110" label="Raf 1 protein kinase inhibitor"/><FilterOption id="262" count="106" label="Muscarinic M3 receptor antagonist"/><FilterOption id="9320" count="103" label="Topoisomerase IV inhibitor"/><FilterOption id="11778" count="102" label="PurH purine biosynthesis protein inhibitor"/><FilterOption id="4913" count="101" label="P2Y12 purinoceptor antagonist"/><FilterOption id="259" count="94" label="Muscarinic receptor antagonist"/><FilterOption id="4542" count="94" label="Raf protein kinase inhibitor"/><FilterOption id="64" count="87" label="Angiotensin II receptor antagonist"/><FilterOption id="13571" count="86" label="Bcr protein inhibitor"/><FilterOption id="3524" count="81" label="Abl tyrosine kinase inhibitor"/><FilterOption id="48489" count="81" label="PDGF receptor alpha antagonist"/><FilterOption id="782" count="80" label="Dihydropyrimidine dehydrogenase inhibitor"/><FilterOption id="6661" count="80" label="Orotate phosphoribosyltransferase inhibitor"/><FilterOption id="4917" count="74" label="Proteasome inhibitor"/><FilterOption id="346" count="74" label="Ribonucleotide reductase inhibitor"/><FilterOption id="261" count="72" label="Muscarinic M1 receptor antagonist"/><FilterOption id="51708" count="71" label="DNA polymerase alpha inhibitor"/><FilterOption id="6830" count="71" label="DNA primase inhibitor"/><FilterOption id="624" count="70" label="Progesterone receptor agonist"/><FilterOption id="788" count="68" label="Angiotensin II AT-1 receptor antagonist"/><FilterOption id="5537" count="68" label="Dipeptidyl peptidase IV inhibitor"/><FilterOption id="111" count="68" label="Factor IIa antagonist"/><FilterOption id="60" count="67" label="Androgen receptor antagonist"/><FilterOption id="7025" count="64" label="Signal transduction inhibitor"/><FilterOption id="293" count="63" label="Opioid receptor mu agonist"/><FilterOption id="3154" count="62" label="CSF-1 antagonist"/><FilterOption id="76469" count="60" label="26S proteasome complex inhibitor"/><FilterOption id="12162" count="59" label="Erythropoietin ligand"/><FilterOption id="113" count="57" label="Factor IX antagonist"/><FilterOption id="114" count="57" label="Factor VII antagonist"/><FilterOption id="119" count="57" label="Factor X antagonist"/><FilterOption id="2585" count="57" label="Glucagon-like peptide 1 receptor agonist"/><FilterOption id="10583" count="57" label="Vitamin K epoxide reductase inhibitor"/><FilterOption id="2588" count="56" label="Calcium channel inhibitor L-type"/><FilterOption id="1001" count="56" label="Cyclooxygenase 2 inhibitor"/><FilterOption id="214" count="56" label="Interferon alpha 2 ligand"/><FilterOption id="204" count="54" label="HIV protease inhibitor"/><FilterOption id="814" count="54" label="Tubulin modulator"/><FilterOption id="81" count="53" label="Benzodiazepine receptor agonist"/><FilterOption id="385" count="48" label="Protein tyrosine kinase inhibitor"/><FilterOption id="10240" count="47" label="mTOR inhibitor"/><FilterOption id="768" count="46" label="HIV-1 protease inhibitor"/><FilterOption id="1919" count="46" label="Insulin sensitizer"/><FilterOption id="1833" count="46" label="Non-nucleoside reverse transcriptase inhibitor"/><FilterOption id="6909" count="44" label="Alpha 1A adrenoceptor antagonist"/><FilterOption id="1741" count="44" label="Low molecular weight heparin"/><FilterOption id="132" count="43" label="Cyclooxygenase inhibitor"/><FilterOption id="777" count="43" label="Lanosterol-14 demethylase inhibitor"/><FilterOption id="66340" count="43" label="Penicillin binding protein inhibitor"/><FilterOption id="6512" count="42" label="DNA methyltransferase inhibitor"/><FilterOption id="3688" count="42" label="FGF3 receptor antagonist"/><FilterOption id="2506" count="42" label="PARP modulator"/><FilterOption id="14007" count="42" label="Programmed cell death ligand 1 inhibitor"/><FilterOption id="5482" count="41" label="Cytotoxic T-lymphocyte protein-4 inhibitor"/><FilterOption id="150" count="41" label="Dopamine D2 receptor antagonist"/><FilterOption id="3682" count="41" label="FGF1 receptor antagonist"/><FilterOption id="3584" count="41" label="Lck tyrosine kinase inhibitor"/></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="100"><FilterOption id="226" count="7827" label="Nausea"/><FilterOption id="829" count="7760" label="Fatigue"/><FilterOption id="102" count="7515" label="Diarrhea"/><FilterOption id="1991" count="6929" label="Neutropenia"/><FilterOption id="110" count="5067" label="Emesis"/><FilterOption id="17" count="4903" label="Anemia"/><FilterOption id="324" count="4754" label="Thrombocytopenia"/><FilterOption id="148" count="3421" label="Headache"/><FilterOption id="3038" count="3234" label="Appetite loss"/><FilterOption id="3020" count="3188" label="Skin rash"/><FilterOption id="1833" count="2721" label="Fever"/><FilterOption id="680" count="2461" label="Leukopenia"/><FilterOption id="404" count="2195" label="Constipation"/><FilterOption id="178" count="1936" label="Hypertension"/><FilterOption id="746" count="1709" label="Infectious disease"/><FilterOption id="20" count="1682" label="Pain"/><FilterOption id="3795" count="1592" label="Febrile neutropenia"/><FilterOption id="3062" count="1588" label="Death"/><FilterOption id="360" count="1547" label="Pneumonia"/><FilterOption id="2400" count="1522" label="Dyspnea"/><FilterOption id="3472" count="1227" label="Abdominal pain"/><FilterOption id="402" count="1200" label="Edema"/><FilterOption id="13" count="1191" label="Alopecia"/><FilterOption id="2439" count="1188" label="Arthralgia"/><FilterOption id="1263" count="1155" label="Mucositis"/><FilterOption id="1016" count="1124" label="Stomatitis"/><FilterOption id="82" count="1103" label="Cough"/><FilterOption id="279" count="1084" label="Pruritus"/><FilterOption id="1992" count="1015" label="Lymphocytopenia"/><FilterOption id="1039" count="970" label="Myalgia"/><FilterOption id="516" count="932" label="Upper respiratory tract infection"/><FilterOption id="2274" count="920" label="Rhinopharyngitis"/><FilterOption id="1821" count="911" label="Hyperglycemia"/><FilterOption id="3454" count="888" label="Dizziness"/><FilterOption id="129" count="830" label="Gastrointestinal disease"/><FilterOption id="259" count="825" label="Peripheral neuropathy"/><FilterOption id="678" count="808" label="Neuropathy"/><FilterOption id="181" count="763" label="Hypokalemia"/><FilterOption id="3221" count="761" label="Back pain"/><FilterOption id="552" count="722" label="Bleeding"/><FilterOption id="1256" count="682" label="Hyponatremia"/><FilterOption id="3050" count="627" label="Chill"/><FilterOption id="408" count="610" label="Hypotension"/><FilterOption id="1009" count="607" label="Urinary tract infection"/><FilterOption id="1280" count="557" label="Hypophosphatemia"/><FilterOption id="114" count="551" label="Sepsis"/><FilterOption id="750" count="525" label="Insomnia"/><FilterOption id="277" count="513" label="Proteinuria"/><FilterOption id="2955" count="482" label="Weight loss"/><FilterOption id="2024" count="442" label="Erythema"/><FilterOption id="1078" count="425" label="Lung embolism"/><FilterOption id="2576" count="411" label="Dysgeusia"/><FilterOption id="1063" count="406" label="Xerostomia"/><FilterOption id="432" count="405" label="Dyspepsia"/><FilterOption id="2434" count="395" label="Vertigo"/><FilterOption id="3073" count="380" label="Drowsiness"/><FilterOption id="172" count="376" label="Hyperbilirubinemia"/><FilterOption id="201" count="360" label="Liver disease"/><FilterOption id="94" count="349" label="Dermatitis"/><FilterOption id="95" count="328" label="Dermatological disease"/><FilterOption id="505" count="325" label="Hypersensitivity"/><FilterOption id="69" count="324" label="Renal failure"/><FilterOption id="445" count="318" label="Hypoglycemia"/><FilterOption id="224" count="311" label="Myocardial infarction"/><FilterOption id="2529" count="305" label="Hot flashes"/><FilterOption id="1835" count="304" label="Epistaxis"/><FilterOption id="142" count="295" label="Hematological disease"/><FilterOption id="325" count="293" label="Thromboembolism"/><FilterOption id="574" count="287" label="Deep vein thrombosis"/><FilterOption id="668" count="279" label="Muscle weakness"/><FilterOption id="182" count="273" label="Hypothyroidism"/><FilterOption id="2733" count="264" label="Hypomagnesemia"/><FilterOption id="3868" count="255" label="Xerosis"/><FilterOption id="1072" count="254" label="Colitis"/><FilterOption id="1076" count="252" label="Thrombosis"/><FilterOption id="191" count="250" label="Influenza virus infection"/><FilterOption id="3098" count="244" label="Hypoalbuminemia"/><FilterOption id="2184" count="239" label="Gastrointestinal bleeding"/><FilterOption id="50" count="237" label="Bronchitis"/><FilterOption id="1876" count="234" label="Syncope"/><FilterOption id="93" count="230" label="Depression"/><FilterOption id="444" count="220" label="Hypocalcemia"/><FilterOption id="3826" count="218" label="Bone marrow depression"/><FilterOption id="1542" count="211" label="Atrial fibrillation"/><FilterOption id="2854" count="211" label="Ostealgia"/><FilterOption id="2469" count="207" label="Paresthesia"/><FilterOption id="12" count="204" label="Allergy"/><FilterOption id="2085" count="203" label="Dysphagia"/><FilterOption id="1061" count="203" label="Sinusitis"/><FilterOption id="810" count="200" label="Esophagitis"/><FilterOption id="188" count="199" label="Inflammatory disease"/><FilterOption id="25" count="194" label="Anxiety disorder"/><FilterOption id="250" count="194" label="Pancreatitis"/><FilterOption id="3209" count="193" label="Oral mucositis"/><FilterOption id="55" count="187" label="Cardiac failure"/><FilterOption id="735" count="186" label="Toxicity"/><FilterOption id="358" count="184" label="Muscle spasm"/><FilterOption id="2440" count="184" label="Musculoskeletal pain"/><FilterOption id="2291" count="182" label="Hematuria"/><FilterOption id="2236" count="177" label="Hypertriglyceridemia"/></Filter></Filters><SearchResults><Trial Id="339289"><Indications><Indication>Metastatic colorectal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN COLORECTAL CANCER</Identifier><Identifier>NCT03524274</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>center, the investigators will be planing to recruit for 90 patients with advanced colorectal &lt;b&gt;cancer&lt;/b&gt;, and all patients will be divided into three groups: Group 1: patients...anti-MUC1 BiTE cytokine induced killer cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical together with cryotherapy. The maximum tumor length &amp;gt;/= 2 cm, cool down... Medium/above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Objective/Overall Response Rate (ORR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Colorectal tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Colorectal tumor - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study Of Activated Cytokine Induced Killer Armed With Bispecific Antibody For Advanced Colorectal Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Colorectal tumor - Subjects with Colon Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Rectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with TNM stage IV/Metastatic/Advanced Colorectal Cancer</PatientSegment><PatientSegment>Colorectal tumor - Subjects with Treatment Resistant Disease - Subjects with chemotherapy resistant disease</PatientSegment><PatientSegment>Colorectal tumor - Subjects with resectable colorectal cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="336775"><Indications><Indication>Metastatic lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-03-27T00:00:00Z</DateEnd><DateStart>2018-03-27T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN LUNG CANCER</Identifier><Identifier>NCT03501056</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The investigators plan to recruit for 90 patients with advanced lung &lt;b&gt;cancer&lt;/b&gt;. This study consist of three treatment arms: Arm 1 (cryotherapy): patients with the...antibody of anti-CD3/MUC1 ; anti-CD3/anti-MUC1 T-cell engager CIK cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical) will be administered. Arm 3 (no Intervention: conventional...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphomamyeloma,and patients are using immunosuppressant Systemic</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Clinical Symptoms</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 3 years</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Hematological Assessments</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Evaluation by MRI/CT scan</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-Induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Resectable/Operable Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-03-27T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="342813"><Indications><Indication>Metastatic stomach cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN GASTRIC CANCER</Identifier><Identifier>NCT03554395</Identifier></Identifiers><InterventionsControlDisplay><Intervention>conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>single-center, the investigators plan to recruit for 90 patients with advanced gastric &lt;b&gt;cancer&lt;/b&gt;,and all patients are divided into three groups: one group will receive...-CD3/MUC1; anti-CD3/anti-MUC1 T-cell engager CIK cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceutical. Group 3 (no intervention: conventional therapy): in this...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients are using immunosuppressant</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Disease Relapse/Recurrence - Assessment of relapse rate</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Mortality/Death Rates - Assessment of all cause mortality</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Response Rates (RR) - Assessment of objective/overall response rate (ORR)</EndpointIndex><EndpointIndex>Stomach tumor - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Resectable Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Stage IV Gastric Cancer</PatientSegment><PatientSegment>Stomach tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Stomach tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="339277"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-05T00:00:00Z</DateEnd><DateStart>2018-04-05T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN BREAST CANCER</Identifier><Identifier>NCT03524261</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>single-center, the investigators will plan to recruit for 90 patients with advanced breast &lt;b&gt;cancer&lt;/b&gt;, and all patients will be divided into three groups: Group 1: patients... Medium/above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma, and patients are using immunosuppressant... Age 18 to 75 years The patient is diagnosed as advanced breast &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10 mm</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Markers of Tumor Growth and Progression</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Remission</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of circulating tumor cell response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments - Computed tomography (CT)/ PET scans</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study Of Activated Cytokine Induced Killer Armed With Bispecific Antibody For Advanced Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1 </BiomarkerName><BiomarkerName> Tumor mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-05T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="337607"><Indications><Indication>Metastatic pancreas cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-12T00:00:00Z</DateEnd><DateStart>2018-04-12T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN PANCREATIC CANCER</Identifier><Identifier>NCT03509298</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention><Intervention>cryotherapy alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>The investigators will plan to recruit 90 patients with advanced pancreatic &lt;b&gt;cancer&lt;/b&gt;, and all patients are divided into three groups. One group will receive cryotherapy...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma,and patients are using immunosuppressant Systemic... Age 18 to 75 years old The patient is diagnosed as advanced pancreatic &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of circulating tumor cells (CTC)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Response Rates (RR) - Assessment of objective response rate (ORR)</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Pancreas tumor - Assessment of Therapy Related Outcomes</EndpointIndex><EndpointIndex>Pancreas tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Pancreas tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment of symptoms</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer</PatientSegment><PatientSegment>Pancreas tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-12T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="341183"><Indications><Indication>Metastatic renal cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>CD3 modulator</Action><Action>Mucin 1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer antibody</Action><Action>Immunostimulant</Action><Action>T-lymphocyte stimulator</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Cell therapy</Technology><Technology>Immuno-oncology</Technology><Technology>Multivalent antibody</Technology><Technology>Systemic formulation unspecified</Technology></Technologies><CompaniesCollaborator><Company>Benhealth Biopharmaceutical (Shenzhen) Co Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2019-06-28T00:00:00Z</DateChangeLast><DateEnd>2021-04-10T00:00:00Z</DateEnd><DateStart>2018-04-10T00:00:00Z</DateStart><Identifiers><Identifier>CD3-MUC1 IN KIDNEY CANCER</Identifier><Identifier>NCT03540199</Identifier></Identifiers><InterventionsControlDisplay><Intervention>Conventional therapy alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Cryotherapy alone</Intervention><Intervention>anti-CD3/anti-MUC1 BiTE cytokine-induced killer-cell therapy (pancreatic/colorectal/liver/lung cancer), Benhealth Biopharmaceutical alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>90</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>CIK cells (activated by PD-1 inhibitor) with bispecific antibody of anti-CD3-MUC1; anti-CD3/anti-MUC1 T-cell engager CIK cell therapy (&lt;b&gt;cancer&lt;/b&gt;), Benhealth Biopharmaceuticaland cryotherapy...Medium or above ascites Patient of second primary tumor or multiple primary &lt;b&gt;cancer&lt;/b&gt; Patients of T cell lymphoma, myeloma and patients are using immunosuppressant Systemic... Age18 to 75 years old The patient is diagnosed as advanced kidney &lt;b&gt;cancer&lt;/b&gt;, MUC1 is positive There is at least one tumor should be measured, and length &amp;gt;/= 10mm</Teaser><TrialCategories><Category>Biological</Category><Category>Cell therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Biomarkers - Assessment of other tumor markers</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Other Measures of Response - Assessment of best response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Other/Unspecified Efficacy Parameters</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of disease control rate</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Response Rates (RR) - Assessment of duration of objective/overall response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal cell carcinoma - Advanced Stage Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes </BiomarkerName><BiomarkerName> Mucin-1</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-04-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Chengsi He, Bachelor</Name><Name>Jibing Chen, Doctor</Name><Name>Peng Ma, Master</Name><Name>Zhengcheng Li, Master</Name><Name>Zhenzhen Wang, Bachelor</Name></ContactNames></Trial><Trial Id="34162"><Indications><Indication>Bladder cancer</Indication><Indication>Cancer</Indication><Indication>Esophagus tumor</Indication><Indication>Hormone refractory prostate cancer</Indication><Indication>Non-small-cell lung cancer</Indication><Indication>Sarcoma</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Cancer testis antigen NY-ESO-1 modulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>DNA vaccine</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Transdermal formulation</Technology><Technology>Transdermal high velocity particle formulation</Technology></Technologies><CompaniesCollaborator><Company>Columbia University</Company><Company>MD Anderson Cancer Center</Company><Company>Memorial Sloan-Kettering Cancer Center</Company></CompaniesCollaborator><CompaniesSponsor><Company>Ludwig Institute for Cancer Research</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2018-11-24T00:00:00Z</DateChangeLast><DateEnd>2007-05-31T00:00:00Z</DateEnd><DateStart>2004-05-31T00:00:00Z</DateStart><Identifiers><Identifier>2005-0013</Identifier><Identifier>LUD2002-006</Identifier><Identifier>NCT00199849</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>NY-ESO-1 DNA vaccine (cancer), Ludwig Institute/PowderMed alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>15</PatientCountEnrollment><Phase>Phase 1 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>LAGE-1 antigen would be assigned to cohorts. NY-ESO-1 Plasmid DNA (pPJV7611) &lt;b&gt;cancer&lt;/b&gt; vaccine would be administered by PMED at a pressure of 500 psi using the XR...skin &lt;b&gt;cancer&lt;/b&gt;, cervical carcinoma in situ and incidental prostate &lt;b&gt;cancer&lt;/b&gt; on radical cystoprostatectomy specimen Mental impairment, in the opinion of...breast &lt;b&gt;cancer&lt;/b&gt;, bladder &lt;b&gt;cancer&lt;/b&gt;, hepatocellular &lt;b&gt;cancer&lt;/b&gt;, synovial sarcoma, leiomyosarcoma, head and neck, lung &lt;b&gt;cancer&lt;/b&gt;, esophageal, ovarian, neuroblastoma</Teaser><TrialCategories><Category>Gene therapy</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Inflammatory &amp; Oxidative Stress Markers - Assessment of lymphocytes</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Antibodies</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Esophagus tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Chemotherapy Induced Toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of grade 1 toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of Safety and Tolerability - Assessment of grade 2 toxicity</EndpointIndex><EndpointIndex>Head and neck tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of immunological response</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Hepatobiliary system tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of clinical response rate</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of immunological markers</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of dermatologic manifestations</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of subject withdrawals</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Immune Response - Assessment of Immune Response to Tumor</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Neuroblastoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Ovary tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events (AE) &amp; serious adverse events (SAEs)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of antibody titers</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Immune Response - Assessment of cellular response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Prostate Specific Antigen(PSA) Dependent Variables - Assessment of PSA response</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR)</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Response Rates (RR) - Assessment of progressive disease</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 1 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of grade 2 toxicity</EndpointIndex><EndpointIndex>Prostate tumor - Assessment of Safety and Tolerability - Assessment of treatment emergent adverse events</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of immunological response</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Response Rates (RR) - Assessment of tumor response rate</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Soft tissue sarcoma - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Metastatic Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Stage IV Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Advanced/Metastatic Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Stage IV Esophageal Cancer</PatientSegment><PatientSegment>Esophagus tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Advanced/Metastatic Head and Neck Cancer</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Specific Histological Sub-type of HNC</PatientSegment><PatientSegment>Head and neck tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Advanced/Metastatic Primary Liver Cancer</PatientSegment><PatientSegment>Hepatobiliary system tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Neuroblastoma - Subjects with INSS Stage 4 Neuroblastoma</PatientSegment><PatientSegment>Neuroblastoma - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Ovary tumor - Advanced Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Platinum-Resistant/Refractory Ovarian Cancer Subjects</PatientSegment><PatientSegment>Ovary tumor - Subjects with Ovarian Cancer Resistant or Refractory to Non-Platinum Therapies</PatientSegment><PatientSegment>Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Stage IV Prostate Cancer</PatientSegment><PatientSegment>Prostate tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Advanced/Metastatic Soft Tissue Sarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Leiomyosarcoma</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)</PatientSegment><PatientSegment>Soft tissue sarcoma - Subjects with Synovial Sarcoma</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>T-cell surface glycoprotein CD4 </BiomarkerName><BiomarkerName> T-cell surface glycoprotein CD8 alpha chain</BiomarkerName></BiomarkerNames><PrimaryCompletionDate/><TrialDuration>36 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Nasser K Altorki, MD</Name><Name>Padmanee Sharma, MD PhD</Name></ContactNames></Trial><Trial Id="321009"><Indications><Indication>Metastatic renal cell carcinoma</Indication></Indications><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Metastasis inhibitor</Action><Action>Therapeutic vaccine</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesCollaborator><Company>Jinan University (Guangdong)</Company></CompaniesCollaborator><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2020-11-30T00:00:00Z</DateEnd><DateStart>2017-11-30T00:00:00Z</DateStart><Identifiers><Identifier>KIDNEY CANCER MV</Identifier><Identifier>NCT03357289</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>mix vaccine (sc, renal tumor), Fuda Cancer Hospital/Jinan University alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>30</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>survival (PFS) and overall survival (OS). Group 1: in this group, the patients will receive mix vaccine (sc, renal tumor), Fuda &lt;b&gt;Cancer&lt;/b&gt; Hospital/Jinan...guidelines or the patient refuses standard therapies after &lt;b&gt;cancer&lt;/b&gt; recurrence Body tumor 1 to 6, the maximum tumor length&amp;lt; 2 cm KPS &amp;gt;/= 70, lifespan &amp;gt; 6 months...is to evaluate the safety and efficacy of mix vaccine (sc, renal tumor), Fuda &lt;b&gt;Cancer&lt;/b&gt; Hospital/Jinan University to small metastasis of kidney &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Biological</Category><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Biomarkers - Assessment of other tumor markers</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Disease Relapse/Recurrence</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Immune Response</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 3 months</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 1 year</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Renal cell carcinoma - Assessment of Tumor Related Parameters</EndpointIndex><EndpointIndex>Renal cell carcinoma - Hematological Assessments</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments - MRI assessment/changes</EndpointIndex><EndpointIndex>Renal cell carcinoma - Imaging/Radiological Assessments - PET/CT scan assessment/changes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Mix Vaccine for Metastatic Kidney Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Renal cell carcinoma - Subjects with Metastatic Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Recurrent/ Relapsed Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with TNM Stage IV Renal Cell Carcinoma</PatientSegment><PatientSegment>Renal cell carcinoma - Subjects with Treatment Resistant Disease - Subjects resistant/refractory to standard treatment</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Circulating Tumor Cells </BiomarkerName><BiomarkerName> Lymphocytes</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2018-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>36 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Jibing Chen, MD, PhD</Name></ContactNames></Trial><Trial Id="338912"><Indications><Indication>Bladder cancer</Indication><Indication>Transitional cell carcinoma</Indication></Indications><CompaniesCollaborator><Company>Johns Hopkins University</Company><Company>National Institutes of Health</Company></CompaniesCollaborator><CompaniesSponsor><Company>H Lee Moffitt Cancer Center and Research Institute</Company></CompaniesSponsor><Countries><Country>US</Country></Countries><DateChangeLast>2019-04-04T00:00:00Z</DateChangeLast><DateEnd>2022-12-31T00:00:00Z</DateEnd><DateStart>2019-09-30T00:00:00Z</DateStart><Identifiers><Identifier>MCC-19574</Identifier><Identifier>NCT03517995</Identifier></Identifiers><InterventionsControlDisplay><Intervention>bladder cancer surgery alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Prostaphane (Nutinov Labs, France) alone</Intervention><Intervention>bladder cancer surgery alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>135</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Not yet recruiting</RecruitmentStatus><Teaser>bladder &lt;b&gt;cancer&lt;/b&gt; to when they undergo a surgical procedure for the treatment or removal of their bladder &lt;b&gt;cancer&lt;/b&gt;. The surgical procedure will be done...from when participants will be diagnosed with bladder &lt;b&gt;cancer&lt;/b&gt; to when they undergo a surgical procedure for the treatment or removal of their bladder &lt;b&gt;cancer&lt;/b&gt;. The...other &lt;b&gt;cancer&lt;/b&gt;, excluding non-melanoma skin &lt;b&gt;cancer&lt;/b&gt; Any treatment for the bladder tumor other than intravesical therapy Prior treatment with</Teaser><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Prevention</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Biomarkers</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of apoptosis</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Oncogenes/Oncoproteins</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of adverse events/serious adverse events</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of Safety and Tolerability - Assessment of toxicity</EndpointIndex><EndpointIndex>Bladder cancer - Assessment of compliance/adherence</EndpointIndex><EndpointIndex>Bladder cancer - Clinical Assessments</EndpointIndex><EndpointIndex>Bladder cancer - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex><EndpointIndex>Bladder cancer - Pharmacogenetic/Pharmacogenomics Analysis</EndpointIndex><EndpointIndex>Bladder cancer - Protocol Specified Other Endpoints - Assessment of Efficacy</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Randomized, Phase II Clinical Trial of Sulforaphane in Bladder Cancer Chemoprevention</TitleDisplay><PatientSegmentTerms><PatientSegment>Bladder cancer - Subjects with Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Resectable Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Superficial or Non-Muscle Invasive Bladder Cancer</PatientSegment><PatientSegment>Bladder cancer - Subjects with Urothelial cell/Transitional Cell Bladder Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Antigen KI-67 </BiomarkerName><BiomarkerName> Blood cells </BiomarkerName><BiomarkerName> Caspase-3 </BiomarkerName><BiomarkerName> DNA replication licensing factor MCM2 </BiomarkerName><BiomarkerName> Epoxide hydrolase 2 </BiomarkerName><BiomarkerName> Glucuronosyltransferase </BiomarkerName><BiomarkerName> NADP </BiomarkerName><BiomarkerName> Nuclear factor erythroid 2 related factor 2 </BiomarkerName><BiomarkerName> Transcription factor p65</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2021-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>39 Months</TrialDuration><NumberOfSites>2</NumberOfSites><ContactNames><Name>Cesar Ercole, M.D.</Name><Name>Kayoko Kennedy</Name><Name>Nagi Kumar, Ph.D</Name><Name>Nagi Kumar, Ph.D.</Name></ContactNames></Trial><Trial Id="240229"><Indications><Indication>Metastatic breast cancer</Indication></Indications><CompaniesSponsor><Company>Fuda Cancer Hospital</Company></CompaniesSponsor><Countries><Country>China</Country></Countries><DateChangeLast>2018-10-15T00:00:00Z</DateChangeLast><DateEnd>2017-08-15T00:00:00Z</DateEnd><DateStart>2015-09-30T00:00:00Z</DateStart><Identifiers><Identifier>BREAST CANCER CAR-T 001</Identifier><Identifier>NCT02547961</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>HER-2-targeting CAR T cells alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>60</PatientCountEnrollment><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>breast &lt;b&gt;cancer&lt;/b&gt;. Autologous T cells would be gene-engineered with the CAR gene using a retrovirus vector. Prior to T cell infusion, the patients would be... Chemotherapy refractory Her2 positive breast &lt;b&gt;cancer&lt;/b&gt; Relapsed patients after anti-Her2 using antibody or kinase inhibitor therapy Patients must be &amp;gt;/= 18 years... The purpose of this study was to evaluate the safety and efficacy of HER2-CAR-T cell infusion for advanced HER2 positive breast &lt;b&gt;cancer&lt;/b&gt;.</Teaser><TrialCategories><Category>Cell therapy</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Hematological Assessments</EndpointIndex><EndpointIndex>Breast tumor - Imaging/Radiological Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Chimeric Antigen Receptor-Modified T Cells for Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Treatment Resistant Disease</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-08-15T00:00:00Z</PrimaryCompletionDate><TrialDuration>22 Months</TrialDuration><NumberOfSites>1</NumberOfSites><ContactNames><Name>Lizhi Niu, PhD</Name></ContactNames></Trial></SearchResults></trialResultsOutput>